

GENOMIC VALLEY BIOTECH LIMITED

[CIN : L01122HR1994PLC033029]



4 KM Stone, Berri Chhara Road, P.O. Tanda Heri, Tehsil
Bahadurgarh, District Jhajjar, HARYANA, INDIA - 124 507



genomicvalley@gmail.com



www.genomicvalley.com



+91 9811341542



Date: 07th December, 2020

To,

BSE Limited

Phiroze Jeejeebhoy Towers,

Dalal Street, Fort

Mumbai-400001

Email ID: corp.relations@bseindia.com

Ref: Genomic Valley Biotech Limited (539206/ GVBL)

Sub: Notice of Annual General Meeting and Annual Report for 2019-20

Dear Sir/Madam,

With reference to the above captioned subject and pursuant to Regulation 30 and 34 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the 26th Annual General Meeting (26th AGM) of Genomic Valley Biotech Limited ("Company") is scheduled to be held on Thursday, December 31, 2020 at 11.00 A.M. at the Registered Office of the Company at 4 K.M. Stone, Berri Chhara Road, P.O. Tandaheri, Teh. Bahadurgarh, Dist. Jhajjar, Haryana-124507. The Notice for the said Annual General Meeting and Annual Report 2019-20 is enclosed herewith.

Further pursuant to the Regulation 42 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, the Register of Members and the Share Transfer Books of the Company will remain closed from Friday, 25th December 2020 to Thursday 31st December 2020 (both days inclusive) for the purpose of 26th Annual General Meeting.

Further as per the provisions of Section 108 of the Companies Act, 2013, Rule 20 of the Companies (Management & Administration) Rules, 2014 and Regulation 44 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, the Company has provided the remote electronic voting (e-voting) facility to the members through electronic voting platform of Central Depository Services Limited (CDSL). Members holding shares either in physical or in dematerialized form as on cut-off date i.e., Thursday, 24th December, 2020 may cast their votes electronically through remote e- voting facility on the businesses set out in the Notice of Annual General Meeting. The E-voting facility will commence on December 28, 2020 at 9.00 a.m. and ends on December 30, 2020 at 5.00 p.m.

You are kindly requested to take the same on records & acknowledgement.

Thanking you.

Yours sincerely

For **Genomic Valley Biotech Limited**



Yogesh Agrawal
Managing Director

DIN: 01165288

Add: G-74, Pushkar Enclave,
Paschim Vihar Delhi – 110063

Encl: A/a

GENOMIC VALLEY BIOTECH LIMITED
Regd. Off: 4 K.M. STONE, BERRI CHHARRA ROAD, P.O. TANDAHERI,
TEHSIL-BAHADURGARH, DISTT-JHAJJAR, HARYANA-124507
CIN: L01122HR1994PLC033029
Tele: +91-9811341542
Email: genomicvalley@gmail.com
Visit: <http://www.genomicvalley.com>

NOTICE OF ANNUAL GENERAL MEETING

Notice is hereby given that the 26th Annual General Meeting (AGM) of the members of Genomic Valley Biotech Limited will be held on Thursday, 31st day of December, 2020 at 11.00 A.M. at the Registered Office of the Company at 4 K.M. Stone, Berri Chharra Road, P.O. Tandaheri, Teh. Bahadurgarh, Dist. Jhajjar, Haryana-124507 to transact the following businesses:

ORDINARY BUSINESS(ES)

1. To receive, consider and adopt the Standalone Audited Financial Statements of the Company for the Financial Year ended 31st March, 2020, the reports of the Board of Directors and Auditors thereon.
2. To re-appoint Mrs. Parul Agrawal (DIN: 01165188) who retires by rotation and eligible offer herself for re-appointment.

SPECIAL BUSINESS(ES)

TO CONSIDER AND IF THOUGHT FIT TO PASS WITH OR WITHOUT MODIFICATION THE FOLLOWING RESOLUTIONS, WHICH WILL BE PROPOSED AS SPECIAL RESOLUTIONS:

3. **RE-APPOINTMENT OF MR. YOGESH AGRAWAL AS CHAIRMAN AND MANAGING DIRECTOR OF THE COMPANY FOR THE PERIOD OF 5 (FIVE) YEARS WITH EFFECT FROM 07.09.2020**

“RESOLVED THAT on the recommendation of the Nomination and Remuneration Committee & Board of Directors and pursuant to the provision of Sections 196, 197, 198 and 203 read with the Companies (Appointment and Remuneration of Managerial Personnel) Rules 2014, Schedule V and other applicable provisions, if any, of the Companies Act, 2013 and SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 (including any statutory modification(s) or re-enactment(s) thereof, for the time being in force), Mr. Yogesh Agrawal be and is hereby re-appointed as a Chairman and Managing Director of the Company for a period of 5 (Five) consecutive years with effect from 07.09.2020 on such remuneration of and terms & conditions as detailed below:

1. **Term:** 07th September, 2020 to 06th September, 2025
2. **Nature of Duties:** Mr. Yogesh Agrawal shall devote his whole time and attention to the business of the Company and carry out such duties as may be entrusted to him by the Board from time to time and exercise such powers as may be assigned to him, subject to the superintendence, control and directions of the Board in connection with and in the best interests of the business of the Company.
3. **Salary & Perquisites:** Rs. 2,50,000/- per month (Consolidated)
4. **Minimum Remuneration:** The above remuneration shall also be paid as minimum remuneration to Mr. Yogesh Agrawal in the event of absence or inadequacy of profit in any year during his remaining tenure subject to the

ceilings specified under the provision of section 197 and Schedule V of the Companies Act, 2013 having regard to the effective capital of the Company.

The appointment and other service terms will be subject to the relevant provision of the Companies Act, 2013 and as amended from time to time. All other terms and conditions of the existing appointment shall be governed by the agreement and Company rules and policies.

RESOLVED FURTHER THAT the Draft Agreement, incorporating the terms of appointment and remuneration placed at the meeting and initiated by the Chairman thereof for the purposes of identification, be and is hereby approved and any Director or Company Secretary, be and are hereby severally authorized to sign the agreement on behalf of the Company.

RESOLVED FURTHER THAT any Director or Company Secretary, be and are hereby severally authorized to do all such acts, deeds, matters and things in this regard and to file the relevant forms, if any with the Ministry of Corporate Affairs (MCA), Registrar of Companies.”

4. APPOINTMENT OF MR. SATENDRA KUMAR GOYAL (DIN: 08767544) AS AN INDEPENDENT DIRECTOR OF THE COMPANY

“RESOLVED THAT pursuant to the provisions of Section 149, 150, 152 read with Schedule IV and other applicable provisions of the Companies Act, 2013 (the Act) and the Companies (Appointment and Qualifications of Directors) Rules, 2014, (including any statutory modification(s) or re-enactment(s) thereof for the time being in force) and Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (‘Listing Regulations’), on the recommendation of the Nomination & Remuneration Committee and approval of the Board of Directors for appointment of Mr. Satendra Kumar Goyal (DIN: 08767544) as an Additional Director in the capacity of an Independent Director of the Company w.e.f. June 30, 2020, who has submitted a declaration that he meets the criteria for independence as provided under Section 149(6) of the Act and Regulation 16(1) (b) of the Listing Regulations and is eligible for appointment, and in respect of whom the Company has received a notice in writing in terms of Section 160(1) of the Act and who holds office as such up to the date of ensuing Annual General Meeting, be and is hereby, appointed as a Non-Executive Independent Director of the Company not liable to retire by rotation, to hold office for a period effective from June 30, 2020 till June 29, 2025.”

5. TO SELL, LEASE, COLLABORATE OR SELF DEVELOP RESIDENTIALLY AND COMMERCIALY OR OTHERWISE DISPOSE OF THE WHOLE OR SUBSTANTIALLY THE WHOLE OF THE LAND, PROPERTY OR UNDERTAKING(S) OF THE COMPANY ALONG WITH ALL DEVELOPMENT RIGHTS AND ENTIRE FACILITIES AVAILABLE WHATSOEVER AT THE LAND, PROPERTY OR UNDERTAKING(S) OF THE COMPANY AS PER SECTION 180(1)(A) OF THE COMPANIES ACT, 2013

“RESOLVED THAT pursuant to provisions of Section 180(1)(a) and other applicable provisions, if any, of the Companies Act, 2013, (“Act”) including any statutory modifications or re-enactment thereof for the time being in force and rules made thereunder and subject to such other requisite approvals, if any, in this regard from appropriate authorities and terms(s), condition(s), amendment(s), modification(s), as may be required or suggested by any such appropriate authorities, and agreed to by the Board of Directors of the Company (hereinafter referred to as “Board” which term shall include any Committee or one or more Directors) and subject to SEBI (Listing Obligations and Disclosure Requirement) Regulations, 2015, the consent of the members of the Company be and is hereby accorded to sell, lease, collaborate or self-develop residentially and commercially or otherwise dispose of the whole or substantially the whole of the land, property or undertaking(s) of the Company along with all development rights and entire facilities available whatsoever at the land, property or undertaking(s) on the terms and conditions shall be set out in the sale deed, lease deed, Agreement to sell and lease, collaboration agreement/understanding/deed, agreement/deed/understanding for self-development residentially and commercially and any other deed, agreement, documents or papers related to sell, lease, collaborate or self-develop residentially and commercially or otherwise dispose of the whole or substantially the whole of the land, property or undertaking(s) of the Company along with all development rights and entire facilities available whatsoever at the land, property or undertaking(s).

RESOLVED FURTHER THAT Mr. Yogesh Agrawal, Managing Director and Mrs. Parul Agrawal, Director of the Company, be and are hereby authorized to do all such other act(s), thing(s), and deed(s), as may be required or deemed necessary to give effect to the above resolution.”

**For and on behalf of
Genomic Valley Biotech Limited**

sd/-

**Yogesh Agrawal
Managing Director
DIN-01165288**

**Address: G-74, Pushkar Enclave,
Paschim Vihar, Delhi- 110063**

Date: 05.12.2020

Place: Haryana

NOTES:

1. A MEMBER ENTITLED TO ATTEND AND VOTE AT THE MEETING IS ENTITLED TO APPOINT A PROXY, OR, WHERE THAT IS ALLOWED, ONE OR MORE PROXIES, TO ATTEND AND VOTE INSTEAD OF HIMSELF AND THE PROXY NEED NOT BE A MEMBER.
2. A PERSON CAN ACT AS A PROXY ON BEHALF OF MEMBERS NOT EXCEEDING FIFTY AND HOLDING IN THE AGGREGATE NOT MORE THAN TEN PER CENT OF THE TOTAL SHARE CAPITAL OF THE COMPANY CARRYING VOTING RIGHTS. A MEMBER HOLDING MORE THAN TEN PER CENT OF THE TOTAL SHARE CAPITAL OF THE COMPANY CARRYING VOTING RIGHTS MAY APPOINT A SINGLE PERSON AS PROXY AND SUCH PERSON SHALL NOT ACT AS A PROXY FOR ANY OTHER PERSON OR SHAREHOLDER.
3. THE INSTRUMENT APPOINTING A PROXY MUST BE DEPOSITED WITH THE COMPANY AT ITS REGISTERED OFFICE NOT LESS THAN 48 HOURS BEFORE THE TIME FOR HOLDING THE MEETING.
4. A Proxy Form, Attendance Slip, Ballot Form (in lieu of E-Voting at Annual General Meeting) and Route Map are enclosed with the Notice of Annual General Meeting.
5. Corporate Members intending to send their authorized representatives under Section 113 of the Act are requested to send a duly certified copy of the Board Resolution authorizing their representatives to attend and vote at the meeting, together with duly certified signatures of such representatives.
6. The Company's Registrar and Transfer Agents for its Share Registry Work (Physical and Electronic) is Beetal Financial & Computer Services Private Limited having their office at Beetal House, 99, Madangir, Behind Local Shopping Centre, Near Dada HarsukhDass Mandir, New Delhi-110062.
7. The Securities and Exchange Board of India (SEBI) has mandated the submission of Permanent Account Number (PAN) and Bank details by every participant in securities market. Member(s) holding shares in electronic form are, therefore, requested to submit the PAN to their Depository Participants with whom they are maintaining their demat accounts. Members holding shares in physical form can submit their PAN and Bank details to the RTA.
8. The Register of Members and Share Transfer Books of the Company shall remain closed on the Book Closure Dates, i.e. from December 25, 2020 to December 31, 2020 both days inclusive.
9. Members can avail of the facility of nomination in respect of shares held by them in physical form pursuant to the provisions of section 72 of the Companies Act, 2013 read with Rule 19(1) of the Companies (Share Capital and Debentures) Rules, 2014. Members desiring to avail of this facility may send their nomination in the prescribed Form duly filled in to Beetal Financial & Computer Services Private Limited (RTA) having their office at Beetal House, 99, Madangir, Behind Local Shopping Centre, Near Dada Harsukh Dass Mandir, New Delhi-110062.
10. Members are requested to:
 - a. Intimate to the Company's Registrar and Transfer Agents, Beetal Financial & Computer Services Private Limited having their office at Beetal House, 99, Madangir, Behind Local Shopping Centre, Near Dada Harsukh Dass Mandir, New Delhi-110062, changes, if any, in their registered addresses/bank mandates at an early date, in case of shares held in physical form;

- b. Intimate to the respective Depository Participant, changes, if any, in their registered addresses/ bank mandates at an early date, in case of shares held in electronic/dematerialised form;
 - c. Quote their folio numbers/Client ID and DP ID in all correspondence;
 - d. Consolidate their holdings into one folio in case they hold shares under multiple folios in the identical order of names.
11. Pursuant to sections 101 and 136 of the Companies Act, 2013, read with the Rules framed thereunder and pursuant to the Circulars issued by the Ministry of Corporate Affairs (MCA) regarding the Green Initiative, the Notice of the 26th Annual General Meeting (AGM) and the Annual Report for the year 2019-20, etc., would be sent in electronic mode to such of the Members of the Company whose e-mail addresses are available with the Company/ Depository Participant and who have not opted to receive the same in physical form.
 12. For Members who have not registered their e-mail addresses, physical copies of the Annual Report for the year 2019-20 and the Notice of the 26th AGM would be sent in the permitted mode.
 13. Members are requested to support the Green Initiative by registering / updating their e-mail addresses, with the Depository Participant (in case of Shares held in dematerialised form) or with Beetal Financial & Computer Services Private Limited having their office at Beetal House, 99, Madangir, Behind Local Shopping Centre, Near Dada HarsukhDass Mandir, New Delhi-110062. **(In case of Shares held in physical form)**
 14. Members may also note that the Notice of the 26th Annual General Meeting and the Annual Report for financial year 2019-20 will also be available on the Company's website at [www. http://genomicvalley.com/investorrelationpage.htm](http://genomicvalley.com/investorrelationpage.htm) and also on the website of the RTA, Beetal Financial & Computer Services Private Limited at <http://beetalfinancial.com> . Even after registering for e-communication, Members are entitled to receive such communication in physical form, upon making a request to the Company for the same. For any communication, the shareholders may also send requests to the Company's Email ID : genomicvalley@gmail.com
 15. Relevant documents referred to in the accompanying Notice shall be open for inspection at the Registered Office of the Company during normal business hours on all working days except Sunday from 10.00 A.M. to 6.00 P.M., up to and including the date of the Annual General Meeting of the Company.
 16. The Register of Directors and Key Managerial Personnel and their Shareholding maintained under Section 170 of the Companies Act, 2013, the Register of Contracts or arrangements in which Directors are interested under Section 189 of Companies Act, 2013 will be available for inspection at the Annual General Meeting.
 17. Appointment of Director and Shareholding in the Company:

Mrs. Parul Agrawal holds 283700 Equity Shares of Rs.10 each fully paid up in the Company. Brief resume, details of shareholdings, and director inter-se relationship of the director seeking reappointment as required is provided as Annexure 1 to this notice.

18. Members/Proxies/Representatives are requested to bring their Attendance Slip along with their copy of Annual Report to the Meeting.

Only bonafide members of the Company whose names appear on the Register of Members/Proxy holders, in possession of valid attendance slips duly filled and signed will be permitted to attend the meeting. The Company reserves its right to take all steps as may be deemed necessary to restrict non-members from attending the meeting.

19. Members are requested to bring their copies of Annual Report to the Meeting. In order to enable us to register your attendance at the venue of the Annual General Meeting, members are requested to please bring their folio number/ demat account number/DP ID-Client ID to enable us to provide a duly filled attendance slip for your signature and participation at the meeting.
20. In case of joint holders attending the meeting, only such joint holder who is higher in the order of names will be entitled to vote.

21. E-voting:

In compliance with the provisions of Section 108 of the Companies Act, 2013 and Rule 20 of the Companies (Management and Administrations) Rules, 2014, the Company is pleased to provide to Members with a facility to exercise their right to vote at the 26th Annual General Meeting by electronic means and the business may be transacted through Electronic Voting (e-voting) services provided by Central Depository Services Limited (CDSL).

The Company has appointed Mr. Rohit Batham, Practicing Company Secretary, New Delhi as the Scrutinizer for conducting the e-voting process in a fair and transparent manner. E-voting is optional. The E-voting rights of the shareholders/beneficiary owners shall be reckoned on the equity shares held by them as on 24th December, 2020 being the Cut-off date for the purpose. Shareholders of the Company holding shares either in physical or in dematerialized form, as on the Cut-off date, may cast their vote electronically.

In order to enable its members, who do not have access to e-voting facility, to send their assent or dissent in writing in respect of the resolutions as set out in this Notice, a ballot paper is annexed. A member desiring to exercise vote by ballot paper shall complete the enclosed ballot paper with assent (for) or dissent (against) and send it to Registered office of the Company so as to reach us on or before 30th December, 2020 by 5.00 P.M. Any ballot paper received after the said date and time shall be treated as if the reply from the Members has not been received. Kindly note that member can opt only one mode of voting i.e., either by ballot paper or through e-voting. If members are opting for e-voting then do not vote by ballot paper or vice versa. However, in case of Members casting their vote both by ballot paper and e-voting, then voting done through e-voting shall prevail and voting done by Physical Ballot will be treated as invalid.

22. Instruction for E-Voting:

22.1 Members whose shareholding is in the dematerialised form and whose e-mail addresses are registered with the Company / Depository Participants will receive an e-mail informing User ID and Password.

- a. The e-voting period begins on December 28, 2020 at 9.00 a.m. and ends on December 30, 2020 at 5.00 p.m. During this period shareholders' of the Company, holding shares either in physical form or in dematerialized form, as on the cut-off date (record date) of December 24, 2020, may cast their vote electronically. The e-voting module shall be disabled by CDSL for voting thereafter.
- b. Shareholders who have already voted prior to the meeting date would not be entitled to vote at the meeting venue.
- c. The shareholders should log on to the e-voting website www.evotingindia.com.
- d. Click on the link "Shareholders" module.
- e. Now Enter your User ID
 - i. For CDSL: 16 digits beneficiary ID,
 - ii. For NSDL: 8 Character DP ID followed by 8 Digits Client ID,
 - iii. Members holding shares in Physical Form should enter Folio Number registered with the Company.

OR

Alternatively, if you are registered for CDSL's EASI/EASIEST e-services, you can log-in at <https://www.cdslindia.com> from [Login - Myeasi](#) using your login credentials. Once you successfully log-in to CDSL's EASI/EASIEST e-services, click on e-Voting option and proceed directly to cast your vote electronically.

- f. Next enter the Image Verification as displayed and Click on Login.
- g. If you are holding shares in demat form and had logged on to www.evotingindia.com and voted on an earlier voting of any company, then your existing password is to be used.
- h. If you are a first time user follow the steps given below:

	For Members holding shares in Demat Form and Physical Form
PAN	Enter your 10 digit alpha-numeric *PAN issued by Income Tax Department (Applicable for both demat shareholders as well as physical shareholders) <ul style="list-style-type: none"> • Shareholders who have not updated their PAN with the Company/Depository Participant are requested to use the sequence number sent by Company/RTA or contact Company/RTA.
Dividend Bank Details	Enter the Dividend Bank Details or Date of Birth (in dd/mm/yyyy format) as recorded in your demat account or in the company records in order to login.

OR Date of Birth (DOB)	<ul style="list-style-type: none"> If both the details are not recorded with the depository or company please enter the member id / folio number in the Dividend Bank details field as mentioned in instruction (e).
------------------------	---

- i. After entering these details appropriately, click on “SUBMIT” tab.
- j. Members holding shares in physical form will then directly reach the Company selection screen. However, members holding shares in demat form will now reach ‘Password Creation’ menu wherein they are required to mandatorily enter their login password in the new password field. Kindly note that this password is to be also used by the demat holders for voting for resolutions of any other company on which they are eligible to vote, provided that company opts for e-voting through CDSL platform. It is strongly recommended not to share your password with any other person and take utmost care to keep your password confidential.
- k. For Members holding shares in physical form, the details can be used only for e-voting on the resolutions contained in this Notice.
- l. Click on the EVSN for the relevant GENOMIC VALLEY BIOTECH LIMITED on which you choose to vote.
- m. On the voting page, you will see “RESOLUTION DESCRIPTION” and against the same the option “YES/NO” for voting. Select the option YES or NO as desired. The option YES implies that you assent to the Resolution and option NO implies that you dissent to the Resolution.
- n. Click on the “RESOLUTIONS FILE LINK” if you wish to view the entire Resolution details.
- o. After selecting the resolution you have decided to vote on, click on “SUBMIT”. A confirmation box will be displayed. If you wish to confirm your vote, click on “OK”, else to change your vote, click on “CANCEL” and accordingly modify your vote.
- p. Once you “CONFIRM” your vote on the resolution, you will not be allowed to modify your vote.
- q. You can also take out print of the voting done by you by clicking on “Click here to print” option on the Voting page.
- r. If Demat account holder has forgotten the login password then enter the User ID and the image verification code and click on Forgot Password & enter the details as prompted by the system.
- s. **Shareholders can also cast their vote using CDSL’s mobile app m-Voting available for android based mobiles. The m-Voting app can be downloaded from Google Play Store. Apple and Windows phone users can download the app from the App Store and the Windows Phone Store**

respectively. Please follow the instructions as prompted by the mobile app while voting on your mobile.

t. Note for Non – Individual Shareholders and Custodians – Remote Voting

- Non-Individual shareholders (i.e. other than Individuals, HUF, NRI etc.) and Custodian are required to log on to www.evotingindia.com and register themselves in the “Corporates” module.
- A scanned copy of the Registration Form bearing the stamp and sign of the entity should be emailed to helpdesk.evoting@cdslindia.com.
- After receiving the login details by custodian a Compliance User should be created using the admin login and password. The Compliance User would be able to link the account(s) for which they wish to vote on.
- The list of accounts linked in the login should be mailed to helpdesk.evoting@cdslindia.com and on approval of the accounts they would be able to cast their vote.
- A scanned copy of the Board Resolution and Power of Attorney (POA) which they have issued in favour of the Custodian, if any, should be uploaded in PDF format in the system for the scrutinizer to verify the same.
- Alternatively Non Individual shareholders are required to send the relevant Board Resolution/ Authority letter etc. together with attested specimen signature of the duly authorized signatory who are authorized to vote, to the Scrutinizer and to the Company at the email address viz; genomicvalley@gmail.com (designated email address by company) , if they have voted from individual tab & not uploaded same in the CDSL e-voting system for the scrutinizer to verify the same.

u. Any person, who acquires shares of the Company and become Member of the Company after dispatch of the Notice and holding shares as on the cut-off date i.e. Thursday 24th December, 2020 may follow the same instructions as mentioned above for e-Voting.

v. In case you have any queries or issues regarding e-voting, you may refer the Frequently Asked Questions (“FAQs”) and e-voting manual available at www.evotingindia.com, under help section or write an email to helpdesk.evoting@cdslindia.com or contact Mr. Nitin Kunder (022- 23058738) or Mr. Mehboob Lakhani (022-23058543) or Mr. Rakesh Dalvi (022-23058542).

All grievances connected with the facility for voting by electronic means may be addressed to Mr. Rakesh Dalvi, Manager, (CDSL,) Central Depository Services (India) Limited, A-Wing, 25th Floor, Marathon Futurex, Mafatlal Mill Compounds, NM Joshi Marg, Lower Parel (East), Mumbai-400013, or send an email to helpdesk.evoting@cdslindia.com or call on 022-23058542/43.

22.2 In case a Member receives physical copy of the Annual General Meeting Notice by post (for members whose email Ids are not registered with the Company/Depository Participant(s)):

- a. User ID and initial password are provided overleaf.
- b. Please follow all steps from Note 22.1 above to cast your vote.

- 22.3 Once the vote on a resolution is cast by a Member, the Member shall not be allowed to change it subsequently or cast the vote again.
- 22.4 In case of any queries, you may refer to the Frequently Asked Questions (FAQs) for Members and e-voting user manual for Members available at the 'downloads' section of www.evoting.india.com.
- 22.5 The facility for ballot / polling paper shall be made available at the Annual General Meeting (AGM) and the members attending AGM who have not cast their vote by e-voting/ ballot paper shall be able to vote at the AGM through ballot / polling paper.
- 22.6 The members who have cast their vote by e-voting may also attend AGM, but shall not be entitled to cast their vote again.
- 22.7 The voting rights of the Members for e-voting shall be in proportion to the paid up value of their shares in the equity share capital of the Company as on the cut-off date i.e. 24th December, 2020.
- 22.8 Persons, whose names are recorded in the register of members or in the register of beneficial owners maintained by the depositories as on the cut-off date i.e. 24th December, 2020 only shall be entitled to avail the facility of e-voting / physical voting.
- 22.9 The poll process shall be conducted and a report thereon shall be prepared in accordance with Section 109 of the Companies Act, 2013 read with the relevant rules made there under. In such an event, votes cast under Poll taken together with the votes cast through remote e-voting shall be counted for the purpose of passing of resolution(s).

The Scrutinizer shall immediately after the conclusion of voting at the AGM, count the votes cast at the AGM and thereafter unblock the votes cast through remote e-voting in the presence of at least two (2) witnesses not in the employment of the Company. The Scrutinizer shall submit a consolidated Scrutinizers Report of the total votes cast in favour of or against, if any, not later than two (3) days after the conclusion of the AGM to the Chairman of the Company.

The Chairman or any other director authorized by him, shall declare the result if the voting forthwith.

23. The results on resolutions shall be declared forthwith after getting the report of Scrutinizer and the resolutions will be deemed to be passed on the date of Annual General Meeting subject to receipt of the requisite number of votes in favour of the resolutions.
24. The Results declared along with the Consolidated Scrutinizer's Report(s) will be available on the website of the Company (www.genomicvalley.com) and on website of CDSL. The results shall simultaneously be communicated to Stock Exchanges.

25. Members desiring any information relating to the accounts are requested to write to the Company well in advance so as to enable the management to keep the information ready.

**For and on behalf of
Genomic Valley Biotech Limited**

sd/-

**Yogesh Agrawal
Managing Director
DIN-01165288**

**Address: G-74, Pushkar Enclave,
Paschim Vihar, Delhi- 110063**

Date: 05.12.2020

Place: Haryana

EXPLANATORY STATEMENT PURSUANT TO SECTION 102(1) OF THE COMPANIES ACT, 2013 (“THE ACT”)

THE FOLLOWING STATEMENT SETS OUT ALL MATERIAL FACTS RELATING TO THE SPECIAL BUSINESS MENTIONED IN THE NOTICE:

ITEM NO. 3

The Board of Directors of the Company (“the Board”) at its meeting held on September 05, 2020 has, subject to approval of members, re-appointed Mr. Yogesh Agrawal as a Chairman and Managing Director of the Company, for a period of 5 (Five) years with effect from September 07, 2020, on terms and conditions including remuneration as recommended by the Nomination and Remuneration Committee (the ‘NR Committee’) of the Board and approved by the Board. It is proposed to seek members’ approval for the appointment of and remuneration payable to Mr. Yogesh Agrawal as a Chairman and Managing Director of the Company, in terms of the applicable provisions of the Act. Broad particulars of the terms of re-appointment of and remuneration payable to Mr. Yogesh Agrawal are as under:

1. **Term:** 07th September 2020 to 06th September 2025.
2. **Nature of Duties:** Mr. Yogesh Agrawal shall devote his whole time and attention to the business of the Company and carry out such duties as may be entrusted to him by the Board from time to time and exercise such powers as may be assigned to him, subject to the superintendence, control and directions of the Board in connection with and in the best interests of the business of the Company.
3. **Salary & Perquisites:** Rs. 2,50,000/- per month (Consolidated)
4. **Minimum Remuneration:** The above remuneration shall also be paid as minimum remuneration to Mr. Yogesh Agrawal in the event of absence or inadequacy of profit in any year during his remaining tenure subject to the ceilings specified under the provision of section 197 and Schedule V of the Companies Act, 2013 having regard to the effective capital of the Company.

Mr. Yogesh Agrawal has rich and varied experience in the industry and has been involved in the operations of the Company. It would be in the interest of the Company to continue to avail of his considerable expertise and to re-appoint Mr. Yogesh Agrawal as a Chairman and Managing Director. Accordingly, approval of the members is sought for passing a Special Resolution for appointment of Mr. Yogesh Agrawal as a Chairman and Managing Director, as set out in Part-I of Schedule V to the Act as also under sub-section (3) of Section 196 of the Act.

Save and except as provided in the foregoing paragraph, Mr. Yogesh Agrawal satisfies all the other conditions set out in Part-I of Schedule V to the Act as also conditions set out under sub-section (3) of Section 196 of the Act for being eligible for his appointment. He is not disqualified from being appointed as Director in terms of Section 164 of the Act.

The above may be treated as a written memorandum setting out the terms of appointment of Mr. Yogesh Agrawal under Section 190 of the Act.

Details of Mr. Yogesh Agrawal are provided in Annexure-1 to the Notice pursuant to the provisions of (i) the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 and (ii) Secretarial Standard on General Meetings (“SS-2”), issued by the Institute of Company Secretaries of India.

Mr. Yogesh Agrawal is interested in the resolution set out at Item No. 3 of the Notice.

The relatives of Mr. Yogesh Agrawal may be deemed to be interested in the resolution set out at Item No. 3 of the Notice, to the extent of their shareholding interest, if any, in the Company.

Save and except the above, none of the other Directors / Key Managerial Personnel of the Company / their relatives are, in any way, concerned or interested, financially or otherwise, in the aforementioned resolution.

The Board recommends the Special Resolution set out at Item No. 3 of the Notice for approval by the members.

ITEM NO. 4

Based on the recommendation of the Nomination & Remuneration Committee, the Board of Directors of the Company have appointed Mr. Satendra Kumar Goyal as an Additional Director in the capacity of Non-Executive Independent Director of the Company to hold office for a period from June 30, 2020 to June 29, 2025, not liable to retire by rotation, subject to consent of the Members of the Company at the ensuing AGM. As an Additional Director, Mr. Satendra Kumar Goyal holds office till the date of the AGM and is eligible for being appointed as an Independent Director. The Company has received necessary declaration(s) from Mr. Satendra Kumar Goyal confirming that he meets the criteria as prescribed under the Companies Act, 2013 (the Act) and SEBI (Listing Obligations and Disclosure requirements) Regulations, 2015 (Listing Regulations). Mr. Satendra Kumar Goyal is not disqualified from being appointed as a Director under provisions of Section 164 of the Companies Act, 2013, nor debarred from holding the office of director by virtue of any SEBI order or any other such authority and has given his consent to act as a Director of the Company. Mr. Satendra Kumar Goyal fulfils the conditions for his appointment as an Independent Director as specified in the Act and Listing Regulations and is independent of the management. Your Board believes that Mr. Satendra Kumar Goyal induction on the Board will support in broadening the overall expertise of the Board. A copy of the appointment letter, setting out his terms and conditions of appointment is available on the website of the Company at www.genomicvalley.com and will be available for inspection, without any fees, by the Members at the Company's registered office during normal hours on working days upto the date of AGM and also at the Meeting. Save and except Mr. Satendra Kumar Goyal and his relatives, to the extent of their shareholding interest, if any, in the Company, none of the Directors/ Key Managerial Personnel and their relatives are in any way, interested or concerned, financially or otherwise in the Resolution set out at Item No. 4. The Board of Directors accordingly recommends the Ordinary Resolution set out at Item No. 4 of the Notice for the approval of the Members.

ITEM NO. 5

Members of the Company are requested to note that Section 180 (1)(a) of the Companies Act, 2013 mandates that the Board of Directors of a company shall exercise the power to sell, lease, collaborate or self-develop residentially and commercially or otherwise dispose of the whole or substantially the whole of any undertaking(s) of the company, only with the approval of the members of the Company by way of a special resolution. Explanation (i) to Section 180(1) (a) of the Companies Act, 2013 states that the meaning of an 'undertaking' for the purposes of Section 180(1) of the Companies Act, 2013 is an undertaking in which the investment of the company exceeds twenty per cent. of its net worth as per the audited balance sheet of the preceding financial year or an undertaking which generates twenty per cent. of the total income of the company during the previous financial year. Explanation (ii) to Section 180 (1)(a) of the Companies Act, 2013 states that the meaning of 'substantially the whole of the undertaking' for the purposes of Section 180(1) is in any financial year, twenty percent or more of the value of the undertaking as per the audited balance sheet of the preceding financial year. Accordingly, pursuant to Section 180(1)(a) of the Companies Act, 2013, members of the Company are further requested to note that their consent to the Board is being sought by way of a Special Resolution to sell, lease, collaborate or self-develop residentially and commercially or otherwise dispose of the whole or substantially the whole of the land, property or undertaking(s) of the Company along with all development rights and entire facilities available whatsoever at the land, property or undertaking(s) on the terms and conditions shall be set out in the sale deed, lease deed, Agreement to sell and lease, collaboration agreement/understanding/deed,

agreement/deed/understanding for self-development residentially and commercially and any other deed, agreement, documents or papers related to sell, lease, collaborate or self-develop residentially and commercially or otherwise dispose of the whole or substantially the whole of the land, property or undertaking(s) of the Company along with all development rights and entire facilities available whatsoever at the land, property or undertaking(s) of the Company. The Directors commend the passing of the resolution under item No.5 of the accompanying Notice for the approval of the members of the company. None of the Directors of the company or their relatives are concerned or interested in the passing of the above resolution.

**For and on behalf of
Genomic Valley Biotech Limited**

sd/-

**Yogesh Agrawal
Managing Director
DIN-01165288**

Date: 05.12.2020

Place: Haryana

**Address: G-74, Pushkar Enclave,
Paschim Vihar, Delhi- 110063**

Annexure 1 to Notice of Annual General Meeting
PROFILE OF DIRECTORS SEEKING APPOINTMENT

Name of Director	Mr. Satendra Kumar Goyal	Mr. Yogesh Agrawal
Age	59 Years	57 Years
Qualification	B.Com from University of Delhi	B.Com (H)
Experience (including expertise in specific functional area) / Brief Resume	36 years' work experience in Marketing-Industrial & Consumer, Human Resources administration, Corporate Law and General Management	<p>He is having wide experience in business activities right from the beginning of his career. He successfully operated several Private Limited and Public Limited Companies during his 30 years of exposure.</p> <p>Under his able and experienced guidance and direction M/s Genomic Valley Biotech Limited is progressing well in leaps and bound.</p> <p>He is one of the promoters of the Company.</p>
Terms and Conditions of Appointment / Re-appointment	As per Agreement	As per Agreement
Remuneration last drawn as director (including sitting fees, if any) (in Rs.)	NIL	1,50,000
Remuneration proposed to be paid	NIL	As per Agreement
Date of first appointment on the Board	-	07.09.2015
Shareholding in the Company as on March 31, 2020	NIL	17,86,750 Shares
Relationship with other Directors / Key Managerial Personnel	NIL	Husband of Mrs. Parul Agrawal, Director of the Company
Number of meetings of the Board attended during the year (as director)	NIL	5
Directorships of other Boards as on March 31, 2020	NIL	Eyoge Technologies Private Limited
Membership / Chairmanship of Committees of other Boards as on March 31, 2020	NIL	Nil

GENOMIC VALLEY BIOTECH LIMITED
Regd. Off: 4 KM STONE, BERRI CHHARRA ROAD, P.O. TANDAHERI,
TEHSIL-BAHADURGARH, DISTT-JHAJJAR, HARYANA-124507
CIN: L01122HR1994PLC033029
Tele :- +91-9811341542
Email : genomicvalley@gmail.com
Visit : <http://www.genomicvalley.com>

Form No. MGT-11
PROXY FORM

[Pursuant to section 105(6) of the Companies Act, 2013 and rule 19(3) of the Companies (Management and Administration) Rules, 2014]

CIN	L01122HR1994PLC033029
Name of the company	Genomic Valley Biotech Limited
Registered office	4 K.M. Stone, Berri Chharra Road, P.O. Tandaheri, Tehsil-Bahadurgarh, District-Jhajjar, Haryana-124507

Name of the Shareholder	
Registered address	
E-mail ID	
Folio No./Client ID	
DP ID	

I/We, being the member (s) of Genomic Valley Biotech Limited holding Equity Shares, hereby appoint:

1.	Name	
	Address	
	E-mail Id	
	Signature	

or failing him

2.	Name	
	Address	
	E-mail Id	
	Signature	

or failing him

3.	Name	
	Address	
	E-mail Id	
	Signature	

as my/our proxy to attend and vote (on a poll) for me/us and on my/our behalf at the 26th Annual General Meeting of the Company, to be held on Thursday, 31st day of December, 2020 at 11.00 A.M. at the Registered Office of the Company at 4 K.M. Stone, Berri Chharra Road, P.O. Tandaheri, Teh. Bahadurgarh, Dist. Jhajjar, Haryana-124507 and at any adjournment thereof in respect of such resolutions as are indicated below:

Ordinary Business(es):

1. To receive, consider and adopt the Audited Financial Statements of the Company for the Financial Year ended 31st March, 2020, the reports of the Board of Directors and Auditors thereon.
2. To re-appoint Mrs. Parul Agrawal (DIN: 01165188) who retires by rotation and eligible offer herself for reappointment.


Special Business(es):

3. RE-APPOINTMENT OF MR. YOGESH AGRAWAL AS CHAIRMAN AND MANAGING DIRECTOR OF THE COMPANY FOR THE PERIOD OF 5 (FIVE) YEARS WITH EFFECT FROM 07.09.2020
4. APPOINTMENT OF MR. SATENDRA KUMAR GOYAL (DIN: 08767544) AS AN INDEPENDENT DIRECTOR OF THE COMPANY
5. TO SELL, LEASE, COLLABORATE OR SELF-DEVELOP RESIDENTIALLY AND COMMERCIALY OR OTHERWISE DISPOSE OF THE WHOLE OR SUBSTANTIALLY THE WHOLE OF THE LAND, PROPERTY OR UNDERTAKING(S) OF THE COMPANY ALONG WITH ALL DEVELOPMENT RIGHTS AND ENTIRE FACILITIES AVAILABLE WHATSOEVER AT THE LAND, PROPERTY OR UNDERTAKING(S) OF THE COMPANY AS PER SECTION 180(1)(A) OF THE COMPANIES ACT, 2013

Signed this..... day of..... 2020.

Signature of shareholder:

Signature of Proxy holder(s):



Note: This form of proxy in order to be effective should be duly completed and deposited at the Registered Office of the Company, not less than 48 hours before the commencement of the Meeting.

GENOMIC VALLEY BIOTECH LIMITED
Regd. Off: 4 KM STONE, BERRI CHHARRA ROAD, P.O. TANDAHERI,
TEHSIL-BAHADURGARH, DISTT-JHAJJAR, HARYANA-124507
CIN: L01122HR1994PLC033029
Tele :- +91-9811341542
Email : genomicvalley@gmail.com
Visit : <http://www.genomicvalley.com>

ATTENDANCE SLIP

PLEASE BRING THIS ATTENDANCE SLIP AND HANDOVER AT THE ENTRANCE OF ANNUAL GENERAL MEETING VENUE AT 4 K.M. STONE, BERRI CHHARRA ROAD P.O. TANDAHERI, TEH. BAHADURGARH, DIST. JHAJJAR, HARYANA-124507.

Name & Address of the Shareholder

.....
.....
.....
.....

SEQUENCE NO. :

FOLIO NO. :

DP ID :

CLIENT ID :

I hereby record my presence at the 26th ANNUAL GENERAL MEETING being held at 4 K.M. Stone, Berri Chharra Road, P.O. Tandaheri, Teh. Bahadurgarh, Distt. Jhajjar, Haryana-124507 on Thursday, the 31st day of December, 2020 at 11.00 A.M.

Signature of Member or Proxy

No. of Shares held

Notes:

1. A member or his duly appointed Proxy wishing to attend the meeting must complete this Attendance Slip and hand it over at the entrance.
2. Name of the Proxy in Block letters..... (in case the Proxy attends the meeting)
1. Those who hold shares in Demat form to quote their Demat Account No. and Depository Participant (D.P.) ID. No.
2. Shareholders/proxy holders desiring to attend the meeting may bring his/her copy of Annual Report for reference at meeting.

Electronic Voting Particulars

Electronic Voting Sequence No. (EVSN)	User ID	Sequence Number
201205021		

Note: Please read the instructions printed in the Notice dated 05th December, 2020 of the Twenty Fifth Annual General Meeting. The voting period starts from Monday, December 28, 2020 at 9.00 a.m. and ends on Wednesday, December 30, 2020 at 5.00 p.m. The voting module shall be disabled by CDSL for voting thereafter.

GENOMIC VALLEY BIOTECH LIMITED
Regd. Off: 4 KM STONE, BERRI CHHARRA ROAD, P.O. TANDAHERI,
TEHSIL-BAHADURGARH, DISTT-JHAJJAR, HARYANA-124507
CIN: L01122HR1994PLC033029
Tele :- +91-9811341542
Email :genomicvalley@gmail.com
Visit :<http://www.genomicvalley.com>

BALLOT FORM (In lieu of E-Voting at the Annual General Meeting)

1	Name of the Sole/First Member	
2	Name(s) of the Joint Member(s), if any	
3	Registered Folio No./DP ID /Client ID	
4	Number of shares held	

I, We hereby exercise my/our vote in respect of the Resolution(s) to be passed through e-voting/ for the business stated in the AGM Notice dated 05th December, 2020 of the Company by conveying my/our assent or dissent to the said Resolution(s) by placing the tick (✓) mark at the appropriate box below:

Item No.	Description	No. of shares held by me	I assent to the resolution	I dissent from the resolution
	Ordinary Business(es)			
1	To receive, consider and adopt the Audited Financial Statements of the Company for the Financial Year ended 31 st March, 2020, the reports of the Board of Directors and Auditors thereon.			
2	To re-appoint Mrs. Parul Agrawal (DIN 01165188) who retires by rotation and eligible offer herself for reappointment.			
	Special Business(es)			
3.	RE-APPOINTMENT OF MR. YOGESH AGRAWAL AS CHAIRMAN AND MANAGING DIRECTOR OF THE COMPANY FOR THE PERIOD OF 5 (FIVE) YEARS WITH EFFECT FROM 07.09.2020			
4.	APPOINTMENT OF MR. SATENDRA KUMAR GOYAL (DIN: 08767544) AS AN INDEPENDENT DIRECTOR OF THE COMPANY			
5.	TO SELL, LEASE, COLLABORATE OR SELF-DEVELOP RESIDENTIALLY AND COMMERCIALY OR OTHERWISE DISPOSE OF THE WHOLE OR SUBSTANTIALLY THE WHOLE OF THE LAND, PROPERTY OR UNDERTAKING(S) OF THE COMPANY ALONG WITH ALL DEVELOPMENT RIGHTS AND ENTIRE FACILITIES AVAILABLE WHATSOEVER AT THE LAND, PROPERTY OR UNDERTAKING(S) OF THE COMPANY AS PER SECTION 180(1)(A) OF THE COMPANIES ACT, 2013			

Place:

Date:

Signature of Member

NOTE: Last date for receipt of forms by the Company is 30th December, 2020.

GENOMIC VALLEY BIOTECH LIMITED
Regd. Off: 4 KM STONE, BERRI CHHARRA ROAD, P.O. TANDAHERI,
TEHSIL-BAHADURGARH, DISTT-JHAJJAR, HARYANA-124507
CIN: L01122HR1994PLC033029
Tele :- +91-9811341542
Email : genomicvalley@gmail.com
Visit : <http://www.genomicvalley.com>

Form No. SH-13
Nomination Form

[Pursuant to Section 72 of the Companies Act, 2013 and rule 19(1) of the Companies (Share Capital and Debentures) Rules 2014]

Name of the Company: Genomic Valley Biotech Limited

Registered Address of the Company: 4 KM STONE, BERRI CHHARRA ROAD, P.O. TANDAHERI, TEHSIL-BAHADURGARH, DISTT-JHAJJAR, HARYANA-124507

I/We _____ the holder(s) of the securities, particulars of which are given hereunder, wish to make nomination and do hereby nominate the following persons in whom shall vest, all the rights in respect of such securities in the event of my/our death.

(1) PARTICULARS OF THESE SECURITIES (in respect of which nomination is being made):

Nature of securities	Folio No.	No. of securities	Certificate No.	Distinctive No.

(2) PARTICULARS OF NOMINEE/S—

- (a) Name:
- (b) Date of Birth:
- (c) Father's/Mother's/Spouse's name:
- (d) Occupation:
- (e) Nationality:
- (f) Address:
- (g) E-mail Id. & Telephone No.:
- (h) Relationship with the security holder(s):

(3) IN CASE NOMINEE IS A MINOR—

- (a) Date of birth:
- (b) Date of attaining majority:
- (c) Name of guardian:
- (d) Address of guardian:

(4) PARTICULARS OF NOMINEE IN CASE MINOR NOMINEE DIES BEFORE ATTAINING AGE OF MAJORITY—

- (a) Name:
- (b) Date of Birth:
- (c) Father's/Mother's/Spouse's name:
- (d) Occupation:

- (e) Nationality:
- (f) Address:
- (g) Email Id. & Telephone No.:
- (h) Relationship with the security holder(s):
- (i) Relationship with the minor nominee:


Name(s) and Address of Security holder(s)


Signature(s)

Name and Address of Witness

Signature

Route Map:



The Symbol  is indicating Registered Office of the Company (4 K.M. Stone, Berri Chharra Road, P.O.Tandaheri, Teh. Bahadurgarh, Dist. Jhajjar, Haryana- 124507) which is nearby Landmark as PDM College of Engineering.

Genomic Valley Biotech Limited



Annual Report

2019-20



॥ विजयी विश्व तिरंगा प्यारा, झण्डा ऊँचा रहे हमारा ॥



The Chairman & Managing Director, Shri Yogesh Agrawal & his daughter Ojaswini Avantika with the then Prime Minister of India Hon'ble Shri Atal Bihari Vajpayee showing him gratitude for suggesting the name of the Company as "Genomic Valley".



PM asks scientists to create genomic valley

Our New Delhi Bureau
NEW DELHI 10 JANUARY



PRIME Minister Atal Bihari Vajpayee today heralded the advent of the 'bioinformatics wave' in India. Ruing the fact that the country caught up with the Silicon Valley phenomenon rather late, he urged the bio-sciences and IT communities in the country to take the lead in creating the new 'Genomic Valley' of the 21st century.

Mr. Vajpayee said bold and unconventional initiatives were needed to seize the big new opportunity arising out of the information generated by the human genomic project. Armed with this 'base' information India could be in the vanguard of a new revolution as it had a vast human genetic diversity that would provide the 'knowledge of variations' required to establish an edge, he pointed out.

Inaugurating the 88th Indian Science Congress in here today, he added that such initiatives

needed huge investments which could not come from budgetary allocation alone and it was necessary to promote public-private partnerships. He, however, expressed concern over the demand and exodus of software professionals which was leading to a lack of enthusiasm for careers in other streams of science. Citing the proposal of a group of US-based entrepreneurs to set up global institutes of science and technology in India, he said the government would facilitate such initiatives.

While the private sector was responding to opportunities in the knowledge sector of late, pressing reforms were needed in the administration and governance to remove bureaucratic control and 'facilitate' science to flourish, he added. Reiterating that his government would hike investments in R&D from the 2 per cent of GDP, he underscored the earmarking of Rs 30 crore for the India Millennium Mission to be executed by the Technology Information, Forecasting and Assessment Council (TIFAC) and an additional Rs 30 crore for the New Millennium Technology Leadership Initiatives by CSIR.



Mandir Parisar of GVBL





GENOMIC VALLEY BIOTECH LIMITED

Company Information

Board of Directors

1. Mr. Yogesh Agrawal
Managing Director
2. Mrs. Parul Agrawal
Non-Executive Director
3. Mr. Satendra Kumar Goyal
Non-Executive Independent Director
4. Mr. Pradeep Gupta
Non-Executive Independent Director

Mr. Lalit Shah

Chief Financial Officer

Kotak Mahindra Bank

State Bank of India

Banker



Net House Cultivation



Poly House Cultivation





Solar Power Plant & Open Field Cultivation





Board Committees

Audit Committee

Mr. Pradeep
Gupta

• Chairman

Mrs. Parul
Agrawal

• Member

Mr. Satendra
Kumar Goyal

• Member

Stakeholder Relationship Committee

Mr. Pradeep
Gupta

• Chairman

Mrs. Parul
Agrawal

• Member

Mr. Satendra
Kumar Goyal

• Member

Nomination and Remuneration Committee

Mr. Pradeep
Gupta

• Chairman

Mrs. Parul
Agrawal

• Member

Mr. Satendra
Kumar Goyal

• Member

Risk Management Committee

Mr. Pradeep
Gupta

• Chairman

Mrs. Parul
Agrawal

• Member

Mr. Satendra
Kumar Goyal

• Member



Plant Tissue Culture Laboratory





In order to widen the company's Future Scope, we have entered into the field of Agricultural Training by signing Agreement with Eden Horticulture Services, Karnal, Haryana as Knowledge Partner.

As former Hon'ble Prime Minister Shri Atal Bihari Vajpayee Ji as well as our current Hon'ble Prime Minister Shri Narendra Modi Ji both looked forward towards a Agriculturally Self Sufficient Nation.

Genomic Valley Biotech Ltd has led the foundation by getting started in Agricultural Training as only through Proper Training the farmers and agri-business entrepreneurs can be empowered to work towards our dream- An Agriculturally Self Sufficient Nation.







The Company Genomic Valley Biotech Ltd is all set to bring in our country the most Modern and Precise Non Spray Pest Control System from Israel. And for this purpose our Managing Director visited Israel and has shortlisted such Companies and is in the process of signing agreement with them and bringing in their products and technologies in India !






Glimpses of Agro-Tech Israel















CONTENTS

Particulars	Page No.
Notice of Annual General Meeting	20-35
Board Report and Management Discussion & Analysis	36-56
Particulars of Employees and Directors	57-58
MGT-9	59-66
Auditor Certificate regarding Compliance of conditions of Corporate Governance	67
Nomination and Remuneration Policy	68-70
Secretarial Audit Report	71-75
Corporate Governance	76-95
Declaration by Managing Director	96
Managing Director & Chief Financial Officer Certification	97
Certificate of Non-Disqualification of Directors	98
Auditors' Report	99-110
Balance Sheet	111
Profit & Loss Account	112
Cash Flow Statement	113
Notes to Accounts	114-121
Proxy Form	122-123
Attendance Slip	124
Ballot Form	125
Nomination Form	126-127
Route Map & Landmark	128
Book Post	129



GENOMIC VALLEY BIOTECH LIMITED
Regd. Off: 4 K.M. STONE, BERRI CHHARRA ROAD, P.O. TANDAHERI,
TEHSIL-BAHADURGARH, DISTT-JHAJJAR, HARYANA-124507
CIN: L01122HR1994PLC033029
Tele: +91-9811341542
Email: genomicvalley@gmail.com
Visit: <http://www.genomicvalley.com>

NOTICE OF ANNUAL GENERAL MEETING

Notice is hereby given that the 26th Annual General Meeting (AGM) of the members of Genomic Valley Biotech Limited will be held on Thursday, 31st day of December, 2020 at 11.00 A.M. at the Registered Office of the Company at 4 K.M. Stone, Berri Chharra Road, P.O. Tandaheri, Teh. Bahadurgarh, Dist. Jhajjar, Haryana-124507 to transact the following businesses:

ORDINARY BUSINESS(ES)

1. To receive, consider and adopt the Standalone Audited Financial Statements of the Company for the Financial Year ended 31st March, 2020, the reports of the Board of Directors and Auditors thereon.
2. To re-appoint Mrs. Parul Agrawal (DIN: 01165188) who retires by rotation and eligible offer herself for re-appointment.

SPECIAL BUSINESS(ES)

TO CONSIDER AND IF THOUGHT FIT TO PASS WITH OR WITHOUT MODIFICATION THE FOLLOWING RESOLUTIONS, WHICH WILL BE PROPOSED AS SPECIAL RESOLUTIONS:

3. **RE-APPOINTMENT OF MR. YOGESH AGRAWAL AS CHAIRMAN AND MANAGING DIRECTOR OF THE COMPANY FOR THE PERIOD OF 5 (FIVE) YEARS WITH EFFECT FROM 07.09.2020**

“RESOLVED THAT on the recommendation of the Nomination and Remuneration Committee & Board of Directors and pursuant to the provision of Sections 196, 197, 198 and 203 read with the Companies (Appointment and Remuneration of Managerial Personnel) Rules 2014, Schedule V and other applicable provisions, if any, of the Companies Act, 2013 and SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 (including any statutory modification(s) or re-enactment(s) thereof, for the time being in force), Mr. Yogesh Agrawal be and is hereby re-appointed as a Chairman and Managing Director of the Company for a period of 5 (Five) consecutive years with effect from 07.09.2020 on such remuneration of and terms & conditions as detailed below:

1. **Term:** 07th September, 2020 to 06th September, 2025
2. **Nature of Duties:** Mr. Yogesh Agrawal shall devote his whole time and attention to the business of the Company and carry out such duties as may be entrusted to him by the Board from time to time and exercise such powers as may be assigned to him, subject to the superintendence, control and directions of the Board in connection with and in the best interests of the business of the Company.



3. **Salary & Perquisites:** Rs. 2,50,000/- per month (Consolidated)
4. **Minimum Remuneration:** The above remuneration shall also be paid as minimum remuneration to Mr. Yogesh Agrawal in the event of absence or inadequacy of profit in any year during his remaining tenure subject to the ceilings specified under the provision of section 197 and Schedule V of the Companies Act, 2013 having regard to the effective capital of the Company.

The appointment and other service terms will be subject to the relevant provision of the Companies Act, 2013 and as amended from time to time. All other terms and conditions of the existing appointment shall be governed by the agreement and Company rules and policies.

RESOLVED FURTHER THAT the Draft Agreement, incorporating the terms of appointment and remuneration placed at the meeting and initiated by the Chairman thereof for the purposes of identification, be and is hereby approved and any Director or Company Secretary, be and are hereby severally authorized to sign the agreement on behalf of the Company.

RESOLVED FURTHER THAT any Director or Company Secretary, be and are hereby severally authorized to do all such acts, deeds, matters and things in this regard and to file the relevant forms, if any with the Ministry of Corporate Affairs (MCA), Registrar of Companies.”

4. APPOINTMENT OF MR. SATENDRA KUMAR GOYAL (DIN: 08767544) AS AN INDEPENDENT DIRECTOR OF THE COMPANY

“RESOLVED THAT pursuant to the provisions of Section 149, 150, 152 read with Schedule IV and other applicable provisions of the Companies Act, 2013 (the Act) and the Companies (Appointment and Qualifications of Directors) Rules, 2014, (including any statutory modification(s) or re-enactment(s) thereof for the time being in force) and Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (‘Listing Regulations’), on the recommendation of the Nomination & Remuneration Committee and approval of the Board of Directors for appointment of Mr. Satendra Kumar Goyal (DIN: 08767544) as an Additional Director in the capacity of an Independent Director of the Company w.e.f. June 30, 2020, who has submitted a declaration that he meets the criteria for independence as provided under Section 149(6) of the Act and Regulation 16(1) (b) of the Listing Regulations and is eligible for appointment, and in respect of whom the Company has received a notice in writing in terms of Section 160(1) of the Act and who holds office as such up to the date of ensuing Annual General Meeting, be and is hereby, appointed as a Non-Executive Independent Director of the Company not liable to retire by rotation, to hold office for a period effective from June 30, 2020 till June 29, 2025.”

5. TO SELL, LEASE, COLLABORATE OR SELF DEVELOP RESIDENTIALLY AND COMMERCIALY OR OTHERWISE DISPOSE OF THE WHOLE OR SUBSTANTIALLY THE WHOLE OF THE LAND, PROPERTY OR UNDERTAKING(S) OF THE COMPANY ALONG WITH ALL DEVELOPMENT RIGHTS AND ENTIRE FACILITIES AVAILABLE WHATSOEVER AT THE LAND, PROPERTY OR UNDERTAKING(S) OF THE COMPANY AS PER SECTION 180(1)(A) OF THE COMPANIES ACT, 2013

“RESOLVED THAT pursuant to provisions of Section 180(1)(a) and other applicable provisions, if any, of the Companies Act, 2013, (“Act”) including any statutory modifications or re-enactment thereof for the time being in



force and rules made thereunder and subject to such other requisite approvals, if any, in this regard from appropriate authorities and terms(s), condition(s), amendment(s), modification(s), as may be required or suggested by any such appropriate authorities, and agreed to by the Board of Directors of the Company (hereinafter referred to as “Board” which term shall include any Committee or one or more Directors) and subject to SEBI (Listing Obligations and Disclosure Requirement) Regulations, 2015 , the consent of the members of the Company be and is hereby accorded to sell, lease, collaborate or self-develop residentially and commercially or otherwise dispose of the whole or substantially the whole of the land, property or undertaking(s) of the Company along with all development rights and entire facilities available whatsoever at the land, property or undertaking(s) on the terms and conditions shall be set out in the sale deed, lease deed, Agreement to sell and lease, collaboration agreement/understanding/deed, agreement/deed/understanding for self-development residentially and commercially and any other deed, agreement, documents or papers related to sell, lease, collaborate or self-develop residentially and commercially or otherwise dispose of the whole or substantially the whole of the land, property or undertaking(s) of the Company along with all development rights and entire facilities available whatsoever at the land, property or undertaking(s).

RESOLVED FURTHER THAT Mr. Yogesh Agrawal, Managing Director and Mrs. Parul Agrawal, Director of the Company, be and are hereby authorized to do all such other act(s), thing(s), and deed(s), as may be required or deemed necessary to give effect to the above resolution.”

**For and on behalf of
Genomic Valley Biotech Limited**

sd/-

**Yogesh Agrawal
Managing Director
DIN-01165288**

**Address: G-74, Pushkar Enclave,
Paschim Vihar, Delhi- 110063**

Date: 05.12.2020

Place: Haryana

NOTES:

1. A MEMBER ENTITLED TO ATTEND AND VOTE AT THE MEETING IS ENTITLED TO APPOINT A PROXY, OR, WHERE THAT IS ALLOWED, ONE OR MORE PROXIES, TO ATTEND AND VOTE INSTEAD OF HIMSELF AND THE PROXY NEED NOT BE A MEMBER.
2. A PERSON CAN ACT AS A PROXY ON BEHALF OF MEMBERS NOT EXCEEDING FIFTY AND HOLDING IN THE AGGREGATE NOT MORE THAN TEN PER CENT OF THE TOTAL SHARE CAPITAL OF THE COMPANY CARRYING VOTING RIGHTS. A MEMBER HOLDING MORE THAN TEN PER CENT OF THE TOTAL SHARE CAPITAL OF THE COMPANY CARRYING VOTING RIGHTS MAY APPOINT A SINGLE PERSON AS PROXY AND SUCH PERSON SHALL NOT ACT AS A PROXY FOR ANY OTHER PERSON OR SHAREHOLDER.
3. THE INSTRUMENT APPOINTING A PROXY MUST BE DEPOSITED WITH THE COMPANY AT ITS REGISTERED OFFICE NOT LESS THAN 48 HOURS BEFORE THE TIME FOR HOLDING THE MEETING.
4. A Proxy Form, Attendance Slip, Ballot Form (in lieu of E-Voting at Annual General Meeting) and Route Map are enclosed with the Notice of Annual General Meeting.
5. Corporate Members intending to send their authorized representatives under Section 113 of the Act are requested to send a duly certified copy of the Board Resolution authorizing their representatives to attend and vote at the meeting, together with duly certified signatures of such representatives.
6. The Company's Registrar and Transfer Agents for its Share Registry Work (Physical and Electronic) is Beetal Financial & Computer Services Private Limited having their office at Beetal House, 99, Madangir, Behind Local Shopping Centre, Near Dada HarsukhDass Mandir, New Delhi-110062.
7. The Securities and Exchange Board of India (SEBI) has mandated the submission of Permanent Account Number (PAN) and Bank details by every participant in securities market. Member(s) holding shares in electronic form are, therefore, requested to submit the PAN to their Depository Participants with whom they are maintaining their demat accounts. Members holding shares in physical form can submit their PAN and Bank details to the RTA.
8. The Register of Members and Share Transfer Books of the Company shall remain closed on the Book Closure Dates, i.e. from December 25, 2020 to December 31, 2020 both days inclusive.
9. Members can avail of the facility of nomination in respect of shares held by them in physical form pursuant to the provisions of section 72 of the Companies Act, 2013 read with Rule 19(1) of the Companies (Share Capital and Debentures) Rules, 2014. Members desiring to avail of this facility may send their nomination in the prescribed Form duly filled in to Beetal Financial & Computer Services Private Limited (RTA) having their office at Beetal House, 99, Madangir, Behind Local Shopping Centre, Near Dada Harsukh Dass Mandir, New Delhi-110062.

10. Members are requested to:
 - a. Intimate to the Company's Registrar and Transfer Agents, Beetal Financial & Computer Services Private Limited having their office at Beetal House, 99, Madangir, Behind Local Shopping Centre, Near Dada Harsukh Dass Mandir, New Delhi-110062, changes, if any, in their registered addresses/bank mandates at an early date, in case of shares held in physical form;
 - b. Intimate to the respective Depository Participant, changes, if any, in their registered addresses/bank mandates at an early date, in case of shares held in electronic/dematerialised form;
 - c. Quote their folio numbers/Client ID and DP ID in all correspondence;
 - d. Consolidate their holdings into one folio in case they hold shares under multiple folios in the identical order of names.
11. Pursuant to sections 101 and 136 of the Companies Act, 2013, read with the Rules framed thereunder and pursuant to the Circulars issued by the Ministry of Corporate Affairs (MCA) regarding the Green Initiative, the Notice of the 26th Annual General Meeting (AGM) and the Annual Report for the year 2019-20, etc., would be sent in electronic mode to such of the Members of the Company whose e-mail addresses are available with the Company/ Depository Participant and who have not opted to receive the same in physical form.
12. For Members who have not registered their e-mail addresses, physical copies of the Annual Report for the year 2019-20 and the Notice of the 26th AGM would be sent in the permitted mode.
13. Members are requested to support the Green Initiative by registering / updating their e-mail addresses, with the Depository Participant (in case of Shares held in dematerialised form) or with Beetal Financial & Computer Services Private Limited having their office at Beetal House, 99, Madangir, Behind Local Shopping Centre, Near Dada HarsukhDass Mandir, New Delhi-110062. **(In case of Shares held in physical form)**
14. Members may also note that the Notice of the 26th Annual General Meeting and the Annual Report for financial year 2019-20 will also be available on the Company's website at [www.http://genomicvalley.com/investorrelationpage.htm](http://genomicvalley.com/investorrelationpage.htm) and also on the website of the RTA, Beetal Financial & Computer Services Private Limited at <http://beetalfinancial.com> . Even after registering for e-communication, Members are entitled to receive such communication in physical form, upon making a request to the Company for the same. For any communication, the shareholders may also send requests to the Company's Email ID : genomicvalley@gmail.com



15. Relevant documents referred to in the accompanying Notice shall be open for inspection at the Registered Office of the Company during normal business hours on all working days except Sunday from 10.00 A.M. to 6.00 P.M., up to and including the date of the Annual General Meeting of the Company.
16. The Register of Directors and Key Managerial Personnel and their Shareholding maintained under Section 170 of the Companies Act, 2013, the Register of Contracts or arrangements in which Directors are interested under Section 189 of Companies Act, 2013 will be available for inspection at the Annual General Meeting.
17. Appointment of Director and Shareholding in the Company:

Mrs. Parul Agrawal holds 283700 Equity Shares of Rs.10 each fully paid up in the Company. Brief resume, details of shareholdings, and director inter-se relationship of the director seeking reappointment as required is provided as Annexure 1 to this notice.
18. Members/Proxies/Representatives are requested to bring their Attendance Slip along with their copy of Annual Report to the Meeting.

Only bonafide members of the Company whose names appear on the Register of Members/Proxy holders, in possession of valid attendance slips duly filled and signed will be permitted to attend the meeting. The Company reserves its right to take all steps as may be deemed necessary to restrict non-members from attending the meeting.
19. Members are requested to bring their copies of Annual Report to the Meeting. In order to enable us to register your attendance at the venue of the Annual General Meeting, members are requested to please bring their folio number/ demat account number/DP ID-Client ID to enable us to provide a duly filled attendance slip for your signature and participation at the meeting.
20. In case of joint holders attending the meeting, only such joint holder who is higher in the order of names will be entitled to vote.
21. **E-voting:**
In compliance with the provisions of Section 108 of the Companies Act, 2013 and Rule 20 of the Companies (Management and Administrations) Rules, 2014, the Company is pleased to provide to Members with a facility to exercise their right to vote at the 26th Annual General Meeting by electronic means and the business may be transacted through Electronic Voting (e-voting) services provided by Central Depository Services Limited (CDSL).



The Company has appointed Mr. Rohit Batham, Practicing Company Secretary, New Delhi as the Scrutinizer for conducting the e-voting process in a fair and transparent manner. E-voting is optional. The E-voting rights of the shareholders/beneficiary owners shall be reckoned on the equity shares held by them as on 24th December, 2020 being the Cut-off date for the purpose. Shareholders of the Company holding shares either in physical or in dematerialized form, as on the Cut-off date, may cast their vote electronically.

In order to enable its members, who do not have access to e-voting facility, to send their assent or dissent in writing in respect of the resolutions as set out in this Notice, a ballot paper is annexed. A member desiring to exercise vote by ballot paper shall complete the enclosed ballot paper with assent (for) or dissent (against) and send it to Registered office of the Company so as to reach us on or before 30th December, 2020 by 5.00 P.M. Any ballot paper received after the said date and time shall be treated as if the reply from the Members has not been received. Kindly note that member can opt only one mode of voting i.e., either by ballot paper or through e-voting. If members are opting for e-voting then do not vote by ballot paper or vice versa. However, in case of Members casting their vote both by ballot paper and e-voting, then voting done through e-voting shall prevail and voting done by Physical Ballot will be treated as invalid.

22. Instruction for E-Voting:

- 22.1 Members whose shareholding is in the dematerialised form and whose e-mail addresses are registered with the Company / Depository Participants will receive an e-mail informing User ID and Password.
- a. The e-voting period begins on December 28, 2020 at 9.00 a.m. and ends on December 30, 2020 at 5.00 p.m. During this period shareholders' of the Company, holding shares either in physical form or in dematerialized form, as on the cut-off date (record date) of December 24, 2020, may cast their vote electronically. The e-voting module shall be disabled by CDSL for voting thereafter.
 - b. Shareholders who have already voted prior to the meeting date would not be entitled to vote at the meeting venue.
 - c. The shareholders should log on to the e-voting website www.evotingindia.com.
 - d. Click on the link "Shareholders" module.
 - e. Now Enter your User ID
 - i. For CDSL: 16 digits beneficiary ID,
 - ii. For NSDL: 8 Character DP ID followed by 8 Digits Client ID,



- iii. Members holding shares in Physical Form should enter Folio Number registered with the Company.

OR

Alternatively, if you are registered for CDSL’s EASI/EASIEST e-services, you can log-in at <https://www.cdslindia.com> from [Login - Myeasi](#) using your login credentials. Once you successfully log-in to CDSL’s EASI/EASIEST e-services, click on e-Voting option and proceed directly to cast your vote electronically.

- f. Next enter the Image Verification as displayed and Click on Login.
- g. If you are holding shares in demat form and had logged on to www.evotingindia.com and voted on an earlier voting of any company, then your existing password is to be used.
- h. If you are a first time user follow the steps given below:

	For Members holding shares in Demat Form and Physical Form
PAN	<p>Enter your 10 digit alpha-numeric *PAN issued by Income Tax Department (Applicable for both demat shareholders as well as physical shareholders)</p> <ul style="list-style-type: none"> • Shareholders who have not updated their PAN with the Company/Depository Participant are requested to use the sequence number sent by Company/RTA or contact Company/RTA.
Dividend Bank Details OR Date of Birth (DOB)	<p>Enter the Dividend Bank Details or Date of Birth (in dd/mm/yyyy format) as recorded in your demat account or in the company records in order to login.</p> <ul style="list-style-type: none"> • If both the details are not recorded with the depository or company please enter the member id / folio number in the Dividend Bank details field as mentioned in instruction (e).

- i. After entering these details appropriately, click on “SUBMIT” tab.
- j. Members holding shares in physical form will then directly reach the Company selection screen. However, members holding shares in demat form will now reach ‘Password Creation’ menu wherein they are required to mandatorily enter their login password in the new password field. Kindly note that this password is to be also used by the demat holders for voting for resolutions of any other company on which they are eligible to vote, provided that company opts for e-voting through CDSL platform. It is strongly recommended not to share your password with any other person and take utmost care to keep your password confidential.



- k. For Members holding shares in physical form, the details can be used only for e-voting on the resolutions contained in this Notice.
- l. Click on the EVSN for the relevant GENOMIC VALLEY BIOTECH LIMITED on which you choose to vote.
- m. On the voting page, you will see “RESOLUTION DESCRIPTION” and against the same the option “YES/NO” for voting. Select the option YES or NO as desired. The option YES implies that you assent to the Resolution and option NO implies that you dissent to the Resolution.
- n. Click on the “RESOLUTIONS FILE LINK” if you wish to view the entire Resolution details.
- o. After selecting the resolution you have decided to vote on, click on “SUBMIT”. A confirmation box will be displayed. If you wish to confirm your vote, click on “OK”, else to change your vote, click on “CANCEL” and accordingly modify your vote.
- p. Once you “CONFIRM” your vote on the resolution, you will not be allowed to modify your vote.
- q. You can also take out print of the voting done by you by clicking on “Click here to print” option on the Voting page.
- r. If Demat account holder has forgotten the login password then enter the User ID and the image verification code and click on Forgot Password & enter the details as prompted by the system.
- s. **Shareholders can also cast their vote using CDSL’s mobile app m-Voting available for android based mobiles. The m-Voting app can be downloaded from Google Play Store. Apple and Windows phone users can download the app from the App Store and the Windows Phone Store respectively. Please follow the instructions as prompted by the mobile app while voting on your mobile.**
- t. **Note for Non – Individual Shareholders and Custodians – Remote Voting**
 - Non-Individual shareholders (i.e. other than Individuals, HUF, NRI etc.) and Custodian are required to log on to www.evotingindia.com and register themselves in the “Corporates” module.



- A scanned copy of the Registration Form bearing the stamp and sign of the entity should be emailed to helpdesk.evoting@cdslindia.com.
 - After receiving the login details by custodian a Compliance User should be created using the admin login and password. The Compliance User would be able to link the account(s) for which they wish to vote on.
 - The list of accounts linked in the login should be mailed to helpdesk.evoting@cdslindia.com and on approval of the accounts they would be able to cast their vote.
 - A scanned copy of the Board Resolution and Power of Attorney (POA) which they have issued in favour of the Custodian, if any, should be uploaded in PDF format in the system for the scrutinizer to verify the same.
 - Alternatively Non Individual shareholders are required to send the relevant Board Resolution/ Authority letter etc. together with attested specimen signature of the duly authorized signatory who are authorized to vote, to the Scrutinizer and to the Company at the email address viz; genomicvalley@gmail.com (designated email address by company) , if they have voted from individual tab & not uploaded same in the CDSL e-voting system for the scrutinizer to verify the same.
- u. Any person, who acquires shares of the Company and become Member of the Company after dispatch of the Notice and holding shares as on the cut-off date i.e. Thursday 24th December, 2020 may follow the same instructions as mentioned above for e-Voting.
- v. In case you have any queries or issues regarding e-voting, you may refer the Frequently Asked Questions (“FAQs”) and e-voting manual available at www.evotingindia.com, under help section or write an email to helpdesk.evoting@cdslindia.com or contact Mr. Nitin Kunder (022- 23058738) or Mr. Mehboob Lakhani (022-23058543) or Mr. Rakesh Dalvi (022-23058542).

All grievances connected with the facility for voting by electronic means may be addressed to Mr. Rakesh Dalvi, Manager, (CDSL,) Central Depository Services (India) Limited, A-Wing, 25th Floor, Marathon Futurex, Mafatlal Mill Compounds, NM Joshi Marg, Lower Parel (East), Mumbai-400013, or send an email to helpdesk.evoting@cdslindia.com or call on 022-23058542/43.

- 22.2 In case a Member receives physical copy of the Annual General Meeting Notice by post (for members whose email Ids are not registered with the Company/Depository Participant(s)):
- a. User ID and initial password are provided overleaf.
 - b. Please follow all steps from Note 22.1 above to cast your vote.



- 22.3 Once the vote on a resolution is cast by a Member, the Member shall not be allowed to change it subsequently or cast the vote again.
- 22.4 In case of any queries, you may refer to the Frequently Asked Questions (FAQs) for Members and e-voting user manual for Members available at the 'downloads' section of www.evoting.india.com.
- 22.5 The facility for ballot / polling paper shall be made available at the Annual General Meeting (AGM) and the members attending AGM who have not cast their vote by e-voting/ ballot paper shall be able to vote at the AGM through ballot / polling paper.
- 22.6 The members who have cast their vote by e-voting may also attend AGM, but shall not be entitled to cast their vote again.
- 22.7 The voting rights of the Members for e-voting shall be in proportion to the paid up value of their shares in the equity share capital of the Company as on the cut-off date i.e. 24th December, 2020.
- 22.8 Persons, whose names are recorded in the register of members or in the register of beneficial owners maintained by the depositories as on the cut-off date i.e. 24th December, 2020 only shall be entitled to avail the facility of e-voting / physical voting.
- 22.9 The poll process shall be conducted and a report thereon shall be prepared in accordance with Section 109 of the Companies Act, 2013 read with the relevant rules made there under. In such an event, votes cast under Poll taken together with the votes cast through remote e-voting shall be counted for the purpose of passing of resolution(s).

The Scrutinizer shall immediately after the conclusion of voting at the AGM, count the votes cast at the AGM and thereafter unblock the votes cast through remote e-voting in the presence of at least two (2) witnesses not in the employment of the Company. The Scrutinizer shall submit a consolidated Scrutinizers Report of the total votes cast in favour of or against, if any, not later than two (3) days after the conclusion of the AGM to the Chairman of the Company.

The Chairman or any other director authorized by him, shall declare the result if the voting forthwith.

23. The results on resolutions shall be declared forthwith after getting the report of Scrutinizer and the resolutions will be deemed to be passed on the date of Annual General Meeting subject to receipt of the requisite number of votes in favour of the resolutions.



24. The Results declared along with the Consolidated Scrutinizer's Report(s) will be available on the website of the Company (www.genomicvalley.com) and on website of CDSL. The results shall simultaneously be communicated to Stock Exchanges.
25. Members desiring any information relating to the accounts are requested to write to the Company well in advance so as to enable the management to keep the information ready.

**For and on behalf of
Genomic Valley Biotech Limited**

**sd/-
Yogesh Agrawal
Managing Director
DIN-01165288**

**Date: 05.12.2020
Place: Haryana**

**Address: G-74, Pushkar Enclave,
Paschim Vihar, Delhi- 110063**

**EXPLANATORY STATEMENT PURSUANT TO SECTION 102(1) OF THE COMPANIES ACT, 2013
("THE ACT")**

**THE FOLLOWING STATEMENT SETS OUT ALL MATERIAL FACTS RELATING TO THE SPECIAL
BUSINESS MENTIONED IN THE NOTICE:**

ITEM NO. 3

The Board of Directors of the Company ("the Board") at its meeting held on September 05, 2020 has, subject to approval of members, re-appointed Mr. Yogesh Agrawal as a Chairman and Managing Director of the Company, for a period of 5 (Five) years with effect from September 07, 2020, on terms and conditions including remuneration as recommended by the Nomination and Remuneration Committee (the 'NR Committee') of the Board and approved by the Board. It is proposed to seek members' approval for the appointment of and remuneration payable to Mr. Yogesh Agrawal as a Chairman and Managing Director of the Company, in terms of the applicable provisions of the Act. Broad particulars of the terms of re-appointment of and remuneration payable to Mr. Yogesh Agrawal are as under:

1. **Term:** 07th September 2020 to 06th September 2025.
2. **Nature of Duties:** Mr. Yogesh Agrawal shall devote his whole time and attention to the business of the Company and carry out such duties as may be entrusted to him by the Board from time to time and exercise such powers as may be assigned to him, subject to the superintendence, control and directions of the Board in connection with and in the best interests of the business of the Company.
3. **Salary & Perquisites:** Rs. 2,50,000/- per month (Consolidated)
4. **Minimum Remuneration:** The above remuneration shall also be paid as minimum remuneration to Mr. Yogesh Agrawal in the event of absence or inadequacy of profit in any year during his remaining tenure subject to the ceilings specified under the provision of section 197 and Schedule V of the Companies Act, 2013 having regard to the effective capital of the Company.

Mr. Yogesh Agrawal has rich and varied experience in the industry and has been involved in the operations of the Company. It would be in the interest of the Company to continue to avail of his considerable expertise and to re-appoint Mr. Yogesh Agrawal as a Chairman and Managing Director. Accordingly, approval of the members is sought for passing a Special Resolution for appointment of Mr. Yogesh Agrawal as a Chairman and Managing Director, as set out in Part-I of Schedule V to the Act as also under sub-section (3) of Section 196 of the Act.

Save and except as provided in the foregoing paragraph, Mr. Yogesh Agrawal satisfies all the other conditions set out in Part-I of Schedule V to the Act as also conditions set out under sub-section (3) of Section 196 of the Act for being eligible for his appointment. He is not disqualified from being appointed as Director in terms of Section 164 of the Act.

The above may be treated as a written memorandum setting out the terms of appointment of Mr. Yogesh Agrawal under Section 190 of the Act.

Details of Mr. Yogesh Agrawal are provided in Annexure-1 to the Notice pursuant to the provisions of (i) the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 and (ii) Secretarial Standard on General Meetings (“SS-2”), issued by the Institute of Company Secretaries of India.

Mr. Yogesh Agrawal is interested in the resolution set out at Item No. 3 of the Notice.

The relatives of Mr. Yogesh Agrawal may be deemed to be interested in the resolution set out at Item No. 3 of the Notice, to the extent of their shareholding interest, if any, in the Company.

Save and except the above, none of the other Directors / Key Managerial Personnel of the Company / their relatives are, in any way, concerned or interested, financially or otherwise, in the aforementioned resolution.

The Board recommends the Special Resolution set out at Item No. 3 of the Notice for approval by the members.

ITEM NO. 4

Based on the recommendation of the Nomination & Remuneration Committee, the Board of Directors of the Company have appointed Mr. Satendra Kumar Goyal as an Additional Director in the capacity of Non-Executive Independent Director of the Company to hold office for a period from June 30, 2020 to June 29, 2025, not liable to retire by rotation, subject to consent of the Members of the Company at the ensuing AGM. As an Additional Director, Mr. Satendra Kumar Goyal holds office till the date of the AGM and is eligible for being appointed as an Independent Director. The Company has received necessary declaration(s) from Mr. Satendra Kumar Goyal confirming that he meets the criteria as prescribed under the Companies Act, 2013 (the Act) and SEBI (Listing Obligations and Disclosure requirements) Regulations, 2015 (Listing Regulations). Mr. Satendra Kumar Goyal is not disqualified from being appointed as a Director under provisions of Section 164 of the Companies Act, 2013, nor debarred from holding the office of director by virtue of any SEBI order or any other such authority and has given his consent to act as a Director of the Company. Mr. Satendra Kumar Goyal fulfils the conditions for his appointment as an Independent Director as specified in the Act and Listing Regulations and is independent of the management. Your Board believes that Mr. Satendra Kumar Goyal induction on the Board will support in broadening the overall expertise of the Board. A copy of the appointment letter, setting out his terms and conditions of appointment is available on the website of the Company at www.genomicvalley.com and will be available for inspection, without any fees, by the Members at the Company’s registered office during normal hours on working days upto the date of AGM and also at the Meeting. Save and except Mr. Satendra Kumar Goyal and his relatives, to the extent of their shareholding interest, if any, in the Company, none of the Directors/ Key Managerial Personnel and their relatives are in any way, interested or concerned, financially or otherwise in the Resolution set out at Item No. 4. The Board of Directors accordingly recommends the Ordinary Resolution set out at Item No. 4 of the Notice for the approval of the Members.

ITEM NO. 5

Members of the Company are requested to note that Section 180 (1)(a) of the Companies Act, 2013 mandates that the Board of Directors of a company shall exercise the power to sell, lease, collaborate or self-develop residentially and commercially or otherwise dispose of the whole or substantially the whole of any undertaking(s) of the company, only with the approval of the members of the Company by way of a special resolution. Explanation (i) to Section 180(1) (a) of the Companies Act, 2013 states that the meaning of an ‘undertaking’ for the purposes of Section



180(1) of the Companies Act, 2013 is an undertaking in which the investment of the company exceeds twenty per cent. of its net worth as per the audited balance sheet of the preceding financial year or an undertaking which generates twenty per cent. of the total income of the company during the previous financial year. Explanation (ii) to Section 180 (1)(a) of the Companies Act, 2013 states that the meaning of 'substantially the whole of the undertaking' for the purposes of Section 180(1) is in any financial year, twenty percent or more of the value of the undertaking as per the audited balance sheet of the preceding financial year. Accordingly, pursuant to Section 180(1)(a) of the Companies Act, 2013, members of the Company are further requested to note that their consent to the Board is being sought by way of a Special Resolution to sell, lease, collaborate or self-develop residentially and commercially or otherwise dispose of the whole or substantially the whole of the land, property or undertaking(s) of the Company along with all development rights and entire facilities available whatsoever at the land, property or undertaking(s) on the terms and conditions shall be set out in the sale deed, lease deed, Agreement to sell and lease, collaboration agreement/understanding/deed, agreement/deed/understanding for self-development residentially and commercially and any other deed, agreement, documents or papers related to sell, lease, collaborate or self-develop residentially and commercially or otherwise dispose of the whole or substantially the whole of the land, property or undertaking(s) of the Company along with all development rights and entire facilities available whatsoever at the land, property or undertaking(s) of the Company. The Directors commend the passing of the resolution under item No.5 of the accompanying Notice for the approval of the members of the company. None of the Directors of the company or their relatives are concerned or interested in the passing of the above resolution.

**For and on behalf of
Genomic Valley Biotech Limited**

sd/-

**Yogesh Agrawal
Managing Director
DIN-01165288**

**Date: 05.12.2020
Place: Haryana**

**Address: G-74, Pushkar Enclave,
Paschim Vihar, Delhi- 110063**

**Annexure 1 to Notice of Annual General Meeting
PROFILE OF DIRECTORS SEEKING APPOINTMENT**

Name of Director	Mr. Satendra Kumar Goyal	Mr. Yogesh Agrawal
Age	59 Years	57 Years
Qualification	B.Com from University of Delhi	B.Com (H)
Experience (including expertise in specific functional area) / Brief Resume	36 years' work experience in Marketing-Industrial & Consumer, Human Resources administration, Corporate Law and General Management	<p>He is having wide experience in business activities right from the beginning of his career. He successfully operated several Private Limited and Public Limited Companies during his 30 years of exposure.</p> <p>Under his able and experienced guidance and direction M/s Genomic Valley Biotech Limited is progressing well in leaps and bound.</p> <p>He is one of the promoters of the Company.</p>
Terms and Conditions of Appointment / Re-appointment	As per Agreement	As per Agreement
Remuneration last drawn as director (including sitting fees, if any) (in Rs.)	NIL	1,50,000
Remuneration proposed to be paid	NIL	As per Agreement
Date of first appointment on the Board	-	07.09.2015
Shareholding in the Company as on March 31, 2020	NIL	17,86,750 Shares
Relationship with other Directors / Key Managerial Personnel	NIL	Husband of Mrs. Parul Agrawal, Director of the Company
Number of meetings of the Board attended during the year (as director)	NIL	5
Directorships of other Boards as on March 31, 2020	NIL	Eyoge Technologies Private Limited
Membership / Chairmanship of Committees of other Boards as on March 31, 2020	NIL	Nil

**BOARD REPORT
AND
MANAGEMENT DISCUSSION AND ANALYSIS**

To,
The Members,

Your Directors have pleasure in presenting their 26th Board Report on the business and operations of the Company along with Audited Financial Statements for the Financial Year ended March 31, 2020.

FINANCIAL RESULTS

The company performance for the financial year ended on March 31st, 2020 is summarized below:

Particulars	In Rs.	
	2019-20	2018-19
Revenue from Operations	84,65,629.00	98,50,101.00
Other Income	1,40,869.00	1,47,952.00
Total Revenue	86,06,499.00	99,98,052.00
Total Expenses	65,49,188.00	76,51,003.00
Profit before Exceptional Items and Tax	20,57,310.00	23,47,049.00
Exceptional Item	0.00	0.00
Profit before Tax	20,57,310.00	23,47,049.00
Tax Expenses	(8,02,616.00)	22,083.00
Profit After Tax for the year	28,59,927.00	23,24,966.00
Paid up Capital (in No. of shares @ Rs. 10 each share)	30,54,500	30,54,500

RESULTS OF OPERATIONS AND THE STATE OF COMPANY'S AFFAIRS

During the Financial Year ended 2020 under review, the Company has earned the profit of Rs. 28,59,927/- against the profit of Rs. 23,24,966/- in the previous Financial Year ended 2019.

In the Financial Year 2019-2020, the company is witnessing sustained commercial production from its Plant Tissue Culture Lab, 2 x 1500 sq. metre Naturally Ventilated Poly House, 2 x 1080 Hi-Tech Poly Houses and a Net House of 500 sq. metres & 1500 sq. metres.

The Company is extensively involved in Commercial Greenhouse/Poly House Cultivation of crops over the year and market the produce profitably. It keeps on changing the crop mix from time to time to meet the seasonal and market demand. Also it is involved in commercial Horticulture activities with Aloe vera, Tomato, Bitter Gourd, Bottle Gourd, Brinjal, Broccoli, Cabbage, Capsicum, Carrot, Cauliflower, Cucumber, Green Chillies, Onion, Radish, Ridge/Sponge Gourd, Leafy Vegetables, Pumpkin, Banana, Guava, Papaya, and Strawberry.

PRESENT AND FUTURE PROSPECTIVES:

PRESENT ACTIVITIES

1. High-Tech Cultivation through Environment Controlled Poly Houses, NFT & DFT etc.

2. Production of Tissue Cultured Improved Varieties of Plants.
3. Organic Farming --- Open Field Cultivation using Bio-Fertilizer.

FUTURE ACTIVITIES

As you all know Honourable Prime Minister Shri Narendra Modi had explicitly stated in his election campaign that farmers would be the priority and the government would ensure they got 50% returns over their total costs. Keeping this in mind your company has started implementing measures to provide all round support to ensure a minimum return and also increase their production and earning multi-fold.

The buzz word in today's agricultural sector is "Farmers Producer Company". Producer companies can help smallholder farmers participate in emerging high-value markets, such as the export market and the unfolding modern retail sector in India. As elsewhere in the developing world, in India, small farmers' livelihoods are being threatened due to the liberalization and privatization of Indian agriculture and the increasing interest of private capital in the agribusiness sector. The withdrawal of the state from productive and economic functions, and changes in the organization of marketing channels, present new challenges for small-scale farmers. In this environment of greater instability and competition, organization and collective action can help to enhance farmers' competitiveness and increase their advantage in emerging market opportunities. We build on the ideas of value-chain governance and collective-action literature and introduce the functions and organizational structure of producer companies in India within this context.

Thus by collecting around 300 small farmers on a single corporate platform your company has formed a "Farmers Producer Company". This model will ensure at least a minimum profit to the farmers and also in the process your company will also earn handsomely.

Thus your company is involved in the following profit making activities and planning for the future progress of your company:

1. Formation of a Farmer Producer Company
2. Has set up a Farmers Training Centre at the company's site and is imparting training to the farmers and agri-entrepreneurs
3. Poly House Construction is going on contractual basis for the clients
4. Contracted Poly House controlled environment and open field cultivation.
5. Agri - Farming Consultancy.
6. Company has already started Farm to Door Step Services for supply of fruits & vegetables.
7. Bringing of Drone Technology.
8. Horticulture without spray, GVBL is all set to bring the most Modern Pest Management Technique from Israel.

FARMER PRODUCER COMPANY

The company has identified a cluster of 300 marginal farmers eligible to form a Farmers Producer Company. The company is in the process to do all the documentations for getting started with the operation of the Producer Company

TRAINING CENTRE

The company has already started imparting training to farmers and agri-entrepreneurs profitably. Response is brisk and is escalating day by day with more and more recognition of the setup and services.

Governmental supports, loans and grants thus fulfilling our years long dream of self sufficient farmers.

Separate courses have been designed for Training like the Ladies to develop kitchen gardens or small farms which can fetch them profits by growing fruits and vegetables. This will be exclusively for ladies and housewives within reasonable course fees. All these courses will also have empowerment facilities and support as mentioned above if some lady wants to do some agricultural activities in a bigger way!

POLYHOUSE CONSTRUCTION

As the company is having a fully functional team of technical persons for setting up and erection of poly-houses and greenhouses, the company is all set to capture orders of its clients for setting up of their poly-houses / greenhouses.

Through effective marketing the company has bagged a few orders of setting up of poly-houses in the nearby areas in the vicinity of its project site

CONTRACTED POLY-HOUSE CONTROLLED ENVIRONMENT AND OPEN FIELD CULTIVATION

With its expert team of agriculturists and technical personnel, the company is taking up Turn Key cultivation projects of its clients on clients land with assured buy back and marketing assurance. In this scope the company is taking up all responsibilities of preparing of the land of the client, then setting up of Environmentally Controlled Poly-houses, deciding of suitable product mix for the cultivation. And finally when production of vegetables comes, the company shoulders all responsibilities to sell the produce in the market to pay the assured amount to the client.

A few projects with the above scope, negotiations are on.

AGRI FARMING CONSULTANCY

With the expert team of agriculturists and other technical people, the company is also providing Agri Farming Consultancy to farmers and other clients on case to case basis. This way company is providing solutions to problems being faced by the HNI clients in agri-farming business as per their specific needs.

FARM 2 DOOR STEP SERVICES

The company intends to develop full packaging system and logistics to deliver fruits and vegetable direct to homes in NCR as per their daily demands and orders. The company is also working on to make an online portal and also create mobile app to reach the masses and thus gathering increase orders and reach more and more households. Thus, eliminating need of middle men will reduce the cost and enhance the quality of fruits and vegetables.

DRONE TECHNOLOGY

Drones are one of the fastest growing technology segments with the potential to provide extraordinary value to the agriculture business.

Imagine a flying robot that you could easily control as an extension of your own eyes and arms - to reach places, see things you can never see and execute tasks that would otherwise be impossible or not affordable.

Drones are remote controlled flying objects having capability to collect different data regarding any agricultural field, any vegetation such that optimal treatments can be given to the soil and crops to increase yields many fold with minimum expenditure.

GVBL is all set to bring in this technology from Israel to be implemented in Indian Agriculture successfully. In this regard the Company is having active talk with a well known Agricultural Drone Technology Company from Israel.

MODERN PEST CONTROL SYSTEM

In assistance with a reputed Israel Company, GVBL is also bringing the most modern technology for controlling and management of oriental fruit flies. The technology allows the use of lure based pesticides. Also the fluid is long lasting, free of spraying and maintenance. It is harmless to human, environment and non targeted organisms.

This pin pointed pesticide management is achieved through new technologies viz (1) Gravity Controlled Fluid Release (GCFR) technology, (2) a scent-specific, targeting only female pest, and (3) characteristics customized for each implementation.

GVBL has started processing for bringing in this technology also in India !

DIVIDEND

Your Director has not recommended a dividend for the financial year because company is having less profit in the financial year 2019-20. The company expects growth in coming years.

RESERVES

The company is having less profit in financial year 2019-20. Therefore, no amount was transferred into reserve account.

MATERIAL CHANGES AND COMMITMENTS

There are no material changes and commitments effecting the financial position of the company which have occurred during the financial year 2019-20 of the company to which the financial statement relates to the date of this report.

NUMBER OF MEETINGS OF THE BOARD

Five (5) meetings of the Board of Directors of the Company were held during the year. For details of the meetings, please refer to the Corporate Governance Report, which forms part of the Annual Report.

DIRECTORS' RESPONSIBILITY STATEMENT

Pursuant to the requirement of Section 134(5) of the Act, and based on the representations received from the management, the directors hereby confirm that:

- (a) In the preparation of the annual accounts for the year ended March 31, 2020, the applicable accounting standards read with requirements set out under Schedule III to the Act, have been followed and there are no material departures from the same;
- (b) we have selected such accounting policies and applied them consistently and made judgements and estimates that are reasonable and prudent so as to give a true and fair view of the state of affairs of the Company as at March 31, 2020 and of the profit of the Company for the year ended on that date;
- (c) we have taken proper and sufficient care for the maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Company and for preventing and detecting fraud and other irregularities;
- (d) we have prepared the annual accounts on a going concern' basis;
- (e) we have laid down internal financial controls to be followed by the Company and that such internal financial controls are adequate and are operating effectively; and

- (f) we have devised proper systems to ensure compliance with the provisions of all applicable laws and that such systems are adequate and operating effectively.

MANAGEMENT'S DISCUSSION AND ANALYSIS

To avoid duplication between the Board Report and the Management Discussion and Analysis, we present below a composite summary of performance of the various businesses and functions of the Company.

Present Status

We are feeling good to inform you about the following developments in the Company:

Recently, the Land Asset of the company has been included in Residential Zone and coming under Sector 42, Bahadurgarh, Haryana. This land is strategically placed - it is on state high way and just 1 km from National Highway, just 6 km from Delhi border. And metro station is just 5 minutes away. Thus price of the land is on an upward movement. Hence your Company asset value is also increasing.

Hence your Company is thinking seriously to develop the land under a residential project.

To facilitate our residential development project your Company is planning to shift its current operations elsewhere. Even after the Covid-19 onslaught we have survived and going ahead as per our plan.

Economy and Markets

India's agriculture sector is likely to grow at 2.1 per cent in 2019-20, followed by Industry (4.4 per cent) and services (8.3 per cent), according to the Economic Survey 2020-21.

Credit from institutional sources will complement all such government initiatives like Soil Health Card, Input Management, Per Drop More Crop in Pradhan Mantri Krishi SinchaiYojana (PMKSY), PMFBY, e-Nam, etc, the survey said.

Indian farmers are adapting to farm mechanisation at a faster rate in comparison to recent past. The Economic Survey further added sale of tractors to a great extent reflects the level of mechanisation.

According to the World Bank estimates, half of the Indian population would be urban by the year 2050. It is estimated that percentage of agricultural workers in total work force would drop to 25.7 per cent by 2050 from 58.2 per cent in 2001. Thus, there is a need to enhance the level of farm mechanisation in the country.

India is expected to be self-sufficient in pulses in the coming few years due to concerted efforts of scientists to get early-maturing varieties of pulses and the increase in minimum support price.

Industry Structure and Development

As you all know Honourable Prime Minister Shri Narendra Modi had explicitly stated in his election campaign that farmers would be the priority and the government would ensure they got 50% returns over their total costs. Keeping this in mind your company has started implementing measures to provide all round support to ensure a minimum return and also increase their production and earning multi-fold.

Your company has started commercial activities to generate earning for the company as well as generating earning for all marginal and other progressive farmers and also simultaneously generating employments for the agriculturists and scientists. We are active in the following fields of operation:

- A. Setting up of Agricultural Training Centre by the name of GVBL Institute of High-Tech Agriculture & Biotechnology.



- B. Setting up of Centre of Excellence for Horticulture --- With the technical expertise and experience of Eden Horticultural Services, Karnal (Haryana) through expert control of the agricultural activities of Eden's Technical Team. The agreement in this regard has also been signed.
- C. Bringing of Drone Technology.
- D. Horticulture without spray, GVBL is all set to bring the most Modern Pest Management Technique from Israel.
- E. Poly House Construction
- F. Contracted Poly House controlled environment and open field cultivation.
- G. Agri - Farming Consultancy.
- H. Farm 2 Door Step Services for supply of fruits & vegetables through its website farm2doorstep.com.
- I. Agri Skill Development Centre
- J. Agri Input Shop for High-Tech Cultivation (Khad Beej Bhandar)

A. TRAINING CENTRE :

With full gusto, GVBL has already started its effort to do networking with various colleges to bring the batches of students for its training centre. And now it is a matter of time to get started with the training centre.

As per the planning all the courses which are being offered by the Institute will be having Job Guarantee and/or empowerment of the students for setting up their own farm houses and agricultural projects by providing all kinds of the Governmental supports, loans and grants thus fulfilling our years long dream of self sufficient farmers.

Separate courses have been designed for Training like the Ladies to develop kitchen gardens or small farms which can fetch them profits by growing fruits and vegetables. This will be exclusively for ladies and housewives within reasonable course fees. All these courses will also having empowerment facilities and support as mentioned above if some lady wants to do some agricultural activities in a bigger way!

B. CENTRE OF EXCELLENCE FOR HORTICULTURE :

With the technical expertise and experience of Eden Horticulture Services, Karnal (Haryana) and with the High-tech agricultural set up with Naturally Ventilated Poly Houses, NFT and DFT Technology and a full functional Plant Tissue Culture Laboratory at its disposal, GVBL is all set to generate record productions and book record profits in the year to come.

C. DRONE TECHNOLOGY :

Drones are one of the fastest growing technology segments with the potential to provide extraordinary value to the agriculture business.

Imagine a flying robot that you could easily control as an extension of your own eyes and arms - to reach places, see things you can never see and execute tasks that would otherwise be impossible or not affordable.

Drones are remote controlled flying objects which is having capability to collect different data regarding any agricultural field, any vegetation such that optimal treatments can be given to the soil and crops to increase yields many fold with minimum expenditure.

GVBL is all set to bring in this technology from Israel to be implemented in Indian Agriculture successfully. In this regard the Company is having active talk with a well known Agricultural Drone Technology Company.

D. MODERN PEST CONTROL SYSTEM :

In assistance with a reputed Israel Company, GVBL is also bringing the most modern technology for controlling and management of oriental fruit flies. The technology allows the use of lure based pesticides. Also the fluid is long lasting, free of spraying and maintenance. It is harmless to human, environment and non targeted organisms.

This pin pointed pesticide management is achieved through new technologies viz (1) Gravity Controlled Fluid Release (GCFR) technology, (2) a scent-specific, targeting only female pest, and (3) characteristics customized for each implementation.

GVBL has started processing for bringing in this technology also in India !

E. POLYHOUSE CONSTRUCTION :

As the company is having a fully functional team of technical persons for setting up and erection of poly-houses and greenhouses, the company is all set to capture orders of its clients for setting up of their poly-houses / greenhouses.

Through effective marketing the company has bagged a few orders of setting up of poly-houses in the nearby areas in the vicinity of its project site

F. CONTRACTED POLY-HOUSE CONTROLLED ENVIRONMENT AND OPEN FIELD CULTIVATION :

With its expert team of agriculturists and technical personnel, the company is taking up Turn Key cultivation projects of its clients on clients land with assured buy back and marketing assurance. In this scope the company is taking up all responsibilities of preparing of the land of the client, then setting up of Environmentally Controlled Poly-houses, deciding of suitable product mix for the cultivation. And finally when production of vegetables comes, the company shoulders all responsibilities to sell the materials in the market to pay the assured amount to the client.

A few projects with the above scope, negotiations are on.

G. AGRI FARMING CONSULTANCY :

With the expert team of agriculturists and other technical people, the company is also providing Agri Farming Consultancy to farmers and other clients on case to case basis. This way company is providing solutions to problems being faced by the HNI clients in agri-farming business as per their specific needs.

H. FARM 2 DOOR STEP SERVICES :

The company intends to develop full packaging system and logistics to deliver fruits and vegetable direct to homes in NCR as per their daily demands and orders. The company is also working on to make it an online portal and also through mobile app to reach the masses and thus gathering increase orders and reach to more and more households. Thus, eliminating of middle man will reduce the cost and enhance the quality of fruits and vegetables.

I. AGRI SKILL DEVELOPMENT CENTRE :

The company is organising paid training to the new age farmers to develop their knowledge and skill such that they can improve their productions and be self-sufficient.



J. AGRI INPUT SHOP :

The company is in process of setting up an Agri Input Shop to sell seeds, fertilizers, and other farming ingredients required for High-Tech Agriculture.

PLANT TISSUE CULTURE INDUSTRY GROWTH

The growth of Biotechnology industry as per Transparency Market Research is estimated to observe substantial growth during 2010 and 2018 as investments from around the world are anticipated to rise, especially from emerging economical regions of the world. The report states that the global market for biotechnology, studied according to its application areas, shall grow at an average annual growth rate of CAGR 11.6% from 2012 to 2018 and reach a value worth USD 414.5 billion by the end of 2018. This market was valued approximately USD 216.5 billion in 2011. The market of bio agriculture, combined with that of bio seeds, is projected to reach a value worth USD 27.46 billion by 2019. The field of biopharmaceuticals dominated the global biotechnology market and accounted for 60% shares of it in the year 2011. Many biotechnological industries flourished by the technological advancements leading to new discoveries and rising demands from the pharmaceutical and agricultural sectors.

Plant Tissue Culture Laboratory

The company is having a fully functional commercial Plant Tissue Culture Laboratory to produce tissue cultured plantlets for selling as well as captive consumption of the same. Work is going on. And also company is having plan to do contractual research in the similar fields

Opportunity and Threats

AGRICULTURE

As you all know Honourable Prime Minister Shri Narendra Modi had explicitly stated in his election campaign that farmers would be the priority and the government would ensure they got 50% returns over their total costs. Keeping this in mind your company has started implementing measures to provide all round support to ensure a minimum return and also increase their production and earning multi-fold.

The buzz word in today's agricultural sector is "Farmers Producer Company". Producer companies can help smallholder farmers participate in emerging high-value markets, such as the export market and the unfolding modern retail sector in India. As elsewhere in the developing world, in India, small farmers' livelihoods are being threatened due to the liberalization and privatization of Indian agriculture and the increasing interest of private capital in the agribusiness sector. The withdrawal of the state from productive and economic functions, and changes in the organization of marketing channels, present new challenges for small-scale farmers. In this environment of greater instability and competition, organization and collective action can help to enhance farmers' competitiveness and increase their advantage in emerging market opportunities. We build on the ideas of value-chain governance and collective-action literature and introduce the functions and organizational structure of producer companies in India within this context.

Thus by collecting around 300 small farmers on a single corporate platform your company has formed a "Farmers Producer Company". This model will ensure at least a minimum profit to the farmers and also in the process your company will also earn handsomely

BIOTECHNOLOGY

Biotechnology is one of the "hot spots" in research and development in this century. Great chances and opportunities lie ahead, but also tremendous threats. While technology and knowledge is easily available all over the world, it can be quite difficult to access markets and to commercialize biotechnological products.

Biotechnology, regardless of red, green or white biotechnology, promises high profits. However, the field is also complex, fast moving and costly. Especially in the field of medical applications there are many risks associated with biotechnology. One example is a drug developed against multiple sclerosis, which had possible profits of 3\$ billion.

After two patients developing a rare brain disease in clinical trials the profits vaporized and the stock market were in an uproar. Nevertheless does the United Nations Development Program see “biotechnology innovation and globalization as a means of helping the poor of the world live fuller, richer and more secure lives”. Only through commercialization this promise will come true. Commercialization is converting or moving technology into a profit making position

In our opinion the most important point is to bridge the gap between technology and markets. The matching of technological challenge and market challenge is difficult and many tools have been developed to address this problem.

Customer Development

As you all know Honourable Prime Minister Shri Narendra Modi had explicitly stated in his election campaign that farmers would be the priority and the government would ensure they got 50% returns over their total costs. Keeping this in mind your company has started implementing measures to provide all round support to ensure a minimum return and also increase their production and earning multi-fold.

The buzz word in today’s agricultural sector is “Farmers Producer Company”. Producer companies can help smallholder farmers participate in emerging high-value markets, such as the export market and the unfolding modern retail sector in India. As elsewhere in the developing world, in India, small farmers’ livelihoods are being threatened due to the liberalization and privatization of Indian agriculture and the increasing interest of private capital in the agribusiness sector. The withdrawal of the state from productive and economic functions, and changes in the organization of marketing channels, present new challenges for small-scale farmers. In this environment of greater instability and competition, organization and collective action can help to enhance farmers’ competitiveness and increase their advantage in emerging market opportunities. We build on the ideas of value-chain governance and collective-action literature and introduce the functions and organizational structure of producer companies in India within this context.

Thus by collecting around 300 small farmers on a single corporate platform your company has formed a “Farmers Producer Company”. This model will ensure at least a minimum profit to the farmers and also in the process your company will also earn handsomely

For marketing and selling of the huge produce of the FPC , the company has tied up with the Fruit & Vegetable Retail Chains and to all the Online Fruits & Vegetable Market Place

Supply Chain

For marketing and selling of the huge produce of the FPC , the company has tied up with the Fruit & Vegetable Retail Chains and to all the Online Fruits & Vegetable Market Places around the country.

For the produces from the Plant Tissue Culture Lab, your company has necessary understanding with the relevant companies and organizations for the purchase of the tissue culture production of your company

Your Company’s supply chain agenda remained focused on five key areas

1. Customer service excellence,
2. Consumer and customer quality,
3. End to end cash and cost savings program,
4. Leading with innovation, and
5. Technology and sustainability.

Your Company made significant progress in its vision to deliver customer service excellence to enable sustainable growth.

Research & Development

India's agricultural research system has contributed in a large way to increasing agriculture production and productivity. Development of high yielding and disease resistant varieties has been its major hall mark. The country has one of the largest Public Agricultural Research Establishments in the world. With Indian Council of Agricultural Research (ICAR) at the top, we have 30 State Agriculture Universities, 46 Institutes including 4 Deemed Universities, 4 National Bureau, 9 Project Directorates, 31 National Research Centres, 158 Regional Stations and 80 All India Coordinated Research Projects. However, despite having such a huge manpower and infrastructure, the predominant critique has been that it is very weak in transfer of technology and does not benefit small farmers.

The company has set up an in-house Plant Tissue Culture Laboratory for doing research in the field of plant tissue culture and also to take such researches through steps to commercial levels.

Apart from this your company is continuing its researches in varied field of biotechnology.

Our Research Team is already conducting Basic Research in Premier Institute in the country in the following prospective fields:

Agriculture

- Crop Biotechnology
- Biofertilizers
- Biopesticides and Crop Management
- Plant Biotechnology

Plant Tissue Culture Micopropagation

- Bio prospecting and Molecular taxonomy
- Bio fuels
- Medicinal and Aromatic Plants

Medical Biotechnology

- Vaccines
- Diagnostic
- Drug Development
- Human Genetics and Genome Analysis

OUTLOOK

The promise of doubling farmers' income by 2022 dangled heavily as reports of severe agrarian distress started pouring in from the country. Farmers dumping their produces for lack of fair price made headlines throughout 2018 and 2019. The report pointed out that agriculture and rural sector is currently in a deep crisis because during 2004-14 the country's agriculture sector witnessed its highest ever growth "recovery phase". Despite the highest ever food grain production the year 2016-17 (275 million tonnes) and 274.55 million tonnes in 2017-18, the rural economy has completely collapsed.

As you all know Honourable Prime Minister Shri Narendra Modi had explicitly stated in his election campaign that farmers would be the priority and the government would ensure they got 50% returns over their total costs. Keeping this in mind your company has started implementing measures to provide all round support to ensure a minimum return and also increase their production and earning multi-fold.

The buzz word in today's agricultural sector is "Farmers Producer Company". Producer companies can help smallholder farmers participate in emerging high-value markets, such as the export market and the unfolding modern retail sector in India. As

elsewhere in the developing world, in India, small farmers' livelihoods are being threatened due to the liberalization and privatization of Indian agriculture and the increasing interest of private capital in the agribusiness sector. The withdrawal of the state from productive and economic functions, and changes in the organization of marketing channels, present new challenges for small-scale farmers. In this environment of greater instability and competition, organization and collective action can help to enhance farmers' competitiveness and increase their advantage in emerging market opportunities. We build on the ideas of value-chain governance and collective-action literature and introduce the functions and organizational structure of producer companies in India within this context.

Thus by collecting around 300 small farmers on a single corporate platform your company has formed a "Farmers Producer Company". This model will ensure at least a minimum profit to the farmers and also in the process your company will also earn handsomely

Environment, safety, Health and Energy Conservation

Your Company has a vision of being a 'Zero Injury' organisation. The Compass, your Company's strategic framework, integrates Safety as a non-negotiable value. Over the past years, your Company has not reported and injuries across its operations.

This has been achieved through a combination of training and hardware upgradation leveraging core technology concepts and safety standards from the Company. Sustainability is deeply rooted in all the operations of your Company ranging from sourcing to Production and logistics. Your Company's aim is to achieve significant reduction in environmental impact of operations.

Your Company has used various majors for conservation of energy. Several efforts has been conferred by your Company in the spheres of Safety, Environment and Sustainability.

Human Resources

Your Company's Human Resource agenda remained focused on reinforcing the key thrust areas; being the employer of choice on campus, building an inclusive culture and a strong talent pipeline, institutionalizing mission critical capabilities in the organisation, driving greater employee engagement and continuing to focus on progressive employee relation policies.

Your Company has developing future leaders and having the best people practices. The Company continued to build on the Diversity and Inclusion agenda.

Keeping in view of its "Research Program Outsourcing (RPO)" philosophy, the company is working on to create "Pool of Scientists". This pool is created in the following two ways:

- By in-house training, through the Study Programs conducted at our Registered Office.
- Through contact program in which our team contacts the premier Biotech Institute in India and internationally to make a "Brain Pool" by inducting the cream talents in the field.

Disclosures with respect to the remuneration of Directors and employees as required under Section 197 of Companies Act, 2013 and Rule 5 (1) Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014 has been appended as Annexure A(1) to this Report.

Details of employee remuneration as required under provisions of Section 197 of the Companies Act, 2013 and Rule 5(2) & 5(3) of Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014 has been appended as Annexure A (2) to this Report and are available at the Registered Office of the Company during working hours before 21 days of the Annual General Meeting and shall be made available to any shareholder on request.

Details of significant changes (i.e. change of 25% or more as compared to the immediately previous financial year) in key financial ratios, along with detailed explanations therefor

Sr. No.	Name of Ratio	Current Financial Year Ratio	Previous Financial Year Ratio	Percentage of Change in Ratio	Explanation therefor
1	Debtors Turnover Ratio	0.121	0.060	104.275	Due to Non-realization of the amount from the debtors

2	Inventory Turnover Ratio	0.146	0.121	21.467	
3	Current Ratio	0.526	4.141	-87.292	Due to increase in Unsecured Loan
4	Debt Equity Ratio	0.434	0.4891	-11.257	
5	Operating Profit Margin	0.456	0.223	104.48	Due to increase in heavy finance cost and normal business growth
6	Net Profit Margin	0.338	0.236	43.126	Due to increase in closing stock of Inventory

Details of any change in Return on Net Worth as compared to the immediately previous financial year along with a detailed explanation thereof

Sr. No.	Name of Ratio	Current Financial Year Ratio	Previous Financial Year Ratio	Percentage of Change in Ratio	Explanation therefor
1	Return on Net Worth	0.056	0.048	16.039	Due to Normal Business Growth

Total Remuneration paid to Statutory Auditors: Rs.25,000-

Risks and concerns

There is a rich public debate about how the potential risks associated with biotechnology methods and bio industry products should be assessed and about whether and how bioethics should influence public policy. A general structure for guiding public policy discourse is emerging but is not fully developed. Groups perceive risks differently depending on their culture, scientific background, perception of government, and other factors. Expert opinion supports a range of positions. Deeply and honestly held but often conflicting beliefs and values about nature, animals, and the community good animate the debate. The result is that biotechnology issues are often highly contentious and debated on both scientific and ethical grounds. Two contemporary examples are:

❖ Do human social benefits such as living a longer and leading more productive life due to biotechnology outweigh the harm that an animal or groups of animals must experience to produce those benefits.

❖ Should an insurance company require information about an individual's genetic inheritance as a condition of eligibility for health insurance?

Biotechnology's risks are sometimes purely conjectural. Without research and clinical trials, risks cannot be fully assessed. Yet conjectural and ethical issues are important because biotechnology affects not only human practices and economic sectors, but also medical practices and the relationship between humanity, animals and the environment.

In Paul Thompson's view, [Biotechnology] is not simply another type of mechanical or chemical creation aimed at making the world better for us. In this instance, we are not simply reshaping matter, but are harnessing life. By manipulating life and natural evolution, we are taking the process that shaped our existence and that of every other living organism on the planet and restructuring it for our own benefit.

Internal control system

The company has started its commercial activity. However, the management is having highly professional outlook at the adequate control system during all its commercial activities

FINANCIAL RESULTS

The company performance for the financial year ended on March 31st, 2020 is summarized below:

Particulars	In Rs.	
	2019-20	2018-19
Revenue from Operations	84,65,629.00	98,50,101.00
Other Income	1,40,869.00	1,47,952.00
Total Revenue	86,06,499.00	99,98,052.00
Total Expenses	65,49,188.00	76,51,003.00
Profit before Exceptional Items and Tax	20,57,310.00	23,47,049.00
Exceptional Item	0.00	0.00
Profit before Tax	20,57,310.00	23,47,049.00
Tax Expenses	(8,02,616.00)	22,083.00
Profit After Tax for the year	28,59,927.00	23,24,966.00
Paid up Capital (in No. of shares @ Rs. 10 each share)	30,54,500	30,54,500.00

RESULTS OF OPERATIONS AND THE STATE OF COMPANY'S AFFAIRS

During the Financial Year ended 2020 under review, the Company has earned the profit of Rs. 28,59,927/- against the profit of Rs. 23,24,966/- in the previous Financial Year ended 2019.

In the Financial Year 2019-2020, the company is witnessing sustained commercial production from its Plant Tissue Culture Lab, 2 x 1500 sq. metre Naturally Ventilated Poly House, 2 x 1080 Hi-Tech Poly Houses and a Net House of 500 sq. metres & 1500 sq. metres.

The Company is extensively involved in Commercial Greenhouse/Poly House Cultivation of crops over the year and market the produce profitably. It keeps on changing the crop mix from time to time to meet the seasonal and market demand. Also it is involved in commercial Horticulture activities with Aloe vera, Tomato, Bitter Gourd, Bottle Gourd, Brinjal, Broccoli, Cabbage, Capsicum, Carrot, Cauliflower, Cucumber, Green Chillies, Onion, Radish, Ridge/Sponge Gourd, Leafy Vegetables, Pumpkin, Banana, Guava, Papaya, and Strawberry.

Cautionary Statement

Certain statements in the above section may be forward looking and be based on expectations/ projections about the future. Company's actual results, performance could thus differ materially from those projected in any such forward looking statements. The Company assumes no responsibility to publicly amend, modify or revise any of such forward looking statements on the basis of subsequent developments, information or events.

LEGAL GOVERNANCE AND BRAND PROTECTION

Corporate Governance

Your Company is renowned for exemplary governance standards since inception and continues to lay a strong emphasis on transparency, accountability and integrity.

The new Companies Act, 2013 and SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 have strengthened the governance regime in the country. Your Company is in compliance with the governance requirements provided under the new law and had proactively adopted many provisions of the new law, ahead of time. Your Company is committed to embrace the new law in letter and spirit. In line with the requirements of new law, your Company has constituted new Board Committees. Your Company has in place all the statutory Committees required under the law. Details of Board Committees along with their terms of reference, composition and meetings of the Board and Board Committees held during the year, are provided in the Corporate Governance Report.

Your Company has adopted new policies under SEBI (Prohibition of Insider Trading) Regulations, 2015 and SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 in line with new governance requirements. These policies are available on the website of the Company at www.genomicvalley.com the Company has established a vigil mechanism for Directors and employees to report their genuine concerns, details of which have been given in the Corporate Governance Report annexed to this Report.

During the year, Secretarial Audit was carried out by Mr. Rohit Batham, a Practicing Company Secretary, Secretarial Auditor of the Company for the financial year 2019-20. There was no qualification, reservation or adverse remarks given by Secretarial Auditors of the Company. The detailed report on the Secretarial Audit is appended as an Annexure E to this Report.

The extract of annual return in Form MGT-9 as required under Section 92(3) and Rule 12 of the Companies (Management and Administration) Rules, 2014 is appended as an Annexure B to this Report and also uploaded the annual return on the website of the Company with the weblink <http://www.genomicvalley.com/investorrelationpage.htm> .

A separate report on Corporate Governance is provided together with a Certificate from the Statutory Auditors of the Company regarding compliance of conditions of Corporate Governance as stipulated under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and annexed as Annexure C to this Report.

A Certificate of the Managing Director and CFO of the Company in terms of Part B of Schedule II of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, inter alia, confirming the correctness of the financial statements and cash flow statements, adequacy of the internal control measures and reporting of matters to the Audit Committee, is also annexed.

The Company is committed to maintain the highest standards of corporate governance and adhere to the corporate governance requirements set out by SEBI. The Company has also implemented several best corporate governance practices as prevalent globally. The report on Corporate Governance as stipulated under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 forms an integral part of this Report. The requisite certificate from the Auditors of the Company confirming compliance with the conditions of corporate governance is attached to the report on Corporate Governance.

Related Party Transactions

In line with the requirements of the Companies Act, 2013 and SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, your Company has formulated a Policy on Related Party Transactions which is also available on Company's website at www.genomicvalley.com. The Policy intends to ensure that proper reporting, approval and disclosure processes are in place for all transactions between the Company and Related Parties.

This Policy specifically deals with the review and approval of Material Related Party Transactions keeping in mind the potential or actual conflicts of interest that may arise because of entering into these transactions. Transactions with related parties as per AS – 18 have been disclosed in the notes forming part of Financial Statements. All Related Party Transactions are placed before the Audit Committee for review and approval. Prior omnibus approval is obtained for Related Party Transactions on a quarterly basis for transactions which are of repetitive nature and / or entered in the Ordinary Course of Business and are at Arm's Length. All Related Party Transactions are subjected to independent review by a reputed accounting firm to establish compliance with the requirements of Related Party Transactions under the Companies Act, 2013 and SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

All Related Party Transactions entered during the year were in Ordinary Course of the Business and on Arm's Length basis. No Material Related Party Transactions, i.e. transactions exceeding ten percent of the annual consolidated turnover as per the last audited financial statements, were entered during the year by your Company. Accordingly, the disclosure of Related Party Transactions as required under Section 134(3) (h) of the Companies Act, 2013 in Form AOC 2 is not applicable.

Corporate social Responsibility (CSR)

The Corporate Social Responsibility and Governance Committee (CSR & G Committee) has not been formulated because this provision is not applicable according to section 135 of the companies Act 2013.

Risk Management

Your Directors have constituted a Risk Management Committee which has been entrusted with the responsibility to assist the Board as follows:

(a) Overseeing and approving the Company's enterprise wide risk management framework; and

(b) Overseeing that all the risks that the organization faces such as strategic, financial, credit, market, liquidity, security, property, IT, legal, regulatory, reputational and other risks have been identified and assessed and there is an adequate risk management infrastructure in place capable of addressing those risks. A Risk Management Policy was reviewed and approved by the Committee. The Company manages monitors and reports on the Principal risks and uncertainties that can impact its ability to achieve its strategic objectives. The Company's management systems, organisational structures, processes, standards, code of conduct and behaviours together form the Management System that governs how the Group conducts the business of the Company and manages associated risks. The Company has introduced several improvements to Integrated Enterprise Risk Management, Internal Controls Management and Assurance Frameworks and processes to drive a common integrated view of risks, optimal risk mitigation responses and efficient management of internal control and assurance activities. This integration is enabled by all three being fully aligned wide Risk Management, Internal Control and Internal Audit methodologies and processes.

Disclosure as per Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013

The Company has complied with provisions related to the constitution of Internal Complaints Committee under the Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013. The Company has zero tolerance for sexual harassment at workplace and has adopted a policy on prevention, prohibition and redressal of sexual harassment at workplace in line with the provisions of Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013 and the rules framed thereunder. During the financial year 2017-18, the Company has not received any complaints on sexual harassment and also, no complaint is pending on sexual harassment.

EXTRACT OF ANNUAL RETURN

The details forming part of the extract of the Annual Return in form MGT-9, as required under Section 92(3) of the Companies Act, 2013 is annexed herewith as Annexure-B and forms an integral part of this report. Weblink for Annual Return is <https://www.genomicvalley.com/gvblreports.htm> .

Disclosure regarding maintenance of Cost Records

The Company has not required maintaining cost records as specified by the Central Government under sub-section (1) of Section 148 of the Companies Act, 2013.

Conservation of Energy, Technology Absorption and Foreign Exchange Earnings and Outgo

The particulars as prescribed under Rule 8(3) of the Companies (Accounts) Rules, 2014, are as follows:



A. CONSERVATION OF ENERGY

i. **The Company ensures that all possible measures are taken to conserve energy including identification of potential areas of saving energy, installation of energy efficient equipments.**

ii. **Steps taken by the Company for utilizing alternate sources of energy:**

The Company has used various majors for conservation of energy.

iii. **Capital investment on energy conservation equipments: NIL**

B. TECHNOLOGY ABSORPTION

i. **Efforts made towards technology absorption:**

The company has set up an in-house Plant Tissue Culture Laboratory for doing research in the field of plant tissue culture and also to take such researches through steps to commercial levels.

The company has developed fully equipped Greenhouse /Poly-house erection team which undertake contracts for its clients for erecting greenhouses/poly houses at their sites and provide turnkey consultancy and support to the client so that they can get profit out of their investment. The company is also committed to buy back the produce of the greenhouses/poly houses at a Minimum Assured Price if the grower wishes to sell his produce to the company thus ensuring a assured minimum profit to it.

Apart from this your company is continuing its researches in varied field of biotechnology.

Our Research Team is already conducting Basic Research in Premier Institute in the country in the following prospective fields:

Agriculture

- Crop Biotechnology
- Biofertilizers
- Biopesticides and Crop Management
- Plant Biotechnology

Plant Tissue Culture Micropogation

- Bioprospecting and Molecular taxonomy
- Biofuels
- Medicinal and Aromatic Plants

Medical Biotechnology

- Vaccines
- Diagnostic
- Drug Development
- Human Genetics and Genome Analysis

ii. **Benefits derived:**

The Company is extensively involved in Commercial Greenhouse/Poly house Cultivation of crops over the year and market the produce profitably. It keeps on changing the crop mix from time to time to meet the seasonal and market demand. Also it is involved in commercial Horticulture activities with Aloe vera, Tomato, Bitter Gourd, Bottle Gourd,



Brinjal, Broccoli, Cabbage, Capsicum, Carrot, Cauliflower, Cucumber, Green Chillies, Onion, Radish, Ridge/Sponge Gourd, Leafy Vegetables, Pumpkin, Banana, Guava, Papaya, and Strawberry.

The Company has started open field cultivation activities at its site at Bahadurgarh and started taking commercial production in this present financial year.

iii. Imported technology:

- a. Detail of Technology: Nil
- b. The technology is imported during the year 2018-19: Nil
- c. This technology is fully absorbed: Not Applicable
- iv. The expenditure incurred on Research and Development is Rs Nil.

C. FOREIGN EXCHANGE EARNING AND OUTGO

- i. **The Company has not earned any foreign exchange during the year under review.**
- ii. **The Company has not incurred any foreign exchange outgo during the year under review.**

Deposit from Public

The Company has not accepted any deposits from public and as such, no amount on account of principal or interest on deposits from public was outstanding as on the date of the Balance Sheet.

Names of the Companies which have become or ceased to be Company's Subsidiaries, Joint Ventures or Associate Companies during the year

During the year, there is no such company which has become or ceased to be Company's subsidiary, joint venture or associate company under review.

Significant and Material Orders

During the year under review, there are no significant or material orders passed by the regulators or courts or tribunals impacting the going concern status and company's operations in future.

Change in Nature of Business

During the year there is no change in nature of business of the Company under review.

Internal Financial Controls

The Company has in place adequate internal financial controls with reference to financial statements. During the year, such controls were tested and no reportable material weakness was observed.

Code of Conduct for Directors and Senior Management

In compliance with Regulation 26(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Company has formulated Code of Conduct for the Board members and senior management personnel of the Company so that the Company's business is conducted in an efficient and transparent manner without having any conflict of personal interests with the interests

of the Company. All the members of the Board and senior management personnel have affirmed compliance with the Code of Conduct.

Declaration by the CEO/Managing Director

It is hereby declared that the Company has obtained from each individual member of the Board of Directors and the Senior Management confirming that none of them has violated the conditions of the said Code of Conduct.

RELATIONSHIP BETWEEN DIRECTORS INTER-SE

Directors are related to each other within the meaning of the term “relative” as per Section 2(77) of the Act and SEBI (Listing Obligations and Disclosure Requirements) regulations, 2015. Details given in Corporate Governance Report are forming part of this report.

PARTICULARS OF LOANS AND BORROWINGS TAKEN BY THE COMPANY

The Company has not taken any Loans and Borrowings during the year under review.

PARTICULARS OF LOANS, GUARANTEES AND INVESTMENTS

During the year under review, the Company has not made any loans or, guarantee, or provided any security or made any investments pursuant to the provisions of Section 186 of the Companies Act, 2013 read with Rules made thereunder.

ACCOUNTING TREATMENT

The Company has adopted Indian Accounting Standards (Ind AS) notified by Ministry of Corporate Affairs from 1st April 2017, with a transition date 1st April 2016 and accordingly these financial statement have been prepared in accordance with the companies (Indian Accounting Standard) Rules, 2015 prescribed under section 133 of the Companies Act, 2013 and other accounting principles generally accepted in India. The financial statements have been prepared on accrual basis. The accounting policies adopted in the preparation of the financial statements are consistent with those followed in the previous year.

VIGIL MECHANISM

The Company has established a vigil mechanism for adequate safeguards against victimization of directors and employees of the Company For details, please refer to the Corporate Governance Report attached to the Annual Report.

PECUNIARY RELATIONSHIP OR TRANSACTIONS OF NON-EXECUTIVE DIRECTORS

During the year, there no pecuniary relationship or transactions has taken place between the Company and Non-Executive Directors of the Company.

DIRECTORS AND KEY MANAGERIAL PERSONNEL

In accordance with the provisions of the Act and the Articles of Association of the Company, Mrs. Parul Agrawal Directors of the Company, retire by rotation at the ensuing Annual General Meeting and being eligible have offered herself for re-appointment.

The Board of Directors of the Company (“the Board”) at its meeting held on September 05, 2020 has, subject to approval of members, re-appointed Mr. Yogesh Agrawal as a Chairman and Managing Director of the Company, for a period of 5 (Five) years with effect from September 07, 2020, on terms and conditions including remuneration as recommended by the Nomination and Remuneration Committee (the ‘NR Committee’) of the Board and approved by the Board. It is proposed to seek members’ approval in ensuing Annual General Meeting for the appointment of and

remuneration payable to Mr. Yogesh Agrawal as a Chairman and Managing Director of the Company, in terms of the applicable provisions of the Act.

Further Based on the recommendation of the Nomination & Remuneration Committee, the Board of Directors of the Company have appointed Mr. Satendra Kumar Goyal as an Additional Director in the capacity of Non-Executive Independent Director of the Company to hold office for a period from June 30, 2020 to June 29, 2025, not liable to retire by rotation, subject to consent of the Members of the Company at the ensuing Annual General Meeting.

The Company has received declarations from all the Independent Directors of the Company under Section 149(7) of the Companies Act, 2013 confirming that they meet the criteria of independence as laid down under Section 149(6) of the Companies Act, 2013 and Regulation 25 of SEBI (Listing Obligations and Disclosure Requirements) regulations, 2015.

The Company has devised a Policy for performance evaluation of Independent Directors, Board, Committees and other individual Directors which include criteria for performance evaluation of the non-executive directors and executive directors.

On the basis of the Policy for performance evaluation of Independent Directors, Board, Committees and other individual Directors, a process of evaluation was followed by the Board for its own performance and that of its Committees and individual Directors.

A separate meeting of the independent directors ("Annual ID meeting") was convened, which reviewed the performance of the Board (as a whole), the non-independent directors and the Chairman. After convening the Annual ID meeting, the collective feedback of each of the Independent Directors was discussed by the Chairman of the NRC with the Board's Chairman covering performance of the Board as a whole; performance of the non-independent directors and performance of the Board Chairman.

The details of Policy for familiarisation of Independent Directors with the Company, their roles, rights, responsibilities in the Company, nature of the industry in which the Company operates, business model of the Company and related matters are put up on the website of the Company at the link: www.genomicvalley.com.

The following policies has been adopted by the Company which are put up on the website of the Company at the link: www.genomicvalley.com:

- (a) Policy for selection of Directors and determining Directors independence; and
- (b) Remuneration Policy for Directors, Key Managerial Personnel and other employees.

Nomination and Remuneration Policy

The Company has adopted the policy and procedures with regard to Nomination and Remuneration of Directors, Key Managerial Personnel (KMP) and Senior Management consistent with the provisions of the Companies Act, 2013 and SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The Nomination and Remuneration Committee and this policy shall be compliance in with Section 178 of the Companies Act, 2013 read along with the applicable rules thereto and SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The objective of this policy is to lay down a framework in relation to remuneration of directors, KMP, senior management personnel and other employees. The key objectives of the Committee would be:

- a) To guide the Board in relation to appointment and removal of directors, KMP and senior management.
- b) Formulate the criteria for determining qualifications, positive attributes, and independence of a director and recommend the Board a Policy, relating to the remuneration for the directors, key managerial personnel and other employees.
- c) Formulation of criteria for evaluation of Independent Directors and the Board.
- d) To evaluate the performance of the members of the Board and provide necessary report to the Board.

- e) To recommend to the Board remuneration payable to the directors, key managerial personnel and senior management.
- f) To retain, motivate and promote talent of directors, managerial personnel required to run the Company successfully.
- g) To assist the Board in fulfilling responsibilities.
- h) To implement and monitor policies and processes regarding principles of corporate governance.

The policy to regulate the Nomination and Remuneration of Directors, Key Managerial Personnel (KMP) and Senior Management is available on the website of the Company www.genomicvalley.com and annexed as Annexure D to this Report.

AUDITORS AND AUDITORS' REPORT

Statutory Auditor

M/s Andros & Co., Chartered Accountant was appointed as statutory auditors of the Company in the Annual General Meeting held on 23rd August, 2019 for five years.

M/s M/s Andros & Co. has conducted the Statutory Audit of the Company for the Financial Year 2019-20.

The Notes on financial statement referred to in the Auditors' Report are self-explanatory and do not call for any further comments. The Auditors' Report does not contain any observation, qualification, reservation or adverse remark.

Internal Auditor

M/s S Sanghi & Associates, Chartered Accountants, New Delhi, Represented by CA Siddharth Sanghi (Membership No. 552468) has been appointed as Internal Auditors of the Company to conduct the Internal Audit of the company for the Financial Year 2020-21.

Secretarial Auditor

The Company has appointed Rohit Batham & Associates, Company Secretaries, New Delhi as Secretarial Auditors of the Company for carrying out the secretarial audit for the financial year 2019-20 in the Board Meeting held on 30.05.2019 at such remuneration as may be decided mutually by Managing Director of the Company and the Secretarial Auditor.

The Secretarial Audit Report for the financial year ended March 31, 2020 is annexed as Annexure E to this Report. The Secretarial Audit Report does not contain any observation, qualification, reservation or adverse remark.

CAUTIONARY STATEMENT

Statements in the Annual Report, particularly those which relate to Management Discussion and Analysis, describing the Company's objectives, projections, estimates and expectations, may constitute 'forward looking statements' within the meaning of applicable laws and regulations. Although the expectations are based on reasonable assumptions, the actual results might differ.

APPRECIATIONS AND ACKNOWLEDGMENTS

Your Directors place on record their deep appreciation to employees at all levels for their hard work, dedication and commitment. The enthusiasm and unstinting efforts of the employees have enabled the Company to remain as industry leaders.

The Board places on record its appreciation for the support and co-operation your Company has been receiving from its suppliers, redistribution stockiest, retailers, business partners and others associated with the Company as its trading partners. Your Company looks upon them as partners in its progress and has shared with them the rewards of growth. It will be the Company's Endeavour to build and nurture strong links with the trade based on mutuality of benefits, respect for and co-operation with each other, consistent with consumer interests.



The Directors also take this opportunity to thank all Investors, Clients, Vendors, Banks, Government and Regulatory Authorities and Stock Exchanges, for their continued support.

For and on behalf of
Genomic Valley Biotech Limited

sd/-

**Yogesh Agrawal
Managing Director**

DIN-01165288

Address: G-74, Pushkar Enclave,
Paschim Vihar, Delhi- 110063

sd/-

**Parul Agrawal
Director**

DIN-01165188

Address: G-74, Pushkar Enclave,
Paschim Vihar, Delhi- 110063

Date: 05.12.2020

Place: Haryana

Annexure A to the Board Report
1. Statement of Disclosure of Remuneration under Section 197 of Companies Act, 2013 and Rule 5(1) of Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014

(i) The percentage increase in remuneration of each Director, Chief Financial Officer and Company Secretary during the financial year 2019-20, ratio of the remuneration of each Director to the median remuneration of the employees of the Company for the financial year 2019-20 and the comparison of remuneration of each Key Managerial Personnel (KMP) against the performance of the Company are as under:

S. No.	Name of the Director/KMP and Designation	Remuneration of Director/KMP for the Financial Year 2019-20 (In Rs.)	% Increase in Remuneration in the Financial year 2019-20	Ratio of remuneration of each Director to median remuneration of Employees
1.	Mr. Yogesh Agrawal (Managing Director)	4,50,000/-	-50%	34.58%
2.	Mr. Hitesh Kumar (Company Secretary & Compliance officer) till 25 th June, 2019	1,68,000/-	58.52%	92.63%
3.	Mr. Sunil Kumar (Company Secretary & Compliance officer) from 26 th June, 2019 to 7 th March, 2020	2,28,558/-	Nil	68.09%
4.	Mr. Lalit Shah (Chief Financial Officer)	4,65,000/-	10.71%	33.47%

- (ii) The median remuneration of employees of the Company during the financial year was Rs. 1,55,624/-
- (iii) The percentage decrease in the median remuneration of employees in the financial year 2019-20 is 44.81%.
- (iv) There were 5 permanent employees on the rolls of Company as on March 31, 2020.
- (v) Average Percentile increase already made in the salaries of employees other than the managerial personnel in the last financial year and its comparison with the percentile increase in the managerial remuneration and justification thereof and point out if there are any exceptional circumstances for increase in the managerial remuneration: Nil
- (vi) It is hereby affirmed that the remuneration is as per the remuneration policy of the Company.

2. Statement of Disclosure of employee remuneration as required under provisions of Section 197 of the Companies Act, 2013 and Rule 5(2) & 5(3) of Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014

i. Detail of Top ten employee in terms of remuneration drawn:

S.No.	Particulars	Name of the Top 10 Employees						
		1	2	4	5	6	7	8
	Name of the Top Ten Employees	Sanjoy Gupta	Lalit Shah	Sikandar Rathi	Shashi Shekhar Singh	Hitesh Kumar	Anuj Sharma	Sunil Kumar
1	Designation	General Manager(Policy Planning & Procurement)	General Manager (Agriculture Planning) and Chief Financial Officer w.e.f 02.09.2017	Agriculture Supervisor	Research Scientist	Company Secretary	Agriculture Supervisor	Company Secretary
2	Remuneration received	133133	465000	42067	128478	168000	143248	228559
3	Nature of employment	Payroll	Payroll	Payroll	Payroll	Payroll	Payroll	Payroll
4	Qualification & Experience	M.Sc. Chemistry from D.U., 35 Yrs.	B. (Sc), 22 Yrs.	Matriculation, 15 Yrs.	P. HD. Pre Submitted, 1.5 Yrs.	Company Secretary, 3 Yrs.	B. (Sc)	Company Secretary, 1 Yrs.
5	Date of Commencement of employment	01.04.2015	01.01.2016	01.04.2015	01.09.2016	23.11.2016	15.04.2019	26.06.2019
6	Age	57	49	36	37	33	26	34
7	Last Employment	Shreeram Industrial Enterprises Ltd	Self Employed	Agriculture Worker	NRCPB, New Delhi as Senior Research Fellow	Chandrasekaran Associates	Student	Student
8	Percentage of Equity shares held	0.03	NIL	NA	NA	NA	NA	NA
9	Relationship with any director or manager and name of the such director	NA	NA	NA	NA	NA	NA	NA

- ii. Employee in the Company in receipt of remuneration aggregating more than Rs. 1,02,00,000 per annum being employed throughout the financial year and Rs. 8,50,000 or more per month being employed for part of the year: NIL
- iii. Employees in the Company who employed throughout the financial year or part thereof, was in receipt of remuneration in that year which, in the aggregate, or as the case may be, at a rate which, in the aggregate, is in excess of that drawn by the managing director or whole-time director or manager and holds by himself or along with his spouse and dependent children, not less than two percent of the equity shares of the company: NIL

For and on behalf of
Genomic Valley Biotech Limited

sd/-
Yogesh Agrawal
Managing Director
DIN-01165288
Address: G-74, Pushkar Enclave,
Paschim Vihar, Delhi- 110063

sd/-
Parul Agrawal
Director
DIN-01165188
Address: G-74, Pushkar Enclave,
Paschim Vihar, Delhi- 110063

Date: 05.12.2020
Place: Haryana

Annexure B to the Board Report
**FORM NO. MGT 9
EXTRACT OF ANNUAL RETURN**
As on financial year ended on 31st March, 2020

(Pursuant to Section 92 (3) of the Companies Act, 2013 and rule 12(1) of the Company (Management & Administration) Rules, 2014)

I. REGISTRATION & OTHER DETAILS:

1.	CIN	L01122HR1994PLC033029
2.	Registration Date	16/05/1994
3.	Name of the Company	GENOMIC VALLEY BIOTECH LIMITED
4.	Category/Sub-category of the Company	PUBLIC COMPANY/LIMITED BY SHARE
5.	Address of the Registered office & contact details	4 K.M. STONE, BERRI CHHARRA ROAD,P.O. TANDAHERI, TEHSIL-BAHADURGARH, DISTT-JHAJJAR, HARYANA- 124507 Contact: +91-9811341542
6.	Whether listed company	YES
7.	Name, Address & contact details of the Registrar & Transfer Agent, if any.	Beetal Financial & Computer Services Private Limited Beetal House, 99, Madangir, Behind Local Shopping Centre, Near Dada HarsukhDass Mandir, New Delhi-110062. Phone- 91-11-2996 1281-83 Fax- 91-11-2996 1284 Email- beetal@beetalfinancial.com

II. PRINCIPAL BUSINESS ACTIVITIES OF THE COMPANY (All the business activities contributing 10 % or more of the total turnover of the company shall be stated)

S. No.	Name and Description of main products / services	NIC Code of the Product/service	% to total turnover of the company
1	HORTICULTURE BUSINESS	01132	100

III. PARTICULARS OF HOLDING, SUBSIDIARY AND ASSOCIATE COMPANIES (All the business activities contributing 10 % or more of the total turnover of the company shall be stated)

S. No.	Name and Address of the Company	CIN/ GNL	Holding/ Subsidiary/ Associate	% of Shares held	Applicable Section
1	NA	NA	NA	NA	NA

**IV. SHARE HOLDING PATTERN (Equity Share Capital Breakup as percentage of Total Equity)
Category-wise Share Holding**

CATEGORY Code	CATEGORY OF SHAREHOLDER	NO. OF SHARES HELD AT THE BEGINNING OF THE YEAR 01/04/2019				NO. OF SHARES HELD AT THE END OF THE YEAR 31/03/2020				% CHANGE DURING THE YEAR
		DEMAT	PHYSICAL	TOTAL	% OF TOTAL SHARES	DEMAT	PHYSICAL	TOTAL	% OF TOTAL SHARES	
(I)	(II)	(III)	(IV)	(V)	(VI)	(VII)	(VIII)	(IX)	(X)	(XI)
(A)	PROMOTER AND PROMOTER GROUP									
(1)	INDIAN									



(a)	Individual /HUF	759015*	0	759015	24.85	2072450	0	2072450	67.85	173.04
(b)	Central Government/State Government(s)	0	0	0	0	0	0	0	0	
(c)	Bodies Corporate	0	0	0	0	0	0	0	0	
(d)	Financial Institutions / Banks	0	0	0	0	0	0	0	0	
(e)	Others	0	0	0	0	0	0	0	0	
	Sub-Total A(1)	759015	0	759015	24.85	2072450	0	2072450	67.85	173.04
(2)	FOREIGN									
(a)	Individuals (NRIs/Foreign Individuals)	0	0	0	0	0	0	0	0	
(b)	Bodies Corporate	0	0	0	0	0	0	0	0	
(c)	Institutions	0	0	0	0	0	0	0	0	
(d)	Qualified Foreign Investor	0	0	0	0	0	0	0	0	
(e)	Others	0	0	0	0	0	0	0	0	
	Sub-Total A(2)	0	0	0	0	0	0	0	0	
	Total A=A(1)+A(2)	759015	0	759015	24.85	2072450	0	2072450	67.85	173.04
(B)	PUBLIC SHAREHOLDING									
(1)	INSTITUTIONS									
(a)	Mutual Funds /UTI	0	0	0	0	0	0	0	0	
(b)	Financial Institutions /Banks	0	0	0	0	0	0	0	0	
(c)	Central Government / State Government(s)	0	0	0	0	0	0	0	0	
(d)	Venture Capital Funds	0	0	0	0	0	0	0	0	
(e)	Insurance Companies	0	0	0	0	0	0	0	0	
(f)	Foreign Institutional Investors	0	0	0	0	0	0	0	0	
(g)	Foreign Venture Capital Investors	0	0	0	0	0	0	0	0	
(h)	Qualified Foreign Investor	0	0	0	0	0	0	0	0	
(i)	Others	0	0	0	0	0	0	0	0	
	Sub-Total B(1)	0	0	0	0	0	0	0	0	



(2)	NON-INSTITUTIONS									
(a)	Bodies Corporate	1313435*	0	1313435	43.00	0	0	0	0	100
(b)	Individuals									
	(i) Individuals holding nominal share capital upto Rs.1 lakh	0	20850	20850	0.68	0	20850	20850	0.68	0
	(ii) Individuals holding nominal share capital in excess of Rs.1 lakh	961200	0	961200	31.47	961200	0	961200	31.47	961200
(c)	Others									
	CLEARING MEMBERS	0	0	0	0	0	0	0	0	
	NON RESIDENT INDIANS	0	0	0	0	0	0	0	0	
(d)	Qualified Foreign Investor	0	0	0	0	0	0	0	0	
	Sub-Total B(2) :	2274635	20850	2295485	75.15	961200	20850	982050	32.15	57.22
	Total B=B(1)+B(2) :	2274635	20850	2295485	75.15	961200	20850	982050	32.15	57.22
	Total (A+B) :	3033650	20850	3054500	100	3033650	20850	3054500	100	
(C)	Shares held by custodians, against which Depository Receipts have been issued	0	0	0	0	0	0	0	0	
	GRAND TOTAL (A+B+C) :	3033650	20850	3054500	100	3033650	20850	3054500	100	

B) Shareholding of Promoter-

SN	Shareholder's Name	Shareholding at the beginning of the year			Shareholding at the end of the year			% change in shareholding during the year
		No. of Shares	% of total Shares of the company	% of Shares Pledged / encumbered to total shares	No. of Shares	% of total Shares of the company	% of Shares Pledged / encumbered to total shares	
1	Mr. Yogesh Agrawal	473315*	15.50	0	1786750	58.49	0	277.36



2	Mrs. Parul Agrawal	283700	9.29	0	283700	9.29	0	0
3	Ms. Ojaswini Avantika	2000	0.07	0	2000	0.07	0	0
	TOTAL	759015	24.85	0	2072450	67.85	0	173.04

C) Change in Promoters' Shareholding (please specify, if there is no change)

SN	Particulars	Shareholding at the beginning of the year		Cumulative Shareholding during the year	
		No. of shares	% of total shares of the company	No. of shares	% of total shares of the company
1.	Mr. Yogesh Agrawal				
	At the beginning of the year	473315*	15.50	473315	15.50
	Bought during the year	1313435	43.00	1313435	43.00
	Sold during the year	NIL	NIL	NIL	NIL
	At the end of the year	1786750	58.49	1786750	58.49

D) Shareholding Pattern of top ten Shareholders as on 31st March 2020: (Other than Directors, Promoters and Holders of GDRs and ADRs):

SN	For Each of the Top 10 Shareholders	Shareholding at the beginning of the year		Cumulative Shareholding during the Year	
		No. of shares	% of total shares of the company	No. of shares	% of total shares of the company
1.	Harish Chandra Sharma				
	At the beginning of the year	348700	11.42	348700	11.42
	Bought during the year	NIL	NIL	NIL	NIL
	Sold during the year	NIL	NIL	NIL	NIL
	At the end of the year	348700	11.42	348700	11.42
2.	Deepti Aggarwal				
	At the beginning of the year	336000	11.00	336000	11.00
	Bought during the year	NIL	NIL	NIL	NIL
	Sold during the year	NIL	NIL	NIL	NIL
	At the end of the year	336000	11.00	336000	11.00
3.	Amar Aggarwal				
	At the beginning of the year	276500	9.05	276500	9.05
	Bought during the year	NIL	NIL	NIL	NIL
	Sold during the year	NIL	NIL	NIL	NIL
	At the end of the year	276500	9.05	276500	9.05
4.	Avani Gupta				
	At the beginning of the year	4,000	0.13	4,000	0.13
	Bought during the year	NIL	NIL	NIL	NIL
	Sold during the year	NIL	NIL	NIL	NIL
	At the end of the year	4,000	0.13	4,000	0.13
5.	Parteek Gupta				
	At the beginning of the year	4,000	0.13	4,000	0.13
	Bought during the year	NIL	NIL	NIL	NIL
	Sold during the year	NIL	NIL	NIL	NIL
	At the end of the year	4,000	0.13	4,000	0.13

6.	Anwar Saidkhan				
	At the beginning of the year	200	0.01	200	0.01
	Bought during the year	NIL	NIL	NIL	NIL
	Sold during the year	NIL	NIL	NIL	NIL
	At the end of the year	200	0.01	200	0.01
7.	Anwar Saidkhan				
	At the beginning of the year	200	0.01	200	0.01
	Bought during the year	NIL	NIL	NIL	NIL
	Sold during the year	NIL	NIL	NIL	NIL
	At the end of the year	200	0.01	200	0.01
8.	Deeba Yunus				
	At the beginning of the year	200	0.01	200	0.01
	Bought during the year	NIL	NIL	NIL	NIL
	Sold during the year	NIL	NIL	NIL	NIL
	At the end of the year	200	0.01	200	0.01
9.	Syed Mohd. Jamal				
	At the beginning of the year	200	0.01	200	0.01
	Bought during the year	NIL	NIL	NIL	NIL
	Sold during the year	NIL	NIL	NIL	NIL
	At the end of the year	200	0.01	200	0.01
10.	Rasiklal H Narechania				
	At the beginning of the year	200	0.01	200	0.01
	Bought during the year	NIL	NIL	NIL	NIL
	Sold during the year	NIL	NIL	NIL	NIL
	At the end of the year	200	0.01	200	0.01

E) Shareholding of Directors and Key Managerial Personnel as on 31st March 2020:

SN	Shareholding of each Directors and each Key Managerial Personnel	Shareholding at the beginning of the year		Date	Increase/Decrease in share holding	Reason	Cumulative Shareholding during the Year	
		No. of shares	% of total shares of the company				No. of shares	% of total shares of the company
1.	Yogesh Agrawal (Managing Director)	473315*	15.50	08.04.2019	1313435*	Purchase of shares through Transfer on market	1786750	58.49
2.	Parul Agrawal (Director)	2,83,700	9.29	NA	NA	NA	2,83,700	9.29
3.	Rajesh Kumar Saxena (Director)	NIL	NIL	NA	NA	NA	NIL	NIL
4.	Pradeep Gupta (Director)	NIL	NIL	NA	NA	NA	NIL	NIL
5.	Lalit Shah (Chief Financial Officer)	NIL	NIL	NA	NA	NA	NIL	NIL
6.	Hitesh Kumar (Company Secretary)	NIL	NIL	NA	NA	NA	NIL	NIL

*We hereby clarify that the due to unawareness of the filing of prescribed form of pledge, Mr. Yogesh Agrawal, Promoter and Managing Director of the Company submitted the wrong form to his Depository Participant SMC Global Securities Limited on 27.03.2019 by mentioning For Pledge in the form but Depository Participant, with their own understanding, instead of pledging of shares, transferred the 1313435 shares in the Account of Sunglow Fininvest Private Limited. His intention was to pledge the shares not to transfer the shares to Sunglow Fininvest Private Limited but SMC Global Securities Limited, due to misunderstanding, has transferred the shares into account of Sunglow Fininvest Private Limited. To correct the above transaction, Sunglow Fininvest Private Limited reverted the 1313435 shares in his account on 08.04.2019 and a fresh pledge form has been submitted by Mr. Yogesh Agrawal to his Depository Participant SMC Global Securities Limited for getting pledge his 1313435 shares in favour of Sunglow Fininvest Private Limited and creation of pledge executed with correct form.

**V) INDEBTEDNESS -Indebtedness of the Company including Service charge outstanding/accrued but not due for payment as on 31st March 2020:
(In Rs.)**

	Secured Loans excluding deposits	Unsecured Loans	Deposits	Total Indebtedness
Indebtedness at the beginning of the financial year				
i) Principal Amount	1,47,88,077	85,00,000	NIL	2,32,88,077
ii) Service charge due but not paid	NIL	NIL	NIL	NIL
iii) service charge accrued but not due	NIL	NIL	NIL	NIL
Total (i+ii+iii)	1,47,88,077	85,00,000	NIL	2,32,88,077
Change in Indebtedness during the financial year				
Addition (Service charge)	NIL	NIL	NIL	NIL
Reduction	NIL	13,80,000	NIL	13,80,000
Net Change	NIL	13,80,000	NIL	13,80,000
Indebtedness at the end of the financial year				
i) Principal Amount	1,47,88,077	71,20,000	NIL	2,19,08,077
ii) Interest due but not paid	NIL	NIL	NIL	NIL
iii) Interest accrued but not due	NIL	NIL	NIL	NIL
Total (i+ii+iii)	1,47,88,077	71,20,000	NIL	2,19,08,077

VI. REMUNERATION OF DIRECTORS AND KEY MANAGERIAL PERSONNEL-

A. Remuneration to Managing Director, Whole-time Directors and/or Manager:

SN.	Particulars of Remuneration	Name of MD/WTD/ Manager	Total Amount
		Mr. Yogesh Agrawal	
1	Gross salary		
	(a) Salary as per provisions contained in section 17(1) of the Income-tax Act, 1961	Rs. 4,50,000	Rs. 4,50,000
	(b) Value of perquisites u/s 17(2) Income-tax Act, 1961	NIL	NIL
	(c) Profits in lieu of salary under section 17(3) Income- tax Act, 1961	NIL	NIL
2	Stock Option	NIL	NIL
3	Sweat Equity	NIL	NIL



4	Commission - as % of profit - others, specify...	NIL	NIL
5	Others, please specify	NIL	NIL
	Total (A)	Rs. 4,50,000	Rs. 4,50,000
	Ceiling as per the Act		Rs. 60,00,000

B. Remuneration to other directors

SN.	Particulars of Remuneration	Name of Directors			Total Amount
		Pradeep Gupta	Rajesh Kumar Saxena	Parul Agrawal	
1	Independent Directors	NIL	NIL	NIL	NIL
	Fee for attending board committee meetings	NIL	NIL	NIL	NIL
	Commission	NIL	NIL	NIL	NIL
	Others, please specify	NIL	NIL	NIL	NIL
	Total (1)	NIL	NIL	NIL	NIL
2	Other Non-Executive Directors	NIL	NIL	NIL	NIL
	Fee for attending board committee meetings	NIL	NIL	NIL	NIL
	Commission	NIL	NIL	NIL	NIL
	Others, please specify	NIL	NIL	NIL	NIL
	Total (2)	NIL	NIL	NIL	NIL
	Total (B)=(1+2)	NIL	NIL	NIL	NIL
	Total Managerial Remuneration	NIL	NIL	NIL	NIL
	Overall Ceiling as per the Act				Rs. 60,00,000

C. REMUNERATION TO KEY MANAGERIAL PERSONNEL OTHER THAN MD/MANAGER/WTD

SN	Particulars of Remuneration	Key Managerial Personnel				Total
		CEO	Hitesh Kumar (Company Secretary & Compliance Officer) till 25.06.2019	Sunil Kumar (Company Secretary & Compliance Officer) from 26.06.2019 to 07.03.2020	Lalit Shah (CFO)	
1	Gross salary					
	(a) Salary as per provisions contained in section 17(1) of the Income-tax Act, 1961	N.A.	1,68,000/-	2,28,559/-	4,65,000/-	8,61,559/-
	(b) Value of perquisites u/s 17(2) Income-tax Act, 1961	N.A.	0		0	0
	(c) Profits in lieu of salary under section 17(3) Income-tax Act, 1961	N.A.	0		0	0
2	Stock Option	N.A.	0		0	0



3	Sweat Equity	N.A.	0		0	0
4	Commission	N.A.	0		0	0
	- as % of profit	N.A.	0		0	0
	others, specify...	N.A.	0		0	0
5	Others, please specify	N.A.	0		0	0
	Total	N.A.	1,68,000/-	2,28,559/-	4,65,000/-	8,61,559/-

VII. PENALTIES / PUNISHMENT/ COMPOUNDING OF OFFENCES:

Type	Section of the Companies Act	Brief Description	Details of Penalty / Punishment/ Compounding fees imposed	Authority [RD / NCLT/ COURT]	Appeal made, if any (give Details)
A. COMPANY					
Penalty	NIL	NIL	NIL	NIL	NIL
Punishment	NIL	NIL	NIL	NIL	NIL
Compounding	NIL	NIL	NIL	NIL	NIL
B. DIRECTORS					
Penalty	NIL	NIL	NIL	NIL	NIL
Punishment	NIL	NIL	NIL	NIL	NIL
Compounding	NIL	NIL	NIL	NIL	NIL
C. OTHER OFFICERS IN DEFAULT					
Penalty	NIL	NIL	NIL	NIL	NIL
Punishment	NIL	NIL	NIL	NIL	NIL
Compounding	NIL	NIL	NIL	NIL	NIL

For and on behalf of
Genomic Valley Biotech Limited

sd/-
Yogesh Agrawal
Managing Director
DIN-01165288
Address: G-74, Pushkar Enclave,
Paschim Vihar, Delhi- 110063

sd/-
Parul Agrawal
Director
DIN-01165188
Address: G-74, Pushkar Enclave,
Paschim Vihar, Delhi- 110063

Date: 05.12.2020
Place: Haryana



Annexure C to the Board Report

ANDROS & CO.
CHARTERED ACCOUNTANTS

901, TOWER-1, PEARL OMAXE, PLOT B-1,
NETAJI SHUBHASH PLACE, PITAMPURA
DELHI-110034
Ph-011-47060901
Email: cabhavukgarg@gmail.com

AUDITORS' CERTIFICATE REGARDING COMPLIANCE OF CONDITIONS OF CORPORATE GOVERNANCE

To
The Members
Genomic Valley Biotech Limited
4 K.M. Stone, Berri Charra Road,
P.O. Tanda Heri, Tehsil- Bahadurgarh,
Distt. Jhajjar, Haryana-124507

We have examined the compliance of conditions of Corporate Governance by Genomic Valley Biotech Limited (**'the Company'**) for the year ended 31 March, 2020, as stipulated in chapter IV of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 pursuant to the Listing Agreement of the said Company with stock exchanges.

The compliance of conditions of Corporate Governance is the responsibility of the Company's management. Our examination was limited to procedures and implementation thereof, adopted by the Company for ensuring the compliance of the conditions of the Corporate Governance. It is neither an audit nor an expression of opinion on the financial statements of the Company.

In our opinion and to the best of our information and according to the explanations given to us, we certify that the Company has complied with the conditions of Corporate Governance as stipulated in the provisions as specified in Chapter IV of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 pursuant to Listing Agreement of the said Company with stock exchanges.

We further state that such compliance is neither an assurance as to the future viability of the Company nor the efficiency or effectiveness with which the management has conducted the affairs of the Company.

For ANDROS & CO.
CHARTERED ACCOUNTANT

sd/-
(CA Bhavuk Garg)
(Partnership Firm)
(Membership No.-502310)
UDIN: 20502310AAAAANE8038

Date: 05.12.2020
Place: New Delhi

Annexure D to the Board Report

NOMINATION AND REMUNERATION POLICY

1. INTRODUCTION:

The Board of Directors (the “**Board**”) of Genomic valley Biotech Limited (the “**Company** or “**GVBL**”) has adopted the following policy and procedures with regard to Nomination and Remuneration.

In terms of the provisions of the Companies Act, 2013 and SEBI (Listing Regulations and Disclosure Requirements) Regulations, 2015, this policy on nomination and remuneration of Directors, Key Managerial Personnel (KMP) and Senior Management has been formulated by the Nomination and Remuneration Committee (“**NRC**”) and approved by the Board of Directors of the Company.

2. CONSTITUTION OF COMMITTEE:

The Board of Directors of the Company (the Board) constituted the Committee known as Nomination and Remuneration Committee consisting of three or more non-executive directors out of which not less than one half are independent directors. The chairman of the Committee is an Independent Director. However, Chairperson of the Board (executive or non executive) may be appointed as a member of the Nomination and Remuneration Committee but shall not chair such Committee.

3. OBJECTIVE:

The Nomination and Remuneration Committee and this policy shall be compliance in with Section 178 of the Companies Act, 2013 read along with the applicable rules thereto and SEBI (Listing Regulations and Disclosure Requirements) Regulations, 2015.

The objective of this policy is to lay down a framework in relation to remuneration of directors, KMP, senior management personnel and other employees. The key objectives of the Committee would be:

- a) To guide the Board in relation to appointment and removal of directors, KMP and senior management.
- b) Formulate the criteria for determining qualifications, positive attributes, and independence of a director and recommend the Board a Policy, relating to the remuneration for the directors, key managerial personnel and other employees.
- c) Formulation of criteria for evaluation of Independent Directors and the Board.
- d) To evaluate the performance of the members of the Board and provide necessary report to the Board.
- e) To recommend to the Board remuneration payable to the directors, key managerial personnel and senior management.
- f) To retain, motivate and promote talent of directors, managerial personnel required to run the Company successfully.
- g) To assist the Board in fulfilling responsibilities.
- h) To implement and monitor policies and processes regarding principles of corporate governance.

4. APPLICABILITY:

- a) Directors (Executive and Non-Executive)
- b) Key Managerial Personnel (KMP)
- c) Senior Management

5. DEFINITIONS:

“**Act**” means the Companies Act, 2013 and Rules framed there under, as amended from time to time.

“**Board**” means Board of Directors of the Company.

“**Directors**” means Directors of the Company.

“**Key Managerial Personnel**” means

- a) Managing Director, or Chief Executive Officer or Manager and in their absence, a Whole Time Director;
- b) Chief Financial Officer;

- c) Company Secretary; and
- d) such other officer as may be prescribed.

“Senior Management” means the personnel of the Company who are members of its core management team excluding Board of Directors comprising all members of management one level below the executive directors.

Unless the context otherwise requires, words and expressions used in this policy and not defined herein but defined under the Companies Act, 2013 as may be amended from time to time.

6. POLICY FOR APPOINTMENT AND REMOVAL OF DIRECTOR, KEY MANAGEMENT PERSONNEL AND SENIOR MANAGEMENT:

I. APPOINTMENT CRITERIA AND QUALIFICATION:

- a) The Committee shall identify and ascertain the integrity, qualification, expertise and experience of the person for appointment as Director or Key Managerial Personnel or Senior Management and recommend to the Board for his / her appointment.
- b) A person should possess adequate qualification, expertise and experience for the position he/ she is considered for appointment. The Committee has discretion to decide whether qualification, expertise and experience possessed by a person is sufficient / satisfactory for the concerned position.
- c) The Company shall not appoint or continue the employment of any director as Whole Time Director who has attained the age of seventy years. Provided that the term of a person holding such office may be extended beyond the age of 70 years with the approval of the shareholders by passing a special resolution. The explanatory statement to be annexed to the notice for passing of such special resolution should indicate the justification for extension of appointment of such person beyond seventy years.

II. TERM / TENURE:

a) Managing Director / Whole Time Director:

The Company shall appoint or re-appoint any person as its Managing Director / Whole Time Director for a term not exceeding five years at a time.

b) Independent Director:

An Independent Director hold office for a term upto five consecutive years on the Board of the Company and will be eligible for re-appointment on passing of a special resolution by the Company and disclosure of such appointment in the Board’s Report.

No Independent Director shall hold office for more than two consecutive terms of upto maximum 5 years each, but such Independent Director shall be eligible for appointment after expiry of three years of ceasing to become an Independent Director. Provided that an Independent Director shall not, during the said period of three years, be appointed in or be associated with the Company in any other capacity, either directly or indirectly.

At the time of appointment of Independent Director it should be ensured that number of Boards on which such Independent Director serves is restricted to seven listed companies as an Independent Director and three listed companies as an Independent Director in case such person is serving as a Whole-Time Director of a listed company or such other number as may be prescribed in the Act.

III. EVALUATION:

The Committee shall carry out evaluation of performance of every director, key managerial personnel and senior management at annual intervals.

IV. REMOVAL:

Due to reasons for any disqualification mentioned in the Act or under any other applicable Act, rules or regulations there under, the Committee may recommend, to the Board with reasons recorded in writing , removal of a Director, Key Managerial Personnel and/or Senior Management Personnel subject to the provisions of the Act, rules and regulations of the said Act.

V. RETIREMENT:

The Director, Key Managerial Personnel and Senior Management Personnel shall retire as per the applicable provisions of the Act. The Board may have the discretion to retain a Director, Key Managerial Personnel and/or Senior Management Personnel in the same position remuneration or otherwise, even after attaining the retirement age, for the benefit of the Company.

7. POLICY FOR REMUNERATION TO DIRECTORS, KEY MANAGERIAL PERSONNEL AND SENIOR MANAGEMENT PERSONNEL:

A. Remuneration to Managing/Whole-time/Executive/Managing Director, Key Managerial Personnel and Senior Management Personnel:

The Remuneration/ Compensation/ Commission etc. to be paid to Director / Managing Director etc. shall be governed as per the provisions of the Companies Act, 2013 and the rules made there under or any other enactment for the time being in force.

B. Remuneration to Independent Directors:

The Non-Executive Independent Director may receive sitting fees subject to ceiling / limits as provided under the Companies Act, 2013 and rules made there under of any other enactment for the time being in force.

C. Roles and Responsibility in relation to Nomination Matters:

- a) Ensure that there is appropriate induction/policy in place for new Directors and members for senior management and reviewing its effectiveness;
- b) Ensuring that on appointment to the Board, Non-Executive Directors receive a formal letter of appointment in accordance with the guidelines provided under the Act;
- c) Identifying and determining the Directors who are to retire by rotation.
- d) Determining the appropriate size, diversity and composition of the Board;
- e) Evaluating the performance of the Board Members and Senior Management in the context of the Company's performance from compliance and business perspective;
- f) Making recommendations to the Board concerning any matters relating to the continuation in office of any Director at any time including the termination or suspension of service of an Executive Director as employee of the Company subject to the provision of the law.
- g) Recommend any necessary changes to the Board.
- h) Considering any other matters, as may be requested by the Board.

D. In Relation to Remuneration Matters:

The duties of the Committee in relation to remuneration matters include:-

- a) Considering and determining the Remuneration Policy, based on the performance and also Bearing in mind that the remuneration is reasonable and sufficient to attract, retain and motivate members of the Board and such other factors as the Committee shall deem appropriate.
- b) Approving the remuneration of the Senior Management including key managerial personnel of the Company, and maintain a balance between objectives appropriate to the working of the Company.
- c) Delegating any of its powers to one or more of its members or the Secretary of the Committee.
- d) Considering any other matters as may be requested by the Board.

8. REVIEW AND AMENDMENT

- a) The Committee or the Board may review the Policy as and when it deems necessary.
- b) The Committee may issue the guidelines, procedures, formats, reporting mechanism and manual in supplement and better implementations to this Policy, if it thinks necessary.
- c) This Policy may be amended or substituted by the Committee or by the Board as and when required where there is any statutory change necessitating change in the policy.

Annexure E to the Board Report

Form No. MR-3

SECRETARIAL AUDIT REPORT

FOR THE PERIOD FROM APRIL 1, 2019 TO MARCH 31, 2020

[Pursuant to section 204(1) of the Companies Act, 2013 and Rule no.9 of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014]

To,
The Members,
GENOMIC VALLEY BIOTECH LIMITED
4 KM STONE BERI CHHARRA ROAD,
P.O. TANDAHERI, TEHSIL-BAHADURGARH,
DISTT-JHAJJAR, HARYANA-124507

I have conducted the secretarial audit of the compliance of applicable statutory provisions and the adherence to good corporate practices by GENOMIC VALLEY BIOTECH LIMITED (hereinafter called "the Company").

Secretarial Audit was conducted in a manner that provided us a reasonable basis for evaluating the corporate conducts/statutory compliances and expressing my opinion thereon.

Based on my verification of the Company's books, papers, minute books, forms and returns filed and other records maintained by the Company as specified in **ANNEXURE-I**, and also the information provided by the Company, its officers, agents and authorized representatives during the conduct of secretarial audit, I hereby report that in our opinion, the Company has, during the period covered by our audit, that is to say, from April 01, 2019 to March 31, 2020 (hereinafter referred to as "Audit Period"), complied with the statutory provisions listed hereunder and also that the Company has proper board-processes and compliance-mechanism place to the extent, in the manner and subject to the reporting made hereinafter:

I have examined the Books, Papers, Minute Books, Forms and Returns filed and other records maintained by the Company for the Audit Period according to the provisions of:

1. The Companies Act, 2013 ("the Act") and the rules made thereunder;
2. The Securities and Exchange Board of India (Listing Obligation and Disclosure Requirements) Regulations, 2015 ("LODR");
3. The Securities Contracts (Regulation) Act, 1956 ("SCRA") and the rules made thereunder;
4. The Depositories Act, 1996 and the regulations and bye-laws framed thereunder;
5. Foreign Exchange Management Act, 1999 and the rules and regulations made thereunder to the extent of Foreign Direct Investment, Overseas Direct Investment and External Commercial Borrowings; Not Applicable
6. The following Regulations and Guidelines prescribed under the Securities and Exchange Board of India Act, 1992 ("SEBI Act"):-
 - a. The Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011;
 - b. The Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 1992;



- c. The Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015;
- d. The Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2009;
- e. The Securities and Exchange Board of India (Employee Stock Option Scheme and Employee Stock Purchase Scheme) Guidelines, 1999; Not Applicable
- f. The Securities and Exchange Board of India (Registrars to an Issue and Share Transfer Agents) Regulations, 1993 regarding the Companies Act and dealing with client;
- g. The Securities and Exchange Board of India (Delisting of Equity Shares) Regulations, 2009; Not Applicable and
- h. The Securities and Exchange Board of India (Buyback of Securities) Regulations, 1998; Not Applicable

I have also examined compliance with the applicable clauses of the following:

1. Secretarial Standards 1 and 2 as issued by the Institute of Company Secretaries of India;
2. Laws specifically applicable to the industry to which the Company belongs: We have been intimated by the Company that no specific laws are applicable to it.

During the Audit Period, the Company has complied with the provisions of the Act, Rules, Regulations, Guidelines, etc. mentioned above subject to the following observations:

My observations:

The Board of Directors of the Company is duly constituted with proper balance of Executive Directors, Non-Executive Directors and Independent Directors. The number of directors liable to retire by rotation is in compliance with provision of 152 (6) of Act, 2013 which provides that 2/3rd of the total directors (except independent directors) of the Company shall be such whose period of office will be liable to determination by retirement of directors by rotation.

As per section 203 of the Companies act, 2013 the KMP has to be appointed within 6 months from the date of vacation which has been complied by the Company.

Recommendations as a matter of best practice:

In the course of our audit, we have made certain recommendations for good corporate practices, separately placed before the Board, for its consideration and implementation by the Company.

I further report that having regard to the compliance system prevailing in the company and on examination of the relevant documents and records in pursuance thereof, on the test check basis, the company has complied with the laws applicable specifically to the company.

I further report that the Company has adopted a proper internal financial controls and risk management policy of the Company. It is the duty of the directors to ensure that there is proper system for the internal financial control and risk management systems of the Company.

I further reported that the company is adequate in filing all forms and returns as per the Act. Company had taken disclosure of interest from directors and taken a note for the same in Board Meeting.

Adequate notices were given to all directors to schedule the Board Meeting, Agenda and detailed notes on agenda were sent at least seven days in advance, and a system exists for seeking and obtaining further information and clarifications on the agenda items before the meeting and for meaningful participation at the meeting.

All the decisions in the Board Meeting and Committee meeting are carried out unanimously and recorded in the minutes of the meetings of the Board of Directors and committee of the Board of Directors, as the case may be.

I further report that subject to above the company has complied with the conditions of Corporate Governance as stipulated in the Act and the Listing Regulations.

I further report that the Company is reportedly in the process, has laid down adequate systems and processes commensurate with the size and operations of the Company to monitor and ensure compliance with applicable laws, rules, regulations and guidelines.

I further reported that during the Audit Period, the Company has not incurred any specific event/ action that can have a major bearing on the company's affairs in pursuance of the above referred laws, rules, regulations, guidelines, standards, etc.

Note: This report is to be read with our letter of even date which is annexed as "Annexure I" and "Annexure A" and forms an integral part of this report.

**Place: Gurgaon
Date: 26.06.2020**

**For and behalf of
Rohit Batham & Associates**

sd/-
Rohit Batham
Membership No.:37260
C P No.:19095
UDIN: A037260B000383958



ANNEXURE-I

LIST OF DOCUMENTS

- 1.1 Minutes books of the following Meetings were provided:
 - i. Board Meeting
 - ii. Audit Committee
 - iii. Nomination and Remuneration Committee
 - iv. Stakeholder Relationship Committee
 - v. General Meeting
 - vi. Minutes of Independent Directors

- 1.2 Annual Report (2018-19), Annual Accounts for the F.Y. 2019-20

- 1.3 Memorandum and Articles of Association

- 1.4 Disclosures under the Act, 2013

- 1.5 Policies framed under the Act, 2013

- 1.6 Documents pertaining to to Compliances under SEBI (LODR) Regulations, 2015

- 1.7 Forms and returns filed with the ROC

- 1.8 Registers maintained under Act, 2013



ANNEXURE 'A' TO THE SECRETARIAL AUDIT REPORT

To,

The Members,
GENOMIC VALLEY BIOTECH LIMITED
4 KM STONE, BERI CHHARRA ROAD,
P.O. TANDAHERI, TEHSIL-BAHADURGARH,
DISTT-JHAJJAR, HARYANA-124507

1. Maintenance of secretarial record is the responsibility of the management of the company. My responsibility is to express an opinion on these secretarial records based on my audit.
2. I have followed the audit practices and processes as were appropriate to obtain reasonable assurance about the correctness of the contents of the secretarial records. The verification was done on the random test basis to ensure that correct facts are reflected in secretarial records. I believe that the processes and practices, I followed provide a reasonable basis for our opinion.
3. I have not verified the correctness and appropriateness of financial records and Books of Accounts of the Company.
4. Where ever required, I have obtained the Management representation about the compliance of laws, rules and regulations and happening of events etc.
5. The compliance of the provisions of Corporate and other applicable laws, rules, regulations, standards is the responsibility of management. My examination was limited to the verification of procedures on the random test basis.
6. The Secretarial Audit report is neither an assurance as to the future viability of the company nor of the efficacy or effectiveness with which the management has conducted the affairs of the Company.

**Place: Gurgaon
Date: 26.06.2020**

**For and behalf of
Rohit Batham & Associates**

sd/-
Rohit Batham
Membership No.:37260
C P No.:19095
UDIN: A037260B000383958

CORPORATE GOVERNANCE

Transparency and accountability are the two basic tenets of Corporate Governance. At Genomic Valley Biotech Limited (GVBL), we feel proud to belong to a Company for good governance long back and made it an integral principle of the business, as demonstrated in the words above.

Responsible corporate conduct is integral to the way we do our business. Our actions are governed by our values and principles, which are reinforced at all levels within the Company. At GVBL, we are committed to doing things the right way which means taking business decisions and acting in a way that is ethical and is in compliance with applicable legislation. Our Code of Business Principles is an extension of our values and reflects our continued commitment to ethical business practices across our operations. We acknowledge our individual and collective responsibilities to manage our business activities with integrity. Our Code of Business Principles inspires us to set standards which not only meet applicable legislation but go beyond in many areas of our functioning.

To succeed, we believe, requires highest standards of corporate behaviour towards everyone we work with, the communities we touch and the environment on which we have an impact. This is our road to consistent, competitive, profitable and responsible growth and creating long term value for our shareholders, our people and our business partners. The above principles have been the guiding force for whatever we do and shall continue to be so in the years to come.

The Board of Directors ('the Board') is responsible for and committed to sound principles of Corporate Governance in the Company. The Board plays a crucial role in overseeing how the management serves the short and long term interests of shareholders and other stakeholders. This belief is reflected in our governance practices, under which we strive to maintain an effective, informed and independent Board. We keep our governance practices under continuous review and benchmark ourselves to best practices across the globe.

The Board of Directors has adopted 'Corporate Governance Code' for the Company which is a statement of practices and the procedures to be followed by the Company. The copy of the code is available on Company's website www.genomicvalley.com.

THE BOARD OF DIRECTORS

The Board of Directors is entrusted with the ultimate responsibility of the management, general affairs, direction and performance of the Company and has been vested with requisite powers, authorities and duties. The Management of the Company is headed by the Managing Director and has business / functional heads as its members, which look after the management of the day-to-day affairs of the Company.

Composition

The Board comprises such number of Non-Executive, Executive and Independent Directors as required under applicable legislation. As on date of this Report, the Board consists of four Directors comprising one Non-Executive director, Two Independent Directors and One Executive Director. The composition of the Board represents an optimal mix of professionalism, knowledge and experience and enables the Board to discharge its responsibilities and provide effective leadership to the business.

The details of each member of the Board along with the number of Directorship(s) / Committee Membership(s)/Chairmanship(s) and date of joining the Board are provided herein below:

Composition and Directorship(s) / Committee Membership(s)/Chairmanship(s) as on 31st March, 2020

Name	Date of Joining the Board	No. of Directorship held in other Companies	*No. of Board Committee Membership held in other Companies.	*No. of Board Committee Chairmanship held in other Companies.
Mr. Yogesh Agrawal	15-03-1996	1	-	-
Mrs. Parul Agrawal	29-09-2010	1	-	-
Mr. Rajesh Kumar Saxena	28-06-2014	1	-	-
Mr. Pradeep Gupta	28-06-2014	1	-	-

*Includes Membership and chairmanship only in Audit committee, Stakeholder relationship Committee.

The number of Directorships, Committee Memberships/ Chairmanships of all Directors is within respective limits prescribed under the Companies Act, 2013 and SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015.

None of the Directors on the Board are Members of more than 10 Committees or Chairman of more than 5 Committees across all the companies in which they are Directors. Necessary disclosures regarding Committee positions including the changes in other listed companies as on 31 March, 2020 have been made by the Directors as per SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015.

Appointment and Tenure

The Directors of the Company are appointed by Members at the General Meetings. In accordance with the Articles of Association of the Company, all Directors, except the Managing Director and Independent Directors of the Company, step down at the Annual General Meeting each year and, if eligible, offer themselves for re-election. The Managing Director of the Company has been appointed for a term of five years in the Last Annual General Meeting as per the requirement of the statute.

As regards the appointment and tenure of Independent Directors, following is the policy adopted by the Board:

- The Company has adopted the provisions with respect to appointment and tenure of Independent Directors which are consistent with the Companies Act, 2013 and SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015.
-
- The Independent Directors will serve a maximum of two terms of five years each.
-
- The Company would not have any upper age limit of retirement of Independent Directors from the Board and their appointment and tenure will be governed by provisions of the Companies Act, 2013.

Board Independence

Our definition of 'Independence' of Directors is derived from Regulation 25 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 and Section 149(6) of the Companies Act, 2013.

Board Meetings

The Board meets at regular intervals to discuss and decide on Company / business policy and strategy apart from other Board business. The Board / Committee Meetings are pre-scheduled and a tentative annual calendar of the Board and Committee Meetings is circulated to the Directors well in advance to facilitate them to plan their schedule and to ensure meaningful participation in the meetings. However, in case of a special and urgent business need, the Board's approval is taken by passing resolutions by circulation, as permitted by law, which is noted and confirmed in the subsequent Board meeting.

The notice of Board meeting is given well in advance to all the Directors. Usually, meetings of the Board are held at registered office. The Agenda of the Board / Committee meetings is set by the Company Secretary in consultation with the Chairman of the Company. The Agenda is circulated a week prior to the date of the meeting.

The Agenda for the Board and Committee meetings includes detailed notes on the items to be discussed at the meeting to enable the Directors to take an informed decision.

During the Financial Year 2019-2020, Five Board meetings were held on 30th May, 2019, 25th June, 2019, 28th July, 2019, 12th November, 2019 and 14th February, 2020. The maximum interval between any two meetings was well within the maximum allowed gap of 120 days.

Board Business

The normal business of the Board includes:

- framing and overseeing progress of the Company's annual plan and operating framework;
- framing strategies for shaping of portfolio and direction of the Company and for corporate resource allocation;
- reviewing financial plans of the Company;
- reviewing quarterly and annual business performance of the Company;
- reviewing the Annual Report and accounts for adoption by the Members;
- reviewing the progress of various functions and businesses of the Company;
- reviewing the functioning of the Board and its Committees;
- considering and approving declaration / recommendation of dividend;
- reviewing and resolving fatal or serious accidents or dangerous occurrences, any materially significant effluent or pollution problems or significant labour issues, if any;
- reviewing the details of significant development in human resources and industrial relations front;
- reviewing details of foreign exchange exposure and steps taken by the management to limit the risks of adverse exchange rate movement;
- reviewing compliance with all relevant legislations and regulations and litigation status, including materially important show cause, demand, prosecution and penalty notices, if any;
- reviewing Board Remuneration Policy and individual remuneration packages of Directors;
- advising on corporate restructuring such as merger, acquisition, joint venture or disposals, if any;
- appointing Directors on the Board and Members of Management Committee;
- reviewing Corporate Social Responsibility policy of the Company and monitoring implementation thereof;
- reviewing details of risk evaluation and internal controls;
- reviewing reports on progress made on the ongoing projects;
- Monitoring and reviewing Board Evaluation framework.

Board Support

The Company Secretary is responsible for collation, review and distribution of all papers submitted to the Board and Committees thereof for consideration. The Company Secretary is also responsible for preparation of the Agenda and convening of the Board and Committee meetings. The Company Secretary attends all the meetings of the Board and its Committees, advises / assures the Board on Compliance and Governance principles and ensures appropriate recording of minutes of the meetings.

Separate Independent Directors' Meetings

The Independent Directors meet at least once in a year, without the presence of Executive Directors or Management representatives. They also have a separate meeting with the Non-Executive Chairman, to discuss issues and concerns, if any.

The Independent Directors met one times during the Financial Year ended 31st March, 2020 on 28th February, 2020 and inter alia discussed:

- The performance of non-Independent Directors and the Board as a whole;
- The performance of the Chairperson of the Company, taking into account the views of Executive Directors and Non- Executive Directors; and
- The quality, quantity and timeliness of flow of information between the Company management and the Board that is necessary for the Board to effectively and reasonably perform their duties.

In addition to these formal meetings, interactions outside the Board meetings also take place between the Chairman and Independent Director.

Directors’ Induction and Familiarization

The provision of an appropriate induction programme for new Directors and ongoing training for existing Directors is a major contributor to the maintenance of high Corporate Governance standards of the Company. The Chief Financial Officer and the Company Secretary are jointly responsible for ensuring that such induction and training programmes are provided to Directors. The Independent Directors, from time to time request management to provide detailed understanding of any specific project, activity or process of the Company. The management provides such information and training either at the meeting of Board of Directors or otherwise. Details of such program have been disclosed on the website of the company (www.genomicvalley.com).

The induction process is designed to:

- a. build an understanding of GVBL, its businesses and the markets and regulatory environment in which it operates;
- b. provide an appreciation of the role and responsibilities of the Director;
- c. fully equip Directors to perform their role on the Board effectively; and
- d. develop understanding of Company’s people and its key stakeholder relationships.

Upon appointment, Directors receive a Letter of Appointment setting out in detail, the terms of appointment, duties, responsibilities and expected time commitments.

In addition to the extensive induction and training provided as part of the familiarization programme, the Independent Directors are also taken through various business and functional sessions in the Board meetings including the Board meetings to discuss strategy.

Board Evaluation

The Nomination and Remuneration Committee of the Company approved Evaluation Policy during the year, which was adopted by the Board of Directors. The policy provides for evaluation of the Board, the Committees of the Board and individual Directors, including the Chairman of the Board. The Policy provides that evaluation of the performance of the Board as a whole; Board Committees and Directors shall be carried out on an annual basis.

During the year, the cycle was completed by the Company internally which included the Evaluation of the Board as a whole, Board Committees and Directors. The exercise was led by the Non-Executive Chairman along with a Senior Independent Director of the Company. The Evaluation process focused on various aspects of the Board and Committees functioning such as composition of the Board and Committees, experience and competencies, performance of specific duties and obligations, governance issues etc. Separate exercise was carried out to evaluate the performance of individual Directors on parameters such as attendance, contribution and independent judgement.

The results of the Evaluation were shared with the Board, Chairman of respective Committees and individual Directors. Based on the outcome of the Evaluation, the Board and Committees have agreed on the action plan to improve on the identified parameters.

KEY BOARD QUALIFICATION, EXPERTISE AND ATTRIBUTES

The Board comprises qualified members who bring in the required skills, competence and expertise that allow them to make effective contributions to the Board and its committees. The Board members are committed to ensuring that the board is in compliance with the highest standards of corporate governance.

Definition of director qualifications	
Financial	Leadership of a financial firm or management of the finance function of an enterprise, resulting in proficiency in complex financial management, capital allocation, and financial reporting processes or experience in actively supervising a principal financial officer, principal accounting officer, controller, public accountant,

	auditor or person performing similar functions
Gender, ethnic, national, or other diversity	Representation of gender, ethnic, geographic, cultural or other perspectives that expand the Board's understanding of the needs and viewpoints of our customers, partners, employees, governments, and other stakeholders worldwide.
Global Business	Experience in driving business success in markets around the world with an understanding of diverse business environments, economic conditions, cultures and regulatory frameworks, and a board perspective on global market opportunities.
Leadership	Extended leadership experience for a significant enterprise, resulting in a practical understanding of organization, processes, strategic planning and risk management. Demonstrated strengths in developing talent, planning succession and driving change and long-term growth.
Technology	A significant background in technology, resulting in knowledge of how to anticipate technological trends, generate disruptive innovation and extend or create new business models.
Mergers and Acquisitions	A history of leading growth through acquisitions and other business combinations, which the ability to assess 'build or buy' decisions, analyze the fit of a target with the Company's strategy and culture, accurately value transactions, and evaluate operational integration plans.
Board Service and Governance	Service on a public company board to develop insights about maintaining board and management accountability, protecting shareholders interests, and observing appropriate governance practices.
Sales and Marketing	Experience in developing strategies to grow sales and market share, build brand awareness and equity and enhance enterprise reputation

In the table below, the specific areas of focus or expertise of individual Board Members have been highlighted. However, the absence of a mark against a member's name does not necessarily mean the member does not possess the corresponding qualification or skill.

Key Board Qualification								
Director	Area of expertise							
	Financial	Diversity	Global Business	Leadership	Technology	Mergers and Acquisitions	Board Service and Governance	Sale and Marketing
YOGESH AGRAWAL	✓	✓	✓	✓	✓	✓	✓	✓
PARUL AGRAWAL	✓	✓	-	✓	✓	-	✓	✓
RAJESH KUMAR SAXENA	✓	✓	✓	✓	✓	✓	✓	✓
PRADEEP GUPTA	✓	✓	✓	✓	✓	✓	✓	✓

DISCLOSURES OF TRANSACTIONS OF THE LISTED ENTITY WITH ANY PERSON OR ENTITY BELONGING TO THE PROMOTER/PROMOTER GROUP WHICH HOLD(S) 10% OR MORE SHAREHOLDING IN THE LISTED ENTITY

RELATED PARTY DISCLOSURES (Indian Accounting Standard (Ind AS) 24

(i) List of Related Parties with whom transactions have taken place and Relationships:

Sr. No.	Name of the Related Party	Relationship
1	Mr. Yogesh Agrawal (Executive Director)	Key Managerial Personnel
	Mrs. Parul Agrawal (Non-Executive - Non Independent Director)	
	Mr. Pradeep Gupta (Non-Executive - Independent Director)*	
	Mr. Rajesh Kumar Saxena (Non-Executive - Independent Director)**	
	Mr. Lalit Shah (Chief Financial Officer)	
	Mr. Hitesh Kumar (Company Secretary & Compliance Officer)***	
	Mr. Sunil Kumar (Company Secretary & Compliance Officer)****	
2	Mr. Yogesh Agrawal h/o Mrs. Parul Agrawal	Relatives of Key Managerial Personnel
	Mrs. Parul Agrawal w/o Mr. Yogesh Agrawal	
	Ms. Ojaswini Avantika d/o Mr. Yogesh Agrawal	

Note:

* Mr. Pradeep Gupta (Non-Executive - Independent Director) is reappointed as Non-Executive - independent Director of Company w.e.f. 28 June, 2019.

** Mr. Rajesh Kumar Saxena (Non-Executive - Independent Director) is reappointed as Non-Executive - Independent Director of Company w.e.f. 28 June, 2019.

*** Mr. Hitesh Kumar resigned from the post of Company Secretary and Compliance officer w.e.f. 25.06.2019.

**** Mr. Sunil Kumar is appointed as Company Secretary and Compliance officer of the company w.e.f. 26.06.2019.

(ii) Transactions for the period 01.04.2019 to 31.03.2020 with Related Parties:					(Rs. in Lakh)
S.NO.	NATURE OF TRANSACTION	KEY MANAGERIAL PERSONNEL	RELATIVES OF KEY MANAGERIAL PERSONNEL	ENTERPRISES OVER WHICH KEY MANAGERIAL PERSONNEL OR THEIR RELATIVES EXERCISE SIGNIFICANT INFLUENCE	TOTAL
		31-Mar-20	31-Mar-20	31-Mar-20	31-Mar-20
1	Purchase of Goods	Nil	Nil	Nil	Nil
2	Sale of Goods	Nil	Nil	Nil	Nil
3	Interest Paid	Nil	Nil	Nil	Nil
4	Rent Paid	Nil	Nil	Nil	Nil
5	Salary	12.507	Nil	Nil	12.507
6	Director's Sitting Fees	Nil	Nil	Nil	Nil
7	Unsecured Loans Received	100.168	Nil	Nil	100.168
8	Repayment Of Unsecured Loans	34.07	Nil	Nil	34.07
9	Outstanding Receivables	Nil	Nil	Nil	Nil
10	Outstanding Payable	65.15258	Nil	Nil	65.15258

(iii) Transaction wise detail of related parties			(Rs. in Lakh)
Sr. No.	Nature of Transaction	Name of Related Party	Transaction Amount 31-03-2020
1	Purchase of Goods		Nil
2	Sale of Goods		Nil
3	Rent Paid		Nil
4	Salary Paid	Mr. Yogesh Agrawal	4.5
		Mr. Lalit Shah	4.2
		Mr. Hitesh Kumar	1.68
		Mr. Sunil Kumar	2.127
		Total	12.507
5	Director's Sitting Fees	Mrs. Parul Agrawal	Nil
		Mr. Rajesh Kumar Saxena	Nil
		Mr. Pradeep Gupta	Nil
		Total	Nil
6	Interest Paid		Nil
7	Unsecured Loan Received		100.168
8	Repayment Of Unsecured Loans		34.07
Outstanding Payable			
9	Salary Payable		0.60834
	Rent Payable		Nil
	Interest Payable		Nil
	Unsecured Loan Payable		64.54424
	Trade Payable		Nil

COMMITTEES OF THE BOARD

The Board Committees play a crucial role in the governance structure of the Company and have been constituted to deal with specific areas / activities which concern the Company and need a closer review. The Board Committees are set up under the formal approval of the Board to carry out clearly defined roles which are considered to be performed by members of the Board, as a part of good governance practice. The Board supervises the execution of its responsibilities by the Committees and is responsible for their action. The minutes of the meetings of all Committees are placed before the Board for review. The Board Committees can request special invitees to join the meeting, as appropriate.

The Board has currently established the following statutory and non-statutory Committees.

Audit Committee

The Company's Audit Committee comprises all the 2 Independent Directors and non- executive director. The Chairman of Audit Committee is Mr. Pradeep Gupta and Mr. Rajesh Kumar Saxena and Mrs. Parul Agrawal are the members of the Committee. Mr. Rajesh Kumar Saxena and Mr. Pradeep Gupta were appointed as a Member of the Committee with effect from 28th June, 2014. All the members of the Committee have relevant experience in financial matters.

The Audit Committee of the Company is entrusted with the responsibility to supervise the Company's internal controls and financial reporting process and inter alia performs the following functions:

- Overseeing the Company's financial reporting process and disclosure of financial information to ensure that the financial statements are correct, sufficient and credible;
- Reviewing and examination with management the quarterly financial results before submission to the Board;
- Reviewing and examination with management the annual financial statements before submission to the Board and the auditors' report thereon;
- Review management discussion and analysis of financial condition and results of operations;

- Scrutiny of inter-corporate loans and investments made by the Company;
- Reviewing with management the annual financial statements as well as investments made by the unlisted subsidiary companies;
- Reviewing, approving or subsequently modifying any Related Party Transactions in accordance with the Related Party Transaction Policy of the Company;
- Approving the appointment of Chief Financial Officer after assessing the qualifications, experience and background, etc. of the candidate;
- Recommending the appointment, remuneration and terms of appointment of Statutory Auditors of the Company and approval for payment of any other services;
- Reviewing and monitoring the auditor's independence and performance, and effectiveness of audit process;
- Reviewing management letters / letters of internal control weaknesses issued by the Statutory Auditors;
- Discussing with Statutory Auditors, before the audit commences, on the nature and scope of audit as well as having post-audit discussion to ascertain area of concern, if any;
- Reviewing with management, Statutory Auditors and Internal Auditor, the adequacy of internal control systems;
- Recommending appointment, remuneration and terms of appointment of Internal Auditor of the Company;
- Reviewing the adequacy of internal audit function and discussing with Internal Auditor any significant finding and reviewing the progress of corrective actions on such issues;
- Evaluating internal financial controls and risk management systems;
- Valuating undertaking or assets of the Company, wherever it is necessary;
- Reviewing the functioning of the Whistle Blowing mechanism;
- Such other matters as the case may from time to time be required by any statutory, contractual or other regulatory requirements.

The Audit Committee also reviews the functioning of the Code of Business Principles and Whistle Blower Policy of the Company and cases reported thereunder. The recommendations of audit committee were duly approved and accepted by the Board.

The Company Secretary acts as the Secretary to the Committee. The minutes of each Audit Committee meeting are placed and confirmed in the next meeting of the Board. The Audit Committee also meets the internal and external auditors separately, without the presence of Management representatives.

The Audit Committee met Four (4) times during the Financial Year ended 31st March, 2020 on 30th May, 2019, 27th July, 2019, 11th November, 2019 and 14th February, 2020.

Risk Management Committee

The Company's Risk Management Committee comprises all the 2 Independent Directors and non-executive director. The chairman of Risk Management Committee is Mr. Pradeep Gupta. The members of the committee are Mr. Rajesh Kumar Saxena and Mrs. Parul Agrawal. The Board has constituted the committee on 12th February 2015.

The Risk Management Committee of the Company is entrusted with the responsibility to corporate risk assessment and mitigation and inter alia performs the following functions:

- Recommend to the Board and then formally announce, implement and maintain a sound system of risk identification oversight, management and internal control.
- To develop and seek Board approval for a range of specific duties that it is to be carried out.
- To detail the functions and processes which are considered necessary to ensure that the Board can be satisfied that the Company's risks are being effectively managed
- Examine and determine the sufficiency of the Company's internal processes for identifying, reporting and managing key risk areas.
- Consider other matters relating to risk management that it considers desirable. In addition, the Committee will examine any other matters referred to it by the Board.

Business Risk Assessment procedures have been set in place for self-assessment of business risks, operating controls and compliance with Corporate Policies. There is an ongoing process to track the evolution of risks and delivery of mitigating action plans.

Nomination and Remuneration Committee

The Nomination and Remuneration Committee comprises Mr. Pradeep Gupta as the Chairman and Mr. Rajesh Kumar Saxena and Mrs. Parul Agrawal as members of the Committee. In terms of Section 178 (1) of the Companies Act, 2013 and SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Nomination and Remuneration Committee should comprise of at least three Directors; all of whom should be Non-Executive Directors. At least half of the Committee members should be Independent with an Independent Director acting as the Chairman of the Committee.

The role of Nomination and Remuneration Committee is as follows:

- Determine/ recommend the criteria for appointment of Executive, Non-Executive and Independent Directors to the Board;
- Determine/ recommend the criteria for qualifications, positive attributes and independence of Director;
- Identify candidates who are qualified to become Directors and who may be appointed in the Management Committee and recommend to the Board their appointment and removal;
- Review and determine all elements of remuneration package of all the Executive Directors, i.e. salary, benefits, bonuses, stock options, pension etc;
- Review and determine fixed component and performance linked incentives for Directors, along with the performance criteria;
- Determine policy on service contracts, notice period, severance fees for Directors and Senior Management;
- Formulate criteria and carryout evaluation of each Director's performance and performance of the Board as a whole;

The Committee also plays a role of a Compensation Committee and is responsible for administering the Stock Option Plan and Performance Share Plan of the Company and determining eligibility of employees for stock options.

The Nomination and Remuneration Committee met Five (5) times during the Financial Year ended 31st March, 2020 on 30th May, 2019, 25th June, 2019, 27th July, 2019, 11th November, 2019 and 14th February, 2020.

Board Membership Criteria

The Board of Directors is collectively responsible for selection of a member on the Board. The Nomination and Remuneration Committee of the Company follows defined criteria for identifying, screening, recruiting and recommending candidates for election as a Director on the Board. The criteria for appointment to the Board include:

- Composition of the Board, which is commensurate with the size of the Company, its portfolio, geographical spread and its status as a listed Company;
- Desired age and diversity on the Board;
- Size of the Board with optimal balance of skills and experience and balance of Executive and Non-Executive Directors consistent with the requirements of law;
- Professional qualifications, expertise and experience in specific area of business;
- Balance of skills and expertise in view of the objectives and activities of the Company;
- Avoidance of any present or potential conflict of interest;
- Availability of time and other commitments for proper performance of duties;
- Personal characteristics being in line with the Company's values, such as integrity, honesty, transparency, pioneering mindset.

In line with the Evaluation Policy of the Company, the Nomination and Remuneration Committee considers the outcome of the annual Evaluation before recommending the changes in the remuneration of the Executive Directors and appointment/re-appointment of Directors.

Independent Directors are currently paid no sitting fees as company will grow it start paying the sitting fees in near future subject to the approval of members at general meeting.

The detail of remuneration paid to Executive Directors and remuneration paid to Non- executive Director for the financial year ended 31st March, 2020 as provided herein under.

S.NO	NAME OF DIRECTOR	SALARY
1.	Mr. Yogesh Agrawal	Rs. 4,50,000
2.	Mrs. Parul Agrawal	NIL
3.	Mr. Rajesh Kumar Saxena*	NIL
4.	Mr. Pradeep Gupta*	NIL

*Director in Independent capacity appointed on 28th June 2014.

Stakeholders' Relationship Committee

The Stakeholders' Relationship Committee is comprised of Mr. Pradeep Gupta, Independent Director as the Chairman and Mr. Rajesh Kumar Saxena and Mrs. Parul Agrawal as members of the Committee.

The role of Stakeholders' Relationship Committee is as follows:

- consider and resolve the grievances of shareholders of the Company with respect to transfer of shares, non-receipt of annual report, non-receipt of declared dividend, etc;
- ensure expeditious share transfer process in line with the proceedings of the Share Transfer Committee;
- evaluate performance and service standards of the Registrar and Share Transfer Agent of the Company;
- provide guidance and make recommendations to improve investor service levels for the investors.

During the Financial Year ended 31st March, 2020, the Committee met Four (4) times on 30th May, 2019, 27th July, 2019, 11th November, 2019 and 14th February, 2020.

Details of Shareholders' / Investors' Complaints

Mr. Sunil Kumar, Company Secretary and Compliance Officer of the Company, was the person who has been authorised for resolution of Shareholder's/Investor's complaints. During the Financial Year ended 31st March, 2020, no complaints were received from the shareholders.

Attendance of Directors at Board and Committee Meeting(s)

Name	Board Meeting: Held (Attended)	Audit Committee Meeting: Held (Attended)	Nomination and Remuneration committee Meeting: Held (Attended)	Stakeholder's Relationship Committee Meeting: Held (Attended)
Mr. Yogesh Agrawal	5(5)	Not Applicable (As He is not a member)	Not Applicable (As He is not a member)	Not Applicable (As He is not a member)
Mrs. Parul Agrawal	5(5)	4(4)	5(5)	4(4)
Mr. Rajesh Kumar Saxena	5(3)	4(2)	5(3)	4(2)
Mr. Pradeep Gupta	5(5)	4(4)	5(5)	4(4)

The last Annual General Meeting of the Company held on 23rd August, 2019 was attended by all members of the Board of Directors.

COMPANY POLICIES AND CODES

Whistle Blower Policy

The Company has adopted a Whistle Blower Policy, as part of vigil mechanism to provide appropriate avenues to the Directors and employees to bring to the attention of the management any issue which is perceived to be in violation of or in conflict with the fundamental business principles of the Company. The Company has provided dedicated e-mail addresses genomicvalley@gmail.com for reporting such concerns and contact person is Mr. Pradeep Gupta, Chairman of Audit Committee. Alternatively, employees can also send written communications to the Company. The employees are encouraged to voice their concerns by way of whistle blowing and all the employees have been given access to the Audit Committee. The Company Secretary is the designated officer for effective implementation of the policy and dealing with the complaints registered under the policy. All cases registered under the Whistle Blower Policy of the Company, are reported to the Committee of Executive Directors and are subject to the review of the Audit Committee. The Whistle Blower Policy is available on the website of the Company www.genomicvalley.com.

Code of Conduct for the members of the Board and Senior Management

The Board of Directors is responsible for ensuring that rules are in place to avoid conflict of interest by the Board members and the Management Committee. The Board has adopted the Code of Conduct for the members of the Board and Senior Management Team. The Code provides that the Directors are required to avoid any interest in contracts entered into by the Company. If such an interest exists, the Directors are required to make disclosure to the Board and to abstain from discussion, voting or otherwise influencing the decision on any matter in which the concerned Director has or may have such interest. The Code also restricts Directors from accepting any gifts or incentives in their capacity as a Director of the Company.

The members of the Board and the Management Committee annually confirm the compliance of the Code of Conduct to the Board. The Code of Conduct is in addition to the Code of Business Principles of the Company. A copy of the said Code of Conduct is available on the website of the Company www.genomicvalley.com.

Policy on dealing with Related Party Transactions

The Company has not entered in any material Related Party Transaction during the year. In line with requirement of the Companies Act, 2013 and SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, your Company has formulated a Policy on Related Party Transactions which is also available at Company's website at www.genomicvalley.com. The Policy intends to ensure that proper reporting, approval and disclosure processes are in place for all transactions between the Company and Related Parties.

This policy specifically deals with the review and approval of Material Related Party Transactions keeping in mind the potential or actual conflicts of interest that may arise because of entering into these transactions. Transactions with related parties as per AS – 18 have been disclosed in the notes forming part of Financial Statements. All Related Party Transactions are placed before the Audit Committee for review and approval. Prior omnibus approval is obtained for Related Party Transactions on a quarterly basis for transactions which are of repetitive nature and / or entered in the ordinary course of business and are at Arm's Length.

Code of Conduct to Regulate, Monitor and Report Trading by Insiders

The Company has instituted mechanism to avoid Insider Trading and abusive self-dealing. In accordance with the SEBI Regulations as amended, the Company has established systems and procedures to restrict insider trading activity.

The Code of the Company prohibits the Directors of the Company and other specified employees dealing in the securities of the Company on the basis of any unpublished price sensitive information, available to them by virtue of their position in the Company. The objective of this Code is to prevent misuse of any unpublished price sensitive information and prohibit any insider trading activity, in order to protect the interest of the shareholders at large. The Board of Directors of the Company have Code, in line with new SEBI (Prohibition of Insider Trading) Regulations, 2015.

The details of dealing in Company's shares by Specified Employees (which include members of the Management Committee and Directors) are placed for intimating the Board on quarterly basis. The Code also prescribes sanction framework and any instance of breach of code is dealt with in accordance with the same. A copy of the Code of the Company is made available to all employees of the Company and compliance of the same is ensured. The Code of Conduct to Regulate, Monitor and Report Trading by Insiders is available on the website of the Company www.genomicvalley.com.

Prevention of Insider Trading

During the year, the Company has adopted the following revised Codes in line with the SEBI (Prohibition of Insider Trading) (Amendment) Regulations, 2018:

- a) Code of Practices and Procedures for Fair Disclosure of Unpublished Price Sensitive Information and
- b) Code of Conduct to Regulate, Monitor and Report Trading by Designated Persons in Securities of the Company

The amended policy is available on our website at www.genomicvalley.com.

Nomination and Remuneration Policy

The Company has adopted the policy and procedures with regard to Nomination and Remuneration of Directors, Key Managerial Personnel (KMP) and Senior Management consistent with the provisions of the Companies Act, 2013 and SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The Nomination and Remuneration Committee and this policy shall be compliance in with Section 178 of the Companies Act, 2013 read along with the applicable rules thereto and SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The objective of this policy is to lay down a framework in relation to remuneration of directors, KMP, senior management personnel and other employees. The key objectives of the Committee would be:

- i) To guide the Board in relation to appointment and removal of directors, KMP and senior management.
- j) Formulate the criteria for determining qualifications, positive attributes, and independence of a director and recommend the Board a Policy, relating to the remuneration for the directors, key managerial personnel and other employees.
- k) Formulation of criteria for evaluation of Independent Directors and the Board.
- l) To evaluate the performance of the members of the Board and provide necessary report to the Board.
- m) To recommend to the Board remuneration payable to the directors, key managerial personnel and senior management.
- n) To retain, motivate and promote talent of directors, managerial personnel required to run the Company successfully.
- o) To assist the Board in fulfilling responsibilities.
- p) To implement and monitor policies and processes regarding principles of corporate governance.

The policy to regulate the Nomination and Remuneration of Directors, Key Managerial Personnel (KMP) and Senior Management is available on the website of the Company www.genomicvalley.com.

AFFIRMATION AND DISCLOSURE

All the members of the Board and the Management Committee have affirmed their compliance with the Code of Conduct as on 31st March, 2020 and a declaration to that effect, signed by the Managing Director is attached as Annexure A and forms part of this Corporate Governance.

There were no materially financial or commercial transaction, between the Company and members of the Management Committee that may have a potential conflict with the interest of the Company at large.

All details relating to financial and commercial transactions where Directors may have a pecuniary interest are provided to the Board and the interested Directors neither participate in the discussion nor vote on such matters.

DISCLOSURE OF PENDING CASES / INSTANCES OF NON-COMPLIANCE

There were no non-compliances by the Company and no instances of penalties and strictures imposed on the Company by the Stock Exchanges or SEBI or any other statutory authority on any matter related to the capital market during the last three year.

None of these cases are material in nature, which may lead to material loss or expenditure to the Company.

DISCRETIONARY REQUIREMENTS UNDER REGULATION 27(1) OF THE SEBI (LODR) REGULATIONS, 2015

The Company has not disclosed and adopted the discretionary requirements as specified in Part-E of Schedule II under SEBI (LODR) Regulations, 2015.

COMPLIANCE WITH CORPORATE GOVERNANCE REQUIREMENTS SPECIFIED IN REGULATION 17 TO 27 AND CLAUSES (B) TO (I) OF SUB-REGULATION (2) OF REGULATION 46

The Company has made compliance with corporate governance requirements specified in regulation 17 to 27 and clauses (b) to (i) of sub-regulation (2) of regulation 46.

CEO and CFO Certification

The Certificate required under Regulation 17(8) of the Listing Regulations, duly signed by the Managing Director and CFO was placed before the Board. The same is annexed as Annexure B to this report.

AUDITORS' CERTIFICATE ON CORPORATE GOVERNANCE

As required under Regulation 34 of the Listing Regulations, the auditors' certificate on Corporate Governance is annexed as Annexure C to the Board's Report.

CERTIFICATE OF NON-DISQUALIFICATION OF DIRECTORS

Pursuant to Regulation 34(3) and Schedule V Para C clause (10)(i) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, a certificate from a company secretary in practice that none of the directors on the board of the company have been debarred or disqualified from being appointed or continuing as directors of companies by the Board/Ministry of Corporate Affairs or any such statutory authority is annexed as Annexure C to this Corporate Governance Report.

DISCLOSURES WITH RESPECT TO DEMAT SUSPENSE ACCOUNT/UNCLAIMED SUSPENSE ACCOUNT

There are no shares in the Demat suspense account or unclaimed suspense account. Hence the disclosures required to be made in Annual Report 2019-20 as per clause (F) (a) to (e) of Schedule V of SEBI (LODR) Regulations, 2015 are not applicable.

COMPLIANCE WITH THE GOVERNANCE FRAMEWORK

The Board of Directors periodically reviewed the compliance of all applicable laws and steps taken by the Company to rectify instances of non-compliance, if any. The Company is in compliance with all mandatory requirements of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. In addition, the Company has also adopted the following requirements to the extent mentioned below:

- **Audit qualifications:** Company's financial statements have unmodified opinion.
- **Reporting of Internal Auditor:** The Internal Auditor of the Company directly reports to the Audit Committee on functional matters.

Non-Executive Directors' compensation and disclosures

The Non-Executive Directors are not paid any sitting fee. No stock options were granted to Non-Executive Directors during the year under review.

During the year, there no pecuniary relationship or transactions has taken place between the Company and Non-Executive Directors of the Company.

Independent Directors of the Company are not serving as Independent Directors in more than seven listed companies.

None of Whole Time Director of the Company serves as Independent Director in more than three listed companies.

Terms and conditions of appointment of independent directors have been disclosed on website of the Company www.genomicvalley.com.

Relationship between directors inter-se

Inter-se relationship between Directors is given below within the meaning of the term “relative” as per Section 2(77) of the Companies Act, 2015 and read with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Sr. No.	Name of Director	Designation	Relationship with other Directors
1.	Mr. Yogesh Agarwal	Managing Director	Husband of Mrs. Parul Agrawal
2.	Mrs.Parul Agrawal	Non –Executive Director	Wife of Mr. Yogesh Agrawal
3.	Mr. Pradeep Gupta	Independent Director	Not Related to any Director
4.	Mr. Rajesh Kumar Saxena	Independent Director	Not Related to any Director

Number of shares and convertible instruments held by non-executive directors: Mrs. Parul Agrawal held 283700 Equity Shares (9.29% of total shareholding) of the Company.

Remuneration paid to Directors during the financial year 2019-20

Name1	Fixed Salary				Bonus/ Incentives/ Commission	Sitting Fee	Total	Stock Options	No of equity Shares Held
	Basic	Perquisites/ Allowances	Retiral Benefits	Total fixed salary					
Mr. Yogesh Agrawal	4,50,000	NIL	NIL	4,50,000	NIL	NIL	4,50,000	NIL	1786750
Mrs.Parul Agrawal	NIL	NIL	NIL	NIL	NIL	NIL	NIL	NIL	283700
Mr. Pradeep Gupta	NIL	NIL	NIL	NIL	NIL	NIL	NIL	NIL	NIL
Mr. Rajesh Kumar Saxena	NIL	NIL	NIL	NIL	NIL	NIL	NIL	NIL	NIL

Service contracts: N.A.

Notice period: One Month

Severance Fees: N.A.

During the year, there no pecuniary relationship or transactions has taken place between the Company and Non-Executive Directors of the Company.

SECRETARIAL STANDARDS AND SECRETARIAL AUDIT REPORT

The Company has undertaken Secretarial Standards Audit for the year 2019-20 for audit of secretarial records and procedures followed by the Company in compliance with relevant Secretarial Standards issued by the Institute of Company Secretaries of India.

The Company has also undertaken Secretarial Audit for the year 2018-19 which, inter alia, includes audit of compliance with the Companies Act, 2013, and the Rules made under the Act, SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and Regulations and Guidelines prescribed by the Securities and Exchange Board of India. The Secretarial Audit Report is part of this Annual Report.

SHAREHOLDER INFORMATION

General Body Meetings

Details of last three Annual General Meetings and the summary of Special Resolutions passed therein are as under:

Financial year Ended	Date and Time	Venue	Special Resolution Passed
31 st March, 2017	27 th September, 2017 11:00 A.M.	4 K.M. Stone, Berri Chharra Road, P.O. Tandaheri, Teh. Bahadurgarh, Dist. Jhajjar, Haryana-124507	1. To increase the Borrowing Powers of the Company 2. Creation of Security on the Properties of the Company in favour of the Lenders 3. Giving of Loans/ Guarantees, Providing of Securities and Making of Investments in Securities
31 st March, 2018	28 th September, 2018 11:00 A.M.	4 K.M. Stone, Berri Chharra Road, P.O. Tandaheri, Teh. Bahadurgarh, Dist. Jhajjar, Haryana-124507	-
31 st March, 2019	23 rd August, 2019 11:00 A.M.	4 K.M. Stone, Berri Chharra Road, P.O. Tandaheri, Teh. Bahadurgarh, Dist. Jhajjar, Haryana-124507	1. To approve the re-appointment of Mr. Rajesh Kumar Saxena (DIN: 06469888) as an Independent Director of the Company, who was appointed as an Independent Director on the Board of the Company on 28.06.2014 for a term of 5 years, under Section 149, read with the Rules made thereunder and Schedule IV of the Companies Act, 2013 and the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 2. To approve the re-appointment of Mr. Pradeep Gupta (DIN: 00503623) as an Independent Director of the Company, who was appointed as an Independent Director on the Board of the Company on 28.06.2014 for a term of 5 years, under Section 149, read with the Rules made thereunder and Schedule IV of the Companies Act, 2013 and the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

			3. Alteration of object clause of Memorandum of Association of the Company 4. To give on the lease the land of the Company as per Section 180(1)(a) of the Companies Act, 2013 5. To purchase of Building for Corporate Office of the Company
--	--	--	---

Postal Ballot

During the year no resolution was passed through postal Ballot.

Extra-Ordinary General Meeting

During the year no Extra-Ordinary General Meeting of the shareholders of the Company has been conducted.

Annual General Meeting for the financial year 2019-20

Date : Thursday, 31st December, 2020
 Venue : 4 KM Stone, Berri, Chharra Road, P.O. Tandaheri, Tehsil- Bahadurgarh, Distt. Jhajjar Haryana -124507.
 Time : 11:00 A.M.
 Book Closure Dates : Friday, 25th December, 2020 to Thursday, 31st December, 2020 (both dates Inclusive)

Calendar of Financial Year ended 31st March, 2020

The meetings of Board of Directors for approval of quarterly financial results during the Financial Year ended 31st March, 2020 were held on the following dates:

Event	Held on
Financial Results for the 1 st Quarter ended 30 th June, 2019	28 th July, 2019
Financial Results for the 2 nd Quarter ended 30 th September, 2019	12 th November, 2019
Financial Results for the 3 rd Quarter ended 31 st December, 2019	14 th February, 2020
Audited Financial Results for the financial year ended 31 st March, 2020	29 th June, 2020

Tentative Calendar for financial year ending 31st March, 2021:

The tentative dates of meeting of Board of Directors for consideration of quarterly financial results for the financial year ending 31st March, 2021 are as follows:

Event	On or Before
Financial Results for the 1 st Quarter ended 30 th June, 2020	14 th August, 2020
Financial Results for the 2 nd Quarter ended 30 th September, 2020	14 th November, 2020
Financial Results for the 3 rd Quarter ended 31 st December, 2020	14 th February, 2021
Audited Financial Results for the financial year ended 31 st March, 2021	30 th May, 2021

Financial Year

Financial year of the Company starts on 1st April and ends on 31st March of the following year.

Listing on Stock Exchanges

The equity shares of the Company are listed on the BSE Limited (BSE) and Ahmedabad Stock Exchange Limited. The annual listing fees for the financial year 2019-20 have been paid to BSE Limited within due date.

The Ahmedabad Stock Exchange Limited (ASE) has not provided any trading platform during the Financial Year 2019-20. Therefore, the Company has not paid any annual listing fees to the Ahmedabad Stock Exchange Limited. The Company intends to pay ASE annual fees once ASE starts providing their part of services viz. the trading platform. With ASE, we have adopted the policy: Provide Services Take Fees.

Dividend

The Board of Directors had not declared any dividend for the Financial Year 2019-20.

Distribution of Shareholding as on 31st March, 2020

Category (Shareholding of Nominal Value of Rs. 10)	No. of Shareholders	% to Total	No of Shares	Amount in Rs.	Percentage to Shares
1-5000	356	97.53	12850	128500	0.42
5001 – 10000	0	0.00	0	0	0.00
10001 – 20000	1	0.27	2000	20000	0.07
20001 – 30000	0	0.00	0	0	0.00
30001 – 40000	2	0.54	8000	80000	0.26
40001 – 50000	0	0.00	0	0	0.00
50001 – 100000	0	0.00	0	0	0.00
100000 and Above	5	1.64	3031650	30316500	99.25
Total	364	100.00	3054500	30545000	100.00

Shareholding Pattern as at 31st March, 2020

Category	No. of Shares	% of Paid up Capital
PROMOTERS AND PROMOTERS GROUP		
Yogesh Agrawal	1786750	58.50
Parul Agrawal	283700	9.29
Ojaswini Avantika	2000	0.07
TOTAL PROMOTERS SHAREHOLDINGS	2072450	67.85
Mutual Funds	0	0
Banks/Financial Institutions	0	0
FII's	0	0
Body Corporate	0	0
Indian Public	982050	32.15
NRI's	0	0
Clearing members	0	0
Total	3054500	100


- *There are no outstanding GDRs / ADRs / Warrants / Convertible Instruments of the Company.
- *Securities of the Company has not been suspended from trading during the year under review.
- *Commodity price risk or foreign exchange risk and hedging activities. N.A

Market Price Data

Monthly high & low price of shares of your Company and No. of Shares traded at BSE Limited are as under:

Month	BSE		
	High Price	Low Price	No. of Shares traded
January, 2020	8.25	8.25	50
February, 2020	8.66	8.66	1010
March, 2020	8.66	8.66	NA

Performance in comparison to broad based indices



De-materialization of Shares & liquidity

The promoter's shareholding of Equity shares of your company are in compulsory de-mat settlement mode and can be traded only in de-mat form. Except 20,850 (0.68%) equity shares out of total paid - up capital of the Company, all the shares of the Company are in de-mat form.

Listing Details

Name of the Stock Exchange	ISIN /SCRIP CODE
BSE Limited	539206
Ahmedabad Stock Exchange Limited	INE574D01010

Share Transfer System

The Company has a Stakeholders Relationship Committee to look into various issues relating to the investors including share transfers/transmissions, duplicate share certificates, splitting, consolidation of share certificates, dematerialization of shares etc. This Stakeholders Relationship Committee of the Board of Directors of the Company meets as and when requests received from

the RTA to give effect to the share transfers/transmissions, duplicate share certificates, splitting, consolidation of share certificates, dematerialization of shares.

M/s Beetal Financial & Computer Services Private Limited (RTA) process the share transfers / transmission, splitting, consolidation of share certificates in physical form and the same are approved by the Stakeholders Relationship Committee. Transfer of shares in physical form are registered and dispatched within 15days of their receipt, subject to documents being valid and complete in all respects. The Board is regularly updated on the matters transacted at the Stakeholders Relationship Committee Meetings.

Plant Location

4 K.M. Stone, Berri Chharra Road, P.O. Tandaheri, Tehsil- Bahadurgarh, Distt. Jhajjar, Haryana-124507

COMMUNICATION TO SHAREHOLDERS

Effective communication of information is an essential component of Corporate Governance. It is a process of sharing information, ideas, thoughts, opinions and plans to all stakeholders which promotes management-shareholder relations. The Company regularly interacts with shareholders through multiple channels of communication such as results announcement, annual report, media releases, Company's website and subject specific communications.

The quarterly, half yearly and annual results of the Company's performance are published in leading newspapers such as Financial Express (English) and Haribhoomi & Awamehind (Hindi). These results are also made available on the website of the Company www.genomicvalley.com. The website also displays vital information relating to the Company and its performance, official press releases. No presentation made to institutional investors or to analysts. The Company also sends quarterly, half yearly and annual results as well as the notice of the Board Meeting to Members on e-mail.

Investor communications / Grievance redressal e-mail id:

Long pending litigations involve significant investment as monetary value of the disputed shares and accrued dividends / other benefits are locked up unutilised till the dispute is settled. Further, in terms of the requirements of the Companies Act, 1956, such dividends / other specified incomes remaining unclaimed / unpaid for a period of seven years are to be credited to the Investor Education and Protection Fund and the Shareholders are not entitled to claim the same thereafter.

The Shareholders who are willing to avail the benefits of Alternative Dispute Redressal mechanism may approach the Investor Service Department of the Company at the Registered Office of the Company or email your query/complaint at genomicvalley@gmail.com.

Address for Correspondence

All shareholders' correspondence should be forwarded to M/s. Beetal Financial & Computer Services Private Limited, the Registrar and Transfer Agent of the Company or to the Investor Service Department at the Registered Office of the Company at the addresses mentioned below.

The Company's dedicated e-mail address for Investors' Complaints and other communications is genomicvalley@gmail.com.

Beetal Financial & Computer Services Private Limited (Registrar Transfer Agent)	Investor Service Department	Company Secretary and Compliance officer	Compliance Officer
BEETAL FINANCIAL & COMPUTER SERVICES PRIVATE LIMITED Beetal House, 99, Madangir, Behind Local Shopping Centre, Near Dada HarsukhDassMandir, New Delhi-110062	Genomic Valley Biotech Limited 4 KM Stone, Berri Chharra Road, P.O. Tandaheri, Tehsil- Bahadurgarh, Distt. Jhajjar, Haryana-124507 Email : genomicvalley@gmail.com	Mr. Sunil Kumar (till 07 th March, 2020) Email Id: cs.gvbl@gmail.com Mobile No. +91 9811341542	Mr. Yogesh Agrawal, Managing Director (from 08 th March, 2020) Email Id: cs.gvbl@gmail.com Mobile No. +91 9811341542



Tel Nos.: +91 11 29961281/82 Fax No.: +91 11 29961284 Email: beetalrta@gmail.com Website: www.beetalfinancial.com	Website: www.genomicvalley.com Mobile: +91 9811341542		
---	---	--	--

For and on behalf of
Genomic Valley Biotech Limited

sd/-
Yogesh Agrawal
Managing Director
DIN-01165288
Address: G-74, Pushkar Enclave,
PaschimVihar, Delhi- 110063

sd/-
Parul Agrawal
Director
DIN-01165188
Address: G-74, Pushkar Enclave,
PaschimVihar, Delhi- 110063

Date: 05.12.2020
Place: Haryana



Annexure A to Corporate Governance

DECLARATION BY MANAGING DIRECTOR

To,
The Board of Directors
Genomic Valley Biotech Limited
4 KM Stone, Berri Chharra Road,
P.O. Tandaheri, Teh.- Bahadurgarh,
Distt. Jhajjar, Haryana-124507

I hereby confirm that Company has received from all members of the Board and Senior Management, for the financial year ended March 31, 2020, a confirmation that they are in compliance with the Company's Code of Conduct.

sd/-
Yogesh Agrawal
Managing Director
DIN: 01165288
Address: G-74, G-Block,
Pushkar Enclave,
Paschim Vihar,
Delhi, 110063

Date: 05.12.2020
Place: Haryana

Annexure B to Corporate Governance

MANAGING DIRECTOR (MD) & CHIEF FINANCIAL OFFICER (CFO) CERTIFICATION

To,
The Board of Directors
Genomic Valley Biotech Limited
4 KM Stone, Berri Chharra Road,
P.O. Tandaheri, Teh.- Bahadurgarh,
Distt. Jhajjar, Haryana-124507

We, Yogesh Agrawal, Managing Director and Lalit Shah, Chief Financial Officer of Genomic Valley Biotech Limited, to the best of our knowledge and belief hereby certify that:

- (a) We have reviewed financial statements and the cash flow statement for the year ended March 31, 2020 and that to the best of our knowledge and belief:
- (i) these statements do not contain any materially untrue statement or omit any material fact or contain statements that might be misleading;
 - (ii) these statements together present a true and fair view of the Company's affairs and are in compliance with existing accounting standards, applicable laws and regulations.
- (b) There are, to the best of our knowledge and belief, no transactions entered into by the Company during the year which are fraudulent, illegal or violative of the Company's code of conduct.
- (c) We accept responsibility for establishing and maintaining internal controls for financial reporting and that we have evaluated the effectiveness of internal control systems of the company pertaining to financial reporting and we have disclosed to the Auditors and the Audit and Risk Management Committee, deficiencies in the design or operation of such internal controls, if any, of which we are aware and the steps we have taken or propose to take to rectify these deficiencies.
- (d) We have indicated to the Auditors and the Audit Committee:
- (i) significant changes in internal control over financial reporting during the year;
 - (ii) significant changes in accounting policies during the year and that the same have been disclosed in the notes to the financial statements; and
 - (iii) instances of significant fraud of which we have become aware and the involvement therein, if any, of the management or an employee having a significant role in the Company's internal control system over financial reporting.

sd/-
Yogesh Agrawal
Managing Director
DIN: 01165288
Address: G-74, G-Block,
Pushkar Enclave,
Paschim Vihar,
Delhi, 110063

Date: 29.06.2020
Place: Haryana

sd/-
Lalit Shah
Chief Financial Officer
PAN: BCHPS9526B
Address: Flat No. 303, Pacific Tower,
Omaxe City, Rohtak Road,
Bahadurgarh, Distt. Jhajjar,
Haryana-124507

**CERTIFICATE OF NON-DISQUALIFICATION OF DIRECTORS
[pursuant to Regulation 34(3) and Schedule V Para C clause (10)(i)
of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015]**

To,
The Members of Genomic Valley Biotech Limited
(CIN: L01122HR1994PLC033029)
4 K.M. Stone, Berri Chharra Road,
P.O. Tandaheri, Teh. Bahadurgarh,
Distt. Jhajjar, Haryana-124507

We have examined the relevant registers, records, forms, returns and disclosures received from the Directors of Genomic Valley Biotech Limited having CIN: L01122HR1994PLC033029) and having registered office at 4 K.M. Stone, Berri Chharra Road, P.O. Tandaheri, Teh. Bahadurgarh, Distt. Jhajjar, Haryana-124507 (hereinafter referred to as **'the Company'**), produced before me/us by the Company for the purpose of issuing this Certificate, in accordance with Regulation 34(3) read with Schedule V Para-C Sub clause 10(i) of the Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

In our opinion and to the best of our information and according to the verifications (including Directors Identification Number (DIN) status at the portal www.mca.gov.in) as considered necessary and explanations furnished to us by the Company & its officers, We hereby certify that none of the Directors on the Board of the Company as stated below for the Financial Year ending on 31st March, 2020 have been debarred or disqualified from being appointed or continuing as Directors of companies by the Securities and Exchange Board of India, Ministry of Corporate Affairs or any such other Statutory Authority.

DIN	Full Name	Date of Appointment
00503623	Pradeep Gupta	28/06/2014
01165188	Parul Agrawal	29/09/2010
01165288	Yogesh Agrawal	07/09/2015
06469888	Rajesh Kumar Saxena	28/06/2014

Ensuring the eligibility of for the appointment / continuity of every Director on the Board is the responsibility of the management of the Company. Our responsibility is to express an opinion on these based on our verification. This certificate is neither an assurance as to the future viability of the Company nor of the efficiency or effectiveness with which the management has conducted the affairs of the Company.

Place: Gurgaon
Date: 04.12.2020

For or on behalf of
Rohit Batham & Associates

Sd/-
Rohit Batham
Membership No.: A37260
CP No.: 19095
UDIN: A037260B001400446

ANDROS & CO.
CHARTERED ACCOUNTANTS

901, TOWER-1, PEARL OMAXE, PLOT B-1,
NETAJI SHUBHASH PLACE, PITAMPURA
DELHI-110034
Ph-011-47060901
Email: cabhavukgarg@gmail.com

INDEPENDENT AUDITOR'S REPORT

TO
THE MEMBERS OF
GENOMIC VALLEY BIOTECH LIMITED

Report on the Audit of the Standalone Financial Statements

Opinion

We have audited the accompanying standalone financial statements of Genomic Valley Biotech Limited ("**the Company**"), which comprise the Balance Sheet as at March 31, 2020, the Statement of Profit and Loss (including Other Comprehensive Income), the Statement of Changes in Equity and the Statement of Cash Flows for the year ended on that date, and a summary of the significant accounting policies and other explanatory information (hereinafter referred to as "the standalone financial statements").

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid standalone financial statements give the information required by the Companies Act, 2013 ("the Act") in the manner so required and give a true and fair view in conformity with the Indian Accounting Standards prescribed under section 133 of the Act read with the Companies (Indian Accounting Standards) Rules, 2015, as amended, ("Ind AS") and other accounting principles generally accepted in India, of the state of affairs of the Company as at March 31, 2020, the profit and total comprehensive income, changes in equity and its cash flows for the year ended on that date.

Basis for Opinion

We conducted our audit of the standalone financial statements in accordance with the Standards on Auditing specified under section 143(10) of the Act (SAs). Our responsibilities under those Standards are further described in the *Auditor's Responsibilities for the Audit of the Standalone Financial Statements* section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India (ICAI) together

with the independence requirements that are relevant to our audit of the standalone financial statements under the provisions of the Act and the Rules made there under, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the ICAI's Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the standalone financial statements.

Information Other than the Standalone Financial Statements and Auditor's Report Thereon

The Company's Board of Directors is responsible for the preparation of the other information. The other information comprises the information included in the Management Discussion and Analysis, Board's Report including Annexures to Board's Report, Business Responsibility Report, Corporate Governance and Shareholder's Information, but does not include the standalone financial statements and our auditor's report thereon.

Our opinion on the standalone financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the standalone financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the standalone financial statements or our knowledge obtained during the course of our audit or otherwise appears to be materially misstated.

If, based on the work we have performed, we conclude that there is a material misstatement of this other information; we are required to report that fact. We have nothing to report in this regard.

Management's Responsibility for the Standalone Financial Statements

The Company's Board of Directors is responsible for the matters stated in section 134(5) of the Act with respect to the preparation of these standalone financial statements that give a true and fair view of the financial position, financial performance, total comprehensive income, changes in equity and cash flows of the Company in accordance with the Ind AS and other accounting principles generally accepted in India. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the standalone financial

statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the standalone financial statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Standalone Financial Statements

Our objectives are to obtain reasonable assurance about whether the standalone financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these standalone financial statements.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the standalone financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal financial controls relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143 (3) (i) of the Act, we are also responsible for expressing our opinion on whether the Company has adequate internal financial controls system in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.



- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the standalone financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the standalone financial statements, including the disclosures, and whether the standalone financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

Materiality is the magnitude of misstatements in the standalone financial statements that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the financial statements may be influenced. We consider quantitative materiality and qualitative factors in (i) planning the scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in the financial statements.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the standalone financial statements of the current period and are therefore the key audit matters. We describe these matters in our auditor's report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.



Report on Other Legal and Regulatory Requirements

1. As required by Section 143(3) of the Act, based on our audit we report that:

a) We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit.

b) In our opinion, proper books of account as required by law have been kept by the Company so far as it appears from our examination of those books.

c) The Balance Sheet, the Statement of Profit and Loss including Other Comprehensive Income, Statement of Changes in Equity and the Statement of Cash Flow dealt with by this Report are in agreement with the relevant books of account.

d) In our opinion, the aforesaid standalone financial statements comply with the Ind AS specified under Section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2014.

e) On the basis of the written representations received from the directors as on March 31, 2019 taken on record by the Board of Directors, none of the directors is disqualified as on March 31, 2020 from being appointed as a director in terms of Section 164 (2) of the Act.

f) With respect to the adequacy of the internal financial controls over financial reporting of the Company and the operating effectiveness of such controls, refer to our separate Report in "Annexure A". Our report expresses an unmodified opinion on the adequacy and operating effectiveness of the Company's internal financial controls over financial reporting.

g) With respect to the other matters to be included in the Auditor's Report in accordance with the requirements of section 197(16) of the Act, as amended:

In our opinion and to the best of our information and according to the explanations given to us, the remuneration paid by the Company to its directors during the year is in accordance with the provisions of section 197 of the Act.

h) With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, as amended in our opinion and to the best of our information and according to the explanations given to us:

i. the Company does not have any pending litigations which would impact its financial position ;



- ii. the Company did not have any long-term contracts including derivative contracts for which there were any material foreseeable losses ; and
- iii. there were no amounts which were required to be transferred to the Investor Education and Protection Fund by the Company.

2. As required by the Companies (Auditor's Report) Order, 2016 ("the Order") issued by the Central Government in terms of Section 143(11) of the Act, we give in "Annexure B" a statement on the matters specified in paragraphs 3 and 4 of the Order.

**For ANDROS & CO.
CHARTERED ACCOUNTANT**

**sd/-
(CA Bhavuk Garg)
(Partnership Firm)
(Membership No.-502310)
UDIN: 20502310AAAAEW9098**

**Date: 29.06.2020
Place: New Delhi**

ANNEXURE “A” TO THE INDEPENDENT AUDITOR’S REPORT

(Referred to in paragraph 1(f) under ‘Report on Other Legal and Regulatory Requirements’ section of our report to the Members of M/S Genomic Valley Biotech Limited of even date)

Report on the Internal Financial Controls Over Financial Reporting under Clause (i) of Sub-section 3 of Section 143 of the Companies Act, 2013 (“the Act”)

We have audited the internal financial controls over financial reporting of **M/S Genomic Valley Biotech Limited** (“the Company”) as of March 31, 2020 in conjunction with our audit of the standalone financial statements of the Company for the year ended on that date.

Management’s Responsibility for Internal Financial Controls

The Board of Directors of the Company is responsible for establishing and maintaining internal financial controls based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India. These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to respective company’s policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Companies Act, 2013.

Auditor’s Responsibility

Our responsibility is to express an opinion on the internal financial controls over financial reporting of the Company based on our audit. We conducted our audit in accordance with the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting (the “Guidance Note”) issued by the Institute of Chartered Accountants of India and the Standards on Auditing prescribed under Section 143(10) of the Companies Act, 2013, to the extent applicable to an audit of internal financial controls. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls over financial reporting was established and maintained and if such controls operated effectively in all material respects.

Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial controls system over financial reporting and their operating effectiveness. Our audit of internal financial controls over financial reporting included obtaining an understanding of internal financial controls over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor's judgement, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error.

We believe that the audit evidence we have obtained, is sufficient and appropriate to provide a basis for our audit opinion on the internal financial controls system over financial reporting of the Company.

Meaning of Internal Financial Controls Over Financial Reporting

A company's internal financial control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal financial control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorisations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorised acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.

Limitations of Internal Financial Controls Over Financial Reporting

Because of the inherent limitations of internal financial controls over financial reporting, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls over financial reporting to future periods are subject to the risk that the internal financial control over financial reporting may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.



Opinion

In our opinion, to the best of our information and according to the explanations given to us, the Company has, in all material respects, an adequate internal financial controls system over financial reporting and such internal financial controls over financial reporting were operating effectively as at March 31, 2020, based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India.

**For ANDROS & CO.
CHARTERED ACCOUNTANT**

**sd/-
(CA Bhavuk Garg)
(Partnership Firm)
(Membership No.-502310)
UDIN: 20502310AAAAEW9098**

**Date: 29.06.2020
Place: New Delhi**

ANNEXURE ‘B’ TO THE INDEPENDENT AUDITOR’S REPORT

(Referred to in paragraph 2 under ‘Report on Other Legal and Regulatory Requirements’ section of our report to the Members of Genomic Valley Biotech Limited of even date)

i. In respect of the Company’s fixed assets:

(a) The Company has maintained proper records showing full particulars, including quantitative details and situation of fixed assets.

(b) The Company has a program of verification to cover all the items of fixed assets in a phased manner which, in our opinion, is reasonable having regard to the size of the Company and the nature of its assets. Pursuant to the program, certain fixed assets were physically verified by the management during the year. According to the information and explanations given to us, no material discrepancies were noticed on such verification.

(c) According to the information and explanations given to us, the records examined by us and based on the examination of the conveyance deeds / registered sale deed provided to us, we report that, the title deeds, comprising all the immovable properties of land and buildings which are freehold, are held in the name of the Company as at the balance sheet date. In respect of immovable properties of land and building that have been taken on lease and disclosed as fixed assets in the standalone financial statements, the lease agreements are in the name of the Company.

ii. The Company is engaged in a Horticulture business and does not have any physical inventories. Accordingly, reporting under clause 3 (ii) of the Order is not applicable to the Company.

iii. The Company has not granted any loans to body corporate therefore section 189 of the Companies Act, 2013 (‘the Act’) is not applicable.

iv. In our opinion and according to the information and explanations given to us, the Company has complied with the provisions of Sections 185 and 186 of the Act in respect of grant of loans, making investments and providing guarantees and securities, as applicable.

v. The Company has not accepted deposits during the year and does not have any unclaimed deposits as at March 31, 2020 and therefore, the provisions of the clause 3 (v) of the Order are not applicable to the Company.

vi. The maintenance of cost records has not been specified by the Central Government under section 148(1) of the Companies Act, 2013 for the business activities carried out by the Company. Thus reporting under clause 3(vi) of the order is not applicable to the Company.



vii. According to the information and explanations given to us, in respect of statutory dues:

(a) The Company has generally been regular in depositing undisputed statutory dues, including Provident Fund, Employees' State Insurance, Income Tax, Goods and Service Tax, GST, Customs Duty, Cess and other material statutory dues applicable to it with the appropriate authorities.

(b) There were no undisputed amounts payable in respect of Provident Fund, Employees' State Insurance, Income Tax, Goods and Service Tax, Customs Duty, Cess and other material statutory dues in arrears as at March 31, 2020 for a period of more than six months from the date they became payable.

viii. The Company has taken loan from Non Banking Financial Company registered with Reserve Bank of India during the concerned year under audit and has not defaulted in any payment of loan amount

ix. The Company has not raised moneys by way of initial public offer or further public offer (including debt instruments) or term loans and hence reporting under clause 3 (ix) of the Order is not applicable to the Company.

x. To the best of our knowledge and according to the information and explanations given to us, no fraud by the Company or no material fraud on the Company by its officers or employees has been noticed or reported during the year.

xi. In our opinion and according to the information and explanations given to us, the Company has paid/provided managerial remuneration in accordance with the requisite approvals mandated by the provisions of section 197 read with Schedule V to the Act.

xii. The Company is not a Nidhi Company and hence reporting under clause 3 (xii) of the Order is not applicable to the Company.

xiii. In our opinion and according to the information and explanations given to us, the Company is in compliance with Section 177 and 188 of the Companies Act, 2013 where applicable, for all transactions with the related parties and the details of related party transactions have been disclosed in the standalone financial statements as required by the applicable accounting standards.

xiv. During the year, the Company has not made any preferential allotment or private placement of shares or fully or partly paid convertible debentures and hence reporting under clause 3 (xiv) of the Order is not applicable to the Company.

xv. In our opinion and according to the information and explanations given to us, during the year the Company has not entered into any non-cash transactions with its Directors or persons connected to its directors and hence provisions of section 192 of the Companies Act, 2013 are not applicable to the Company.



xvi. The Company is not required to be registered under section 45-IA of the Reserve Bank of India Act, 1934.

**For ANDROS & CO.
CHARTERED ACCOUNTANT**

**sd/-
(CA Bhavuk Garg)
(Partnership Firm)
(Membership No.-502310)
UDIN: 20502310AAAAEW9098**

**Date: 29.06.2020
Place: New Delhi**



GENOMIC VALLEY BIOTECH LIMITED

REGD. OFF: 4 K.M. STONE BERI CHHARA ROAD, TEHSIL BAHADURGARH, DISTT. JHAJJAR, HARYANA-124507

CIN: L01122HR1994PLC033029

Balance Sheet as at 31.03.2020

Particulars	Note No.	Figures as at the end of 31.03.2020	Figures as at the end of 31.03.2019
ASSETS			
Non Current Assets			
Property, plant and equipment	1	44,530,253	43,077,029
Capital work in progress		4,879,339	4,885,459
Other Intangible assets		156,109	-
Intangible assets under development		-	-
Financial assets		-	-
Investment		-	-
Loans & Advances	2	25,600,000	20,600,000
Security Deposits	3	200,000	200,000
Other financial assets		-	-
Deferred tax assets (Net)		653,183	-
Other non current assets		-	-
Total Non-Current Assets		76,018,884	68,762,488
Current Assets			
Inventories	4	1,239,623	1,187,441
Financial Assets:		-	-
Investments		-	-
Trade Receivables	5	1,026,692	584,798
Cash and Cash equivalents	6	319,100	30,820
Other Balances with banks	6	58,454	719,824
Loans & Advances		-	-
Other financial assets		-	-
Other Current assets	7	1,400,361	489,866
Total Current Assets		4,044,230	3,012,749
Total Assets		80,063,114	71,775,237
EQUITY AND LIABILITIES			
Equity			
Equity Share Capital	8	30,545,000	30,545,000
Other Equity	9	19,925,159	17,065,232
Total Equity		50,470,159	47,610,232
Non Current Liabilities			
Financial liabilities			
Borrowings	10	14,788,077	14,788,077
Security Deposits		-	-
Other Financials liabilities		7,120,000	8,500,000
Deferred tax liabilities (Net)		-	149,433
Provisions		-	-
Other Non Current liabilities		-	-
Total Non Current Liabilities		21,908,077	23,437,510
Current Liabilities			
Financial liabilities			
Borrowings		-	-
Trade Payables	11	639,363	39,947
Other Financials liabilities		-	-
Provisions	12	121,860	342,610
Other Current liabilities	13	6,923,655	344,937
Total Current Liabilities		7,684,878	727,494
TOTAL EQUITY AND LIABILITIES		80,063,114	71,775,237

AS PER OUR REPORT OF EVEN DATE ANNEXED
For ANDROS & CO.
CHARTERED ACCOUNTANTS

sd/-
(CA Bhavuk Garg)
(Partnership Firm)
(Membership No.-502310)

DATE: 29/06/2020
PLACE: DELHI

For and on behalf of
GENOMIC VALLEY BIOTECH LIMITED

sd/-
Yogesh Agrawal
Managing Director
DIN-01165288

sd/-
Parul Agrawal
Director
DIN-01165188

sd/-
Lalit Shah
Chief Financial Officer

GENOMIC VALLEY BIOTECH LIMITED
REGD. OFF: 4 K.M. STONE BERI CHHARA ROAD, TEHSIL BAHADURGARH, DISTT. JHAJJAR, HARYANA-124507
CIN: L01122HR1994PLC033029
Profit & Loss A/c as at 31.03.2020

Particulars		Note No.	Figures for the year ending 31.03.2020	Figures for the year ending 31.03.2019
I.	Revenue from Operations	14	8,465,629	9,850,101
II.	Other Income	15	140,869	147,952
III.	Total Revenue (I + II)		8,606,499	9,998,052
IV.	Expenses:			
	Cost of materials consumed	16	88,265	471,545
	Purchases of Stock-in-Trade		-	-
	Changes in inventories of finished goods work-in-progress and Stock-in-Trade		-765,600	-
	Employee benefits expense	17	1,765,260	2,668,923
	Finance costs		1,798,878	-
	Depreciation and amortization expense	18	1,785,803	1,937,408
	Other expenses	19	1,876,582	2,573,127
	Total expenses		6,549,188	7,651,003
V.	Profit before exceptional and extraordinary items and tax (III- IV)		2,057,310	2,347,049
VI.	Exceptional items			
VII.	Profit before extraordinary items and tax (V - VI)		2,057,310	2,347,049
VIII.	Extraordinary Items		-	-
IX.	Profit before tax (VII- VIII)		2,057,310	2,347,049
X	Tax Expense:			
	(1) Current tax		-	-
	(2) Deferred tax		-802,616	22,083
XI	Profit (Loss) for the period from continuing operations (VII- VIII)		2,859,927	2,324,966
XII	Profit/(loss) from discontinuing operations		-	-
XIII	Tax expense of discontinuing operations		-	-
XIV	Profit/(loss) from Discontinuing Operations (after tax) (XII- XIII)		-	-
XV	Profit (Loss) for the period (XI + XIV)		2,859,927	2,324,966
XVI	Earnings per equity share:			
	(1) Basic		0.94	0.76
	(2) Diluted		0.94	0.76

AS PER OUR REPORT OF EVEN DATE ANNEXED
For ANDROS & CO.
CHARTERED ACCOUNTANTS

For and on behalf of
GENOMIC VALLEY BIOTECH LIMITED

sd/-
(CA Bhavuk Garg)
(Partnership Firm)
(Membership No.-502310)

sd/-
Yogesh Agrawal
Managing Director
DIN-01165288

sd/-
Parul Agrawal
Director
DIN-01165188

DATE: 29/06/2020
PLACE: DELHI

sd/-
Lalit Shah
Chief Financial Officer

GENOMIC VALLEY BIOTECH LIMITED
REGD. OFF: 4 K.M. STONE BERI CHHARA ROAD, TEHSIL BAHADURGARH, DISTT. JHAJJAR, HARYANA-
CIN: L01122HR1994PLC033029
CASH FLOW STATEMENT FOR THE YEAR 2019-20

	Particulars	Amount in INR	
		31.03.2020	31.03.2019
A.	CASH FLOW FROM OPERATING ACTIVITIES		
	Net Profit As Statement Profit & Loss	2,057,310	2,347,049
	Adjustment For		
	Discount received	-	-
	Non-Operating Income	-	-139,000
	Interest Income	-21,851	-8,579
	Loss on sale of assets	-	-
	Depreciation	1,785,803	1,937,408
	Operating Profit Before Change in Working Capital	3,821,262	4,136,877
	ADJUSTMENTS FOR WORKING CAPITAL:		
	Increase/Decrease in Loans and Advances	-5,000,000	-
	Inventories	-52,182	-855,643
	Increase/Decrease in Security Deposits	-	87,788
	Increase/Decrease in Trade Receivables	-441,894	-352,360
	Other Current Assets	-910,495	-284,905
	Increase/Decrease in Current Liabilities	6,957,383	-13,102,464
	CASH GENERATED FROM OPERATIONS	4,374,074	-10,370,707
	Taxes Paid	-	-
	Total (a)	4,374,074	-10,370,707
B.	CASH FLOW FROM INVESTING ACTIVITIES		
	Additions/Sales to fixed assets	-4,769,015	3,572,223
	Purchase/Sell of Investments	-	-
	Discount received	-	-
	Non-Operating Income	-	139,000
	Interest Income	21,851	8,579
		-4,747,164	3,719,803
C.	CASH FLOWS FROM FINANCING ACTIVITIES		
	Proceeds from Borrowings	-	7,288,077
	Preliminary Expenses	-	-
	total (C)	-	7,288,077
	NET CASH FLOWS DURING THE YEAR (A+B+C)	-373,090	637,173
	Cash and Cash Equivalents (Opening Balance)	750,644	113,472
	Cash and Cash Equivalents (Closing Balance)	377,554	750,644

AS PER OUR REPORT OF EVEN DATE ANNEXED
For ANDROS & CO.
CHARTERED ACCOUNTANTS

For and on behalf of
GENOMIC VALLEY BIOTECH LIMITED

sd/-
(CA Bhavuk Garg)
(Partnership Firm)
(Membership No.-502310)

sd/-
Yogesh Agrawal
Managing Director
DIN-01165288

sd/-
Parul Agrawal
Director
DIN-01165188

DATE: 29/06/2020
PLACE: DELHI

sd/-
Lalit Shah
Chief Financial Officer

GENOMIC VALLEY BIOTECH LIMITED
REGD. OFF: 4 K.M. STONE BERI CHHARA ROAD, TEHSIL BAHADURGARH, DISTT. JHAJJAR, HARYANA-124507
NOTES TO ACCOUNTS YEAR ENDED 31.03.2020
CIN: L01122HR1994PLC033029
Note 1 Property Plant and Equipments

<u>Assets</u>	Land & Building	Plant & Equipment	Furniture & Fixtures	Green house	Total
Gross Block					
Balance as at March 31, 2018	35,583,225	5,576,166	294,578	1,728,864	43,182,833
Additions	3,180,968	587,137	41,288	0	3,809,394
Deletions	0	0	0	0	0
Balance as at March 31, 2019	38,764,193	6,163,303	335,866	1,728,864	46,992,226
Additions	102,300	2,609,291	0	636,481	3,348,072
Deletions	0	-38,500	0	-260,000	-298,500
Balance as at March 31, 2020	38,866,493	8,734,094	335,866	2,105,345	50,041,798
Accumulated Depreciation					
Balance as at March 31, 2018	68,505	543,424	59,295	1,306,566	1,977,789
Additions	990,072	568,904	29,577	348,855	1,937,408
Deletions	0	0	0	0	0
Balance as at March 31, 2019	1,058,577	1,112,328	88,872	1,655,421	3,915,197
Additions	1,057,762	666,439	31,907	138,740	1,894,848
Deletions	0	-38,500	0	-260,000	-298,500
Balance as at March 31, 2020	2,116,339	1,740,267	120,779	1,534,161	5,511,545
Net Block					
Balance as at March 31, 2019	37,705,616	5,050,975	246,994	73,443	43,077,029
Balance as at March 31, 2020	36,750,154	6,993,827	215,087	571,185	44,530,253

Note 2 Loans

	As at 31 March 2020	As at 31 March 2019
Advance For Purchase of Land	20,600,000	20,600,000
Advance for corporate office	5,000,000	0
Total	25,600,000	20,600,000

Note 3 Security Deposits

	As at 31 March 2020	As at 31 March 2019
Netafim Security Deposit	50,000	50,000
Security Deposited- Eden Horticulture	150,000	150,000
Total	200,000	200,000

Note 4 Inventories

	As at 31 March 2020	As at 31 March 2019
Stock in Hand	1,239,623	1,187,441
Total	1,239,623	1,187,441



Note 5 Trade Receivables

	As at 31 March 2020	As at 31 March 2019
Garware	973	973
Hydro green Leaf	125,000	125,000
Netafim India Pvt. Ltd.	24,189	24,276
KVIC Education	0	40,034
Rajesh	205,700	205,700
Sharma Nursery	155,450	0
Swami Seeds	138,780	187,500
Kath Seeds	361,600	0
Madan Rakesh	15,000	0
Union Adv Service P Ltd	0	1,315
Total	1,026,692	584,798

Note 6 CASH AND CASH EQUIVALENTS

	As at 31 March 2020		As at 31 March 2019	
a. Balances with banks				
In current a/c	58,454		719,824	
		58,454		719,824
b. Cash in hand		319,100		30,820
		377,554		750,644

Note 7 Other Current Assets

	As at 31 March 2020	As at 31 March 2019
TDS Deducted	2,389	2,389
Lalit Shah Advance	662,972	238,000
Input Credit-GST	0	79,452
Ashish Advance	15,000	15,000
TDS Receivable AY 2020.21	720,000	0
Yogesh Agrawal	0	155,025
Total	1,400,361	489,866

Note 8 Equity Share Capital

Share Capital	As at 31 March 2020		As at 31 March 2019	
	Number		Number	
Authorised				
Equity Shares of Rs 10 each	9,000,000	90,000,000	9,000,000	90,000,000
Issued				
Equity Shares of Rs 10 each	8,150,000	81,500,000	8,150,000	81,500,000
Subscribed				
Equity Shares of Rs 10 each	7,697,300	-	7,697,300	-
Less: Share Foreiture	4,642,800	-	4,642,800	-
Balances Shares of Rs 10 each	3,054,500	30,545,000	3,054,500	30,545,000
Paid up Capital				
Equity Shares of Rs 10 each Fully paidup	3,054,500	30,545,000	3,054,500	30,545,000
Total	3,054,500	30,545,000	3,054,500	30,545,000

List of shareholders holding more than 5% shares

Name of shareholders	No. of shares	%
Yogesh Agrawal*	1,786,750	58.50
Deepthi Aggarwal	336,000	11.00
Harish Chandra Sharma	348,700	11.42
Parul Agrawal	283,700	9.29
Amar Aggarwal	276,500	9.05

* See Note No. 20 Point 7.



Note 9 Other Equity

	As at 31 March 2020	As at 31 March 2019
Reserves		
Capital Foreiture	16,000,000	16,000,000
Subsidy for Green House	70,000	70,000
Sugarcane Development Fund	1,000,000	1,000,000
Share Foreiture	11,607,000	11,607,000
Misc. Expenditure	-10,211,019	-10,211,019
Total	18,465,981	18,465,981
Surplus		
Opening balance	-1,400,749	-3,725,715
Net Profit/Loss of Current Year	2,859,927	2,324,966
Total	1,459,178	-1,400,749
Total	19,925,159	17,065,232

Note 10 Borrowings

	As at 31 March 2020	As at 31 March 2019
Secured Loan from-Sunglow Fininvest P Ltd	14,788,077	14,788,077
Total	14,788,077	14,788,077

Note 11 Trades Payable

	As at 31 March 2020	As at 31 March 2019
Allied Scientific Sales	0	39,947
Bal Building material	73,172	0
Garg & Co	559,347	0
SBR Telecom P Ltd	6,844	0
Total	639,363	39,947

Note 12 Provisions

	As at 31 March 2020	As at 31 March 2019
Provision for NSDL fees payable	76,860	66,240
Provision for Electricity charges	20,000	276,370
Audit Fees payable	25,000	0
Total	121,860	342,610

Note 13 Other Current Liabilities

	As at 31 March 2020	As at 31 March 2019
Beetal RTA	0	2,807
SBR Telecom P Ltd	0	4,720
Advance against sales	0	321,035
Credit Card Machine	2,047	0
Advance for Training	0	15,000
Duties and Taxes	226,457	0
Payroll Liabilities	60,834	0
Yogesh Agrawal-Imprest	6,454,428	0
TDS Payable	179,888	1,375
Total	6,923,655	344,937

Note 14 Revenue From Operation

	As at 31 March 2020	As at 31 March 2019
Sales & Services	8,465,629	9,850,101
Total	8,465,629	9,850,101



Note 15 Other Income

	As at 31 March 2020	As at 31 March 2019
Discount received	518	372
Interest Received	21,851	8,579
Provision for DVAT w/back	0	139,000
Expenses Written back of Fy 2018-19	103,500	0
Other Income	15,000	0
Total	140,869	147,952

Note 16 Cost of materials consumed

	As at 31 March 2020	As at 31 March 2019
Seeds, Khad & Other Consumable Item	88,265	471,545
Total	88,265	471,545

Note 17 Employee benefits expense

	As at 31 March 2020	As at 31 March 2019
Salary, Wage & Other Staff Welfare	1,765,260	2,668,923
Total	1,765,260	2,668,923

Note 18 Depreciation

	As at 31 March 2020	As at 31 March 2019
Depreciation	1,785,803	1,937,408
Total	1,785,803	1,937,408

Note 19 Other Expenses

	As at 31 March 2020	As at 31 March 2019
AMC PTC lab	0	47,572
AGM Expenses	6,450	13,888
Audit Fee	25,000	25,000
Bank Charges	4,584	16,115
Business Promotion	0	134,925
BSE Listing FEE	300,000	295,000
CDSL FEE	20,000	24,780
CONVEYANCE	76,606	30,339
Carriage Outward	10,060	29,666
Carriage Inward	22,974	25,980
Computer Maintenance Expense	21,885	0
Courier Expenses	7,240	0
Credit card fees	30,581	0
Daily Wages to Casual Labours	154,020	449,879
Job Work Charges	0	3,400
Electricity Expenses	153,903	461,711
Educational Workshop Expenses	0	32,860
Freight Inward	250	0
GST Late Fees	11,310	3,020
Interest Paid-TDS	0	76
Internet Expense	45,900	0
Legal & Profession Expense	10,000	0
Legal & Roc Expenses	12,530	42,321
Misc. Expenses	23,005	19,734
News Paper Advertisement	40,097	143,967
News paper & Periodicals	3,500	0
NHB Service Charges	0	320,508
NSDL fees	10,620	10,620
Office Expenses	0	46,380
Printing Stationery and Postal Expenses	4,550	4,785
Professional Fees	54,747	0
Penalty-HVAT	0	10,000
Repair & Maintanance	501,527	44,587
Processing Fees-Loan	0	8,260
ROC Return Filing Fees	15,367	0
RTA Fee	14,867	24,313
Software	0	15,000
Staff Welfare Expense	42,388	0
Subscription Fees	0	11,800
Travelling Expenses	87,120	41,641
Valuation Expenses	0	118,000
Water Expense	131,000	117,000
Website Expense	4,726	0
Cost of Cultivation	2,000	0
Car Expense	17,951	0
Car Insurance	9,824	0
Total	1,876,582	2,573,127



Note 20:- NOTES ON ACCOUNTS

1. ACCOUNTING POLICIES

(a) System of Accounting

These Audited financial statements have been prepared to comply in all material aspects with applicable accounting principles in India, the applicable Accounting Standards prescribed under Section 133 of the Companies Act, 2013 ('Act') read with Rule 7 of the Companies (Accounts) Rules, 2014, the provisions of the Act (to the extent notified) and other accounting principles generally accepted in India, to the extent applicable.

The financial statements of the Company have been combined on a line-by-line basis by adding together the book values of like items of assets, liabilities, income and expenses.

The financial statements have been prepared using uniform accounting policies for like transactions and other events in similar circumstances. The accounting policies adopted in the preparation of financial statements are consistent with those of previous year.

All assets and liabilities have been classified as current or non-current as per the Group's normal operating cycle and other criteria set out in the Schedule III to the Companies Act, 2013.

Based on the nature of products and the time between acquisition of assets for processing and their realisation in cash and cash equivalents, the Group has ascertained its operating cycle as 12 months for the purpose of current/non-current classification of assets and liabilities.

(b) Depreciation

Depreciation on Fixed Assets is provided in compliance of schedule II of the Companies Act, 2013 read with relevant circulars issued by the Department of Company Law Affairs from time to time. The company provided depreciation on the Basis of Straight Line Method on Fixed Assets.



(c) Preliminary and Share Issue Expenses

Preliminary and Share Issue Expenses has been amortised over ten years.

2. CONTINGENT LIABILITIES : NIL

3. Profit and Loss Account has been prepared and showing profit for the year under consideration.

4. In the opinion of the Board of Directors and to the best of their knowledge and belief, the value on realisation of Loans, Advance and Current Assets in the ordinary course of business will not be less than the amount at which they are stated in Balance Sheet.

5. PAYMENT TO AUDITORS :

	Current Year	Previous year
	(Rupees)	(Rupees)
Audit Fees	25000	25000

6. Figures of the previous year has been rearranged & regrouped wherever deemed necessary.

7. That the due to unawareness of the filing of prescribed form of pledge, Mr. Yogesh Agrawal, Promoter and Managing Director of the Company submitted the wrong form to his Depository Participant SMC Global Securities Limited on 27.03.2019 by mentioning For Pledge in the form but Depository Participant, with their own understanding, instead of pledging of shares, transferred the 1313435 shares in the Account of Sunglow Fininvest Private Limited. His intention was to pledge the shares not to transfer the shares to Sunglow Fininvest Private Limited but SMC Global Securities Limited, to correct the above transaction, Sunglow Fininvest Private Limited has reverted the 1313435 shares in his account on 08.04.2019 and a fresh pledge form has been submitted by Mr. Yogesh Agrawal to his Depository Participant SMC Global Securities Limited for getting pledge his 1313435 shares in favour of Sunglow Fin invest Private Limited and creation of pledge executed with correct form.

8. RELATED PARTY DISCLOSURES (Indian Accounting Standard (Ind AS) 24)
(i) List of Related Parties with whom transactions have taken place and Relationships:

Sr. No.	Name of the Related Party	Relationship
1	Mr. Yogesh Agrawal (Executive Director)	Key Managerial Personnel
	Mrs. Parul Agrawal (Non-Executive - Non Independent Director)	
	Mr. Pradeep Gupta (Non-Executive - Independent Director)*	
	Mr. Rajesh Kumar Saxena (Non-Executive - Independent Director)**	
	Mr. Lalit Shah (Chief Financial Officer)	
	Mr. Hitesh Kumar (Company Secretary & Compliance Officer)***	
	Mr. Sunil Kumar (Company Secretary & Compliance Officer)****	
2	Mr. Yogesh Agrawal h/o Mrs. Parul Agrawal	Relatives of Key Managerial Personnel
	Mrs. Parul Agrawal w/o Mr. Yogesh Agrawal	
	Ms. Ojaswini Avantika d/o Mr. Yogesh Agrawal	

Note:

* Mr. Pradeep Gupta (Non-Executive - Independent Director) is reappointed as Non-Executive - independent Director of Company w.e.f. 28 June, 2019.

** Mr. Rajesh Kumar Saxena (Non-Executive - Independent Director) is reappointed as Non-Executive - Independent Director of Company w.e.f. 28 June, 2019.

*** Mr. Hitesh Kumar resigned from the post of Company Secretary and Compliance officer w.e.f. 25.06.2019.

**** Mr. Sunil Kumar is appointed as Company Secretary and Compliance officer of the company w.e.f. 26.06.2019.

(ii) Transactions for the period 01.04.2019 to 31.03.2020 with Related Parties: (Rs. in Lakh)

S.NO.	NATURE OF TRANSACTION	KEY MANAGERIAL PERSONNEL	RELATIVES OF KEY MANAGERIAL PERSONNEL	ENTERPRISES OVER WHICH KEY MANAGERIAL PERSONNEL OR THEIR RELATIVES EXERCISE SIGNIFICANT INFLUENCE	TOTAL
		31-Mar-20	31-Mar-20	31-Mar-20	31-Mar-20
1	Purchase of Goods	Nil	Nil	Nil	Nil
2	Sale of Goods	Nil	Nil	Nil	Nil
3	Interest Paid	Nil	Nil	Nil	Nil
4	Rent Paid	Nil	Nil	Nil	Nil
5	Salary	12.51	Nil	Nil	12.51
6	Director's Sitting Fees	Nil	Nil	Nil	Nil
7	Unsecured Loans Received	100.17	Nil	Nil	100.17
8	Repayment Of Unsecured Loans	34.07	Nil	Nil	34.07
9	Outstanding Receivables	Nil	Nil	Nil	Nil
10	Outstanding Payable	65.15	Nil	Nil	65.15



(iii) Transaction wise detail of related parties			(Rs. in Lakh)
Sr. No.	Nature of Transaction	Name of Related Party	Transaction Amount 31-03-2020
1	Purchase of Goods		Nil
2	Sale of Goods		Nil
3	Rent Paid		Nil
4	Salary Paid	Mr. Yogesh Agrawal	4.50
		Mr. Lalit Shah	4.20
		Mr. Hitesh Kumar	1.68
		Mr. Sunil Kumar	2.13
		Total	12.51
5	Director's Sitting Fees	Mrs. Parul Agrawal	Nil
		Mr. Rajesh Kumar Saxena	Nil
		Mr. Pradeep Gupta	Nil
		Total	Nil
6	Interest Paid		Nil
7	Unsecured Loan Received		100.17
8	Repayment Of Unsecured Loans		34.07
Outstanding Payable			
9	Salary Payable		0.61
	Rent Payable		Nil
	Interest Payable		Nil
	Unsecured Loan Payable		64.54
	Trade Payable		Nil

9. Notes No. 20 Notes on account form an integral part of the accounts.

**AS PER OUR REPORT OF EVEN DATE ANNEXED
For ANDROS & CO.
CHARTERED ACCOUNTANTS**

**For and on behalf of
GENOMIC VALLEY BIOTECH LIMITED**

sd/-
(CA Bhavuk Garg)
(Partnership Firm)
(Membership No.-502310)

sd/-
Yogesh Agrawal
Managing Director
DIN-01165288

sd/-
Parul Agrawal
Director
DIN-01165188

DATE: 29/06/2020
PLACE: DELHI

sd/-
Lalit Shah
Chief Financial Officer

GENOMIC VALLEY BIOTECH LIMITED
 Regd. Off: 4 KM STONE, BERRI CHHARRA ROAD, P.O. TANDAHERI,
 TEHSIL-BAHADURGARH, DISTT-JHAJJAR, HARYANA-124507
 CIN: L01122HR1994PLC033029
 Tele :- +91-9811341542
 Email :genomicvalley@gmail.com
 Visit :<http://www.genomicvalley.com>

**Form No. MGT-11
PROXY FORM**

[Pursuant to section 105(6) of the Companies Act, 2013 and rule 19(3) of the Companies (Management and Administration) Rules, 2014]

CIN	L01122HR1994PLC033029
Name of the company	Genomic Valley Biotech Limited
Registered office	4 K.M. Stone, Berri Chharra Road, P.O. Tandaheri, Tehsil-Bahadurgarh, District-Jhajjar, Haryana-124507

Name of the Shareholder	
Registered address	
E-mail ID	
Folio No./Client ID	
DP ID	

I/We, being the member (s) of Genomic Valley Biotech Limited holding Equity Shares, hereby appoint:

1.	Name	
	Address	
	E-mail Id	
	Signature	

or failing him

2.	Name	
	Address	
	E-mail Id	
	Signature	

or failing him

3.	Name	
	Address	
	E-mail Id	
	Signature	

as my/our proxy to attend and vote (on a poll) for me/us and on my/our behalf at the 26th Annual General Meeting of the Company, to be held on Thursday, 31st day of December, 2020 at 11.00 A.M. at the Registered Office of the

Company at 4 K.M. Stone, Berri Chharra Road, P.O. Tandaheri, Teh. Bahadurgarh, Dist. Jhajjar, Haryana-124507 and at any adjournment thereof in respect of such resolutions as are indicated below:

Ordinary Business(es):

1. To receive, consider and adopt the Audited Financial Statements of the Company for the Financial Year ended 31st March, 2020, the reports of the Board of Directors and Auditors thereon.
2. To re-appoint Mrs. Parul Agrawal (DIN: 01165188) who retires by rotation and eligible offer herself for reappointment.

Special Business(es):

3. RE-APPOINTMENT OF MR. YOGESH AGRAWAL AS CHAIRMAN AND MANAGING DIRECTOR OF THE COMPANY FOR THE PERIOD OF 5 (FIVE) YEARS WITH EFFECT FROM 07.09.2020
4. APPOINTMENT OF MR. SATENDRA KUMAR GOYAL (DIN: 08767544) AS AN INDEPENDENT DIRECTOR OF THE COMPANY
5. TO SELL, LEASE, COLLABORATE OR SELF-DEVELOP RESIDENTIALLY AND COMMERCIALY OR OTHERWISE DISPOSE OF THE WHOLE OR SUBSTANTIALLY THE WHOLE OF THE LAND, PROPERTY OR UNDERTAKING(S) OF THE COMPANY ALONG WITH ALL DEVELOPMENT RIGHTS AND ENTIRE FACILITIES AVAILABLE WHATSOEVER AT THE LAND, PROPERTY OR UNDERTAKING(S) OF THE COMPANY AS PER SECTION 180(1)(A) OF THE COMPANIES ACT, 2013

Signed this..... day of..... 2020.

Signature of shareholder:

Signature of Proxy holder(s):



Note: This form of proxy in order to be effective should be duly completed and deposited at the Registered Office of the Company, not less than 48 hours before the commencement of the Meeting.



GENOMIC VALLEY BIOTECH LIMITED
Regd. Off: 4 KM STONE, BERRI CHHARRA ROAD, P.O. TANDAHERI,
TEHSIL-BAHADURGARH, DISTT-JHAJJAR, HARYANA-124507
CIN: L01122HR1994PLC033029
Tele :- +91-9811341542
Email : genomicvalley@gmail.com
Visit : <http://www.genomicvalley.com>

ATTENDANCE SLIP

PLEASE BRING THIS ATTENDANCE SLIP AND HANDOVER AT THE ENTRANCE OF ANNUAL GENERAL MEETING VENUE AT 4 K.M. STONE, BERRI CHHARRA ROAD P.O. TANDAHERI, TEH. BAHADURGARH, DIST. JHAJJAR, HARYANA-124507.

Name & Address of the Shareholder

.....

SEQUENCE NO. :
 FOLIO NO. :
 DP ID :
 CLIENT ID :

I hereby record my presence at the 26th ANNUAL GENERAL MEETING being held at 4 K.M. Stone, Berri Chharra Road, P.O. Tandaheri, Teh. Bahadurgarh, Distt. Jhajjar, Haryana-124507 on Thursday, the 31st day of December, 2020 at 11.00 A.M.

Signature of Member or Proxy

.....

No. of Shares held

Notes:

1. A member or his duly appointed Proxy wishing to attend the meeting must complete this Attendance Slip and hand it over at the entrance.
2. Name of the Proxy in Block letters..... (in case the Proxy attends the meeting)
3. Those who hold shares in Demat form to quote their Demat Account No. and Depository Participant (D.P.) ID. No.
4. Shareholders/proxy holders desiring to attend the meeting may bring his/her copy of Annual Report for reference at meeting.

Electronic Voting Particulars

Electronic Voting Sequence No. (EVSN)	User ID	Sequence Number
201205021		

Note: Please read the instructions printed in the Notice dated 05th December, 2020 of the Twenty Fifth Annual General Meeting. The voting period starts from Monday, December 28, 2020 at 9.00 a.m. and ends on Wednesday, December 30, 2020 at 5.00 p.m. The voting module shall be disabled by CDSL for voting thereafter.

GENOMIC VALLEY BIOTECH LIMITED
 Regd. Off: 4 KM STONE, BERRI CHHARRA ROAD, P.O. TANDAHERI,
 TEHSIL-BAHADURGARH, DISTT-JHAJJAR, HARYANA-124507
 CIN: L01122HR1994PLC033029
 Tele :- +91-9811341542
 Email : genomicvalley@gmail.com
 Visit : <http://www.genomicvalley.com>

BALLOT FORM (In lieu of E-Voting at the Annual General Meeting)

1	Name of the Sole/First Member	
2	Name(s) of the Joint Member(s), if any	
3	Registered Folio No./DP ID /Client ID	
4	Number of shares held	

I, We hereby exercise my/our vote in respect of the Resolution(s) to be passed through e-voting/ for the business stated in the AGM Notice dated 05^h December, 2020 of the Company by conveying my/our assent or dissent to the said Resolution(s) by placing the tick (v) mark at the appropriate box below:

Item No.	Description	No. of shares held by me	I assent to the resolution	I dissent from the resolution
	Ordinary Business(es)			
1	To receive, consider and adopt the Audited Financial Statements of the Company for the Financial Year ended 31 st March, 2020, the reports of the Board of Directors and Auditors thereon.			
2	To re-appoint Mrs. Parul Agrawal (DIN 01165188) who retires by rotation and eligible offer herself for reappointment.			
	Special Business(es)			
3.	RE-APPOINTMENT OF MR. YOGESH AGRAWAL AS CHAIRMAN AND MANAGING DIRECTOR OF THE COMPANY FOR THE PERIOD OF 5 (FIVE) YEARS WITH EFFECT FROM 07.09.2020			
4.	APPOINTMENT OF MR. SATENDRA KUMAR GOYAL (DIN: 08767544) AS AN INDEPENDENT DIRECTOR OF THE COMPANY			
5.	TO SELL, LEASE, COLLABORATE OR SELF-DEVELOP RESIDENTIALLY AND COMMERCIALY OR OTHERWISE DISPOSE OF THE WHOLE OR SUBSTANTIALLY THE WHOLE OF THE LAND, PROPERTY OR UNDERTAKING(S) OF THE COMPANY ALONG WITH ALL DEVELOPMENT RIGHTS AND ENTIRE FACILITIES AVAILABLE WHATSOEVER AT THE LAND, PROPERTY OR UNDERTAKING(S) OF THE COMPANY AS PER SECTION 180(1)(A) OF THE COMPANIES ACT, 2013			

Place:

Date:

Signature of Member

NOTE: Last date for receipt of forms by the Company is 30th December, 2020.



GENOMIC VALLEY BIOTECH LIMITED
Regd. Off: 4 KM STONE, BERRI CHHARRA ROAD, P.O. TANDAHARI,
TEHSIL-BAHADURGARH, DISTT-JHAJJAR, HARYANA-124507
CIN: L01122HR1994PLC033029
Tele :- +91-9811341542
Email :genomicvalley@gmail.com
Visit :<http://www.genomicvalley.com>

**Form No. SH-13
Nomination Form**

[Pursuant to Section 72 of the Companies Act, 2013 and rule 19(1) of the Companies (Share Capital and Debentures) Rules 2014]

Name of the Company: Genomic Valley Biotech Limited

Registered Address of the Company: 4 KM STONE, BERRI CHHARRA ROAD, P.O. TANDAHARI, TEHSIL-BAHADURGARH, DISTT-JHAJJAR, HARYANA-124507

I/We _____ the holder(s) of the securities, particulars of which are given hereunder, wish to make nomination and do hereby nominate the following persons in whom shall vest, all the rights in respect of such securities in the event of my/our death.

(1) PARTICULARS OF THE SECURITIES (in respect of which nomination is being made):

Nature of securities	Folio No.	No. of securities	Certificate No.	Distinctive No.

(2) PARTICULARS OF NOMINEE/S-

- (a) Name:
- (b) Date of Birth:
- (c) Father's/Mother's/Spouse's name:
- (d) Occupation:
- (e) Nationality:
- (f) Address:
- (g) E-mail Id. & Telephone No.:
- (h) Relationship with the security holder(s):

(3) IN CASE NOMINEE IS A MINOR-

- (a) Date of birth:
- (b) Date of attaining majority:
- (c) Name of guardian:
- (d) Address of guardian:



(4) PARTICULARS OF NOMINEE IN CASE MINOR NOMINEE DIES BEFORE ATTAINING AGE OF MAJORITY—

- (a) Name:
- (b) Date of Birth:
- (c) Father's/Mother's/Spouse's name:
- (d) Occupation:
- (e) Nationality:
- (f) Address:
- (g) Email Id. & Telephone No.:
- (h) Relationship with the security holder(s):
- (i) Relationship with the minor nominee:

Name(s) and Address of Security holder(s)


Signature(s)


Name and Address of Witness

Signature



Route Map:



The Symbol  is indicating Registered Office of the Company (4 K.M. Stone, Berri Chharra Road, P.O.Tandaheri, Teh. Bahadurgarh, Dist. Jhajjar, Haryana- 124507) which is nearby Landmark as PDM College of Engineering.



BOOK POST

If undelivered please return to:

Genomic Valley Biotech Limited
4 K.M. Stone, Berri Chharra Road,
P.O. Tandaheri, Teh. Bahadurgarh,
Dist. Jhajjar, Haryana- 124507

